{
    "questions": [
        {
            "id": "55031181e9bde69634000014",
            "body": "Is Hirschsprung disease a mendelian or a multifactorial disorder?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11106284",
                "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                "http://www.ncbi.nlm.nih.gov/pubmed/11324313",
                "http://www.ncbi.nlm.nih.gov/pubmed/11324313",
                "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                "http://www.ncbi.nlm.nih.gov/pubmed/12239580",
                "http://www.ncbi.nlm.nih.gov/pubmed/23001136",
                "http://www.ncbi.nlm.nih.gov/pubmed/15617541",
                "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                "http://www.ncbi.nlm.nih.gov/pubmed/22174542"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11106284",
                    "text": "Thus, HSCR has become a model of a complex polygenic disorder in which the interplay of different genes is currently being elucidated.",
                    "score_reranked": 1.3122508525848389
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                    "text": "Hirschsprung's disease (HSCR, aganglionic megacolon) is a frequent congenital malformation regarded as a multigenic neurocristopathy.",
                    "score_reranked": 1.3065779209136963
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11324313",
                    "text": "Hirschsprung's disease (HSCR, aganglionic megacolon) is a frequent congenital malformation regarded as a multigenic neurocristopathy.",
                    "score_reranked": 1.3065779209136963
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11324313",
                    "text": "The dissection of the genetic etiology of HSCR disease may then provide a unique opportunity to distinguish between a polygenic and a genetically heterogeneous disease, thereby helping to understand other complex disorders and congenital malformations hitherto considered as multifactorial in origin.",
                    "score_reranked": 1.00062894821167
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                    "text": "The dissection of the genetic etiology of HSCR disease may then provide a unique opportunity to distinguish between a polygenic and a genetically heterogeneous disease, thereby helping to understand other complex disorders and congenital malformations hitherto considered as multifactorial in origin.",
                    "score_reranked": 1.00062894821167
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12239580",
                    "text": "Therefore, HSCR has become a model for a complex oligo-/polygenic disorder in which the relationship between different genes creating a non-mendelian inheritance pattern still remains to be elucidated.",
                    "score_reranked": 0.8374942541122437
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23001136",
                    "text": "Chromosomal and related Mendelian syndromes associated with Hirschsprung's disease.",
                    "score_reranked": 0.5062975883483887
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15617541",
                    "text": "The non-Mendelian inheritance of sporadic non-syndromic Hirschsprung's disease proved to be complex; involvement of multiple loci was demonstrated in a multiplicative model.",
                    "score_reranked": 0.4933721125125885
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9885824",
                    "text": "[From monogenic to polygenic: model of Hirschsprung disease].",
                    "score_reranked": -0.21883940696716309
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22174542",
                    "text": "Furthermore, the genetics of Hirschsprung's disease are highly complex and not strictly Mendelian.",
                    "score_reranked": -0.4210287630558014
                }
            ]
        },
        {
            "id": "55046d5ff8aee20f27000007",
            "body": "List signaling molecules (ligands) that interact with the receptor EGFR?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19429859",
                "http://www.ncbi.nlm.nih.gov/pubmed/14708119",
                "http://www.ncbi.nlm.nih.gov/pubmed/27378759",
                "http://www.ncbi.nlm.nih.gov/pubmed/7908191",
                "http://www.ncbi.nlm.nih.gov/pubmed/7908191",
                "http://www.ncbi.nlm.nih.gov/pubmed/39275996",
                "http://www.ncbi.nlm.nih.gov/pubmed/39275996",
                "http://www.ncbi.nlm.nih.gov/pubmed/39456468",
                "http://www.ncbi.nlm.nih.gov/pubmed/19429859",
                "http://www.ncbi.nlm.nih.gov/pubmed/39456468"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429859",
                    "text": "Of special relevance is the fact that the EGFR engages in extensive crosstalk with other signaling pathways, serving as a \"signaling hub\" for an increasing list of growth factors, cytokines, and inflammatory mediators.",
                    "score_reranked": 1.9190356731414795
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14708119",
                    "text": "Even a simple list of the complexes that can potentially form in response to a ligand stimulus is problematic because of the number of ways signaling molecules can be modified and combined.",
                    "score_reranked": 0.9898474216461182
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27378759",
                    "text": "Epidermal growth factor receptor (EGFR)-dependent signaling is involved in many physiological processes, and its deregulation leads to cellular dysfunctions and pathologies, of which cancer tops the list.",
                    "score_reranked": 0.9353440999984741
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7908191",
                    "text": "A growing list of orphan receptors, of which some are oncogenic, holds the promise that many unknown ligands may be discovered by tracking the corresponding surface molecules.",
                    "score_reranked": 0.6330493688583374
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7908191",
                    "text": "Other open questions relate to the transmembrane topology of various precursors, the identity of a putative coreceptor, the possible existence of additional ligands of Neu and the functional significance of the interaction between Neu and at least three highly related receptor tyrosine kinases.",
                    "score_reranked": 0.5313720703125
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39275996",
                    "text": "The epidermal growth factor (EGF) receptor (EGFR) is activated by the binding of one of seven EGF-like ligands to its ectodomain.",
                    "score_reranked": 0.40358367562294006
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39275996",
                    "text": "To this end, we analyze the EGFR interfaces of known inhibitory biologics with determined structures in the context of endogenous ligands, using the Rosetta macromolecular modeling software to highlight the most important interactions on a per-residue basis.",
                    "score_reranked": 0.22379937767982483
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39456468",
                    "text": "Here we summarize recent findings on EGFR signaling as a well-studied example for receptor trafficking and",
                    "score_reranked": -0.012610405683517456
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19429859",
                    "text": "Among them is the pathway governed by the epidermal growth factor receptor (EGFR), which can be bound and activated by a broad family of ligands.",
                    "score_reranked": -0.7517105340957642
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39456468",
                    "text": "One example of such potential interaction is epidermal growth factor receptor (EGFR) signaling.",
                    "score_reranked": -0.9774478673934937
                }
            ]
        },
        {
            "id": "54e25eaaae9738404b000017",
            "body": "Is the protein Papilin secreted?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11076767",
                "http://www.ncbi.nlm.nih.gov/pubmed/11076767",
                "http://www.ncbi.nlm.nih.gov/pubmed/38284126",
                "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                "http://www.ncbi.nlm.nih.gov/pubmed/36997062",
                "http://www.ncbi.nlm.nih.gov/pubmed/12666201",
                "http://www.ncbi.nlm.nih.gov/pubmed/12666201"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076767",
                    "text": "Papilin in development; a pericellular protein with a homology to the ADAMTS metalloproteinases.",
                    "score_reranked": 1.7687559127807617
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11076767",
                    "text": "Papilin is an extracellular matrix glycoprotein that we have found to be involved in, (1) thin matrix layers during gastrulation, (2) matrix associated with wandering, phagocytic hemocytes, (3) basement membranes and (4) space-filling matrix during Drosophila development.",
                    "score_reranked": 1.4506709575653076
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38284126",
                    "text": "In mammals, the ADAMTSL protein family comprises seven members, ADAMTSL1-6 and papilin.",
                    "score_reranked": 1.2852243185043335
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                    "text": "A distinctly conserved cassette of domains at the amino-end of papilins is homologous with a cassette of protein domains at the carboxyl-end of the ADAMTS subgroup of secreted, matrix-associated metalloproteases.",
                    "score_reranked": 1.1663018465042114
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                    "text": "Papilin, a novel component of basement membranes, in relation to ADAMTS metalloproteases and ECM development.",
                    "score_reranked": 0.9805965423583984
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                    "text": "Papilins interact with several extracellular matrix components and ADAMTS enzymes.",
                    "score_reranked": 0.6394543647766113
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15094122",
                    "text": "Papilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains.",
                    "score_reranked": 0.5238230228424072
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36997062",
                    "text": "We also observed the accumulation of many structural and extracellular proteins such as papilin-like protein, which glycosylation increase its stability-based molecular modeling.",
                    "score_reranked": 0.38414254784584045
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12666201",
                    "text": "Alternative splicing of papilin and the diversity of Drosophila extracellular matrix during embryonic morphogenesis.",
                    "score_reranked": 0.2641626298427582
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12666201",
                    "text": "Papilins are extracellular matrix proteins that share a particular, common order of types of protein domains.",
                    "score_reranked": -0.00015142560005187988
                }
            ]
        },
        {
            "id": "535d292a9a4572de6f000003",
            "body": "Are long non coding RNAs spliced?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39698821",
                "http://www.ncbi.nlm.nih.gov/pubmed/40048072",
                "http://www.ncbi.nlm.nih.gov/pubmed/39157585",
                "http://www.ncbi.nlm.nih.gov/pubmed/39157585",
                "http://www.ncbi.nlm.nih.gov/pubmed/39989619",
                "http://www.ncbi.nlm.nih.gov/pubmed/40185099",
                "http://www.ncbi.nlm.nih.gov/pubmed/40033900",
                "http://www.ncbi.nlm.nih.gov/pubmed/40048072",
                "http://www.ncbi.nlm.nih.gov/pubmed/39513614",
                "http://www.ncbi.nlm.nih.gov/pubmed/39157585"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39698821",
                    "text": "SFPQ and NONO are involved in all steps of post-transcriptional regulation and are primarily located in mammalian paraspeckles: liquid phase-separated, ribonucleoprotein sub-nuclear bodies templated by NEAT1 long non-coding RNA.",
                    "score_reranked": 1.9370687007904053
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40048072",
                    "text": "This set consisted of 104 messenger RNAs (mRNAs) and 66 long non-coding RNAs (lncRNAs) isoforms.",
                    "score_reranked": 1.5827398300170898
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157585",
                    "text": "Long non-coding RNAs involved in",
                    "score_reranked": 1.0323150157928467
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157585",
                    "text": "The discovery of functional long non-coding RNAs (lncRNAs) changed their initial concept as transcriptional noise.",
                    "score_reranked": 0.6691876649856567
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39989619",
                    "text": "Long non-coding RNAs (lncRNAs) represent a groundbreaking class of RNA molecules that exert regulatory functions with remarkable tissue and cellular specificity.",
                    "score_reranked": 0.4947175681591034
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40185099",
                    "text": "This revealed that an alternatively spliced isoform of lncRNA colorectal neoplasia differentially expressed (CRNDE) containing an ultraconserved element (UCE), referred to as CRNDE",
                    "score_reranked": -0.32782676815986633
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40033900",
                    "text": "We also discuss the mechanisms that enable their resistance to degradation and the biological functions of stable lariat RNAs, shedding light on these seemingly \"nonsense\" yet inevitably produced non-coding intronic RNAs.",
                    "score_reranked": -0.4788370430469513
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40048072",
                    "text": "Recent improvements in the accuracy of long-read sequencing (LRS) technologies have expanded the scope for novel transcriptional isoform discovery.",
                    "score_reranked": -0.48503437638282776
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39513614",
                    "text": "Long non\u2011coding RNA (lncRNA) is a class of non\u2011coding RNA molecules located in the cytoplasm or nucleus, which can regulate chromosome structure and function by interacting with DNA, RNA, proteins and other molecules; binding to mRNA bases in a complementary manner, affecting the splicing, stabilization, translation and degradation of mRNA; acting as competing endogenous RNA competitively binds to microRNAs to regulate gene expression and participate in the regulation of various vital activities of the body.",
                    "score_reranked": -0.5438885688781738
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39157585",
                    "text": "LncRNAs have been identified as regulators of multiple biological processes, including chromatin structure, gene expression, splicing, mRNA degradation, and translation.",
                    "score_reranked": -1.077790379524231
                }
            ]
        },
        {
            "id": "55262a9787ecba3764000009",
            "body": "Is RANKL secreted from the cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40244002",
                "http://www.ncbi.nlm.nih.gov/pubmed/39954074",
                "http://www.ncbi.nlm.nih.gov/pubmed/40032017",
                "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                "http://www.ncbi.nlm.nih.gov/pubmed/40147673",
                "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                "http://www.ncbi.nlm.nih.gov/pubmed/39956215",
                "http://www.ncbi.nlm.nih.gov/pubmed/40059949",
                "http://www.ncbi.nlm.nih.gov/pubmed/40147673"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40244002",
                    "text": "Osteoclastogenesis is tightly regulated by receptor activator of nuclear factor kappa-B ligand (RANKL) signaling, yet the role of matrix metalloproteinase-9 (MMP-9) in this process remains controversial.",
                    "score_reranked": -0.1685716211795807
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39954074",
                    "text": "LGR4 was endocytosed into endosomes after binding to RANKL in RAW 264.7\u00a0s osteoclast precursor cells.",
                    "score_reranked": -0.19548198580741882
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40032017",
                    "text": "In vitro, MHP1-AcN bound to both RANK and TNFR1, suppressing osteoclast activity via the RANKL-RANK pathway and reducing sclerostin expression through the TNF\u03b1-TNFR1-nuclear factor-kappa B pathway.",
                    "score_reranked": -0.48712024092674255
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                    "text": "Therefore, in this study, we aimed to investigate the interaction between receptor activators of nuclear factor kappa B (RANK) released from mature human osteoclasts and the membranous RANK ligand (RANKL) in human PDL cells.",
                    "score_reranked": -0.5298018455505371
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                    "text": "Multinucleated mature human osteoclasts were differentiated from peripheral blood mononuclear cells upon incubation with recombinant macrophage colony-stimulating factor and RANKL.",
                    "score_reranked": -0.5468610525131226
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40147673",
                    "text": "Receptor activator of NF\u03baB (RANK)-receptor activator of NF\u03baB ligand (RANKL) binding triggers the differentiation of osteoclasts, bone-resorbing cells.",
                    "score_reranked": -0.6322159767150879
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39993474",
                    "text": "Mature osteoclasts can induce osteogenesis in human PDL cells via RANK-RANKL reverse signaling.",
                    "score_reranked": -0.7978451251983643
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39956215",
                    "text": "Upon binding to its receptor, RANK, RANKL activates various signaling cascades that induce osteoclast differentiation of osteoclast precursor cells into osteoclasts.",
                    "score_reranked": -0.8423902988433838
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40059949",
                    "text": "Multiple signaling pathways such as receptor activator of nuclear factor-kappa B ligand (RANKL) signaling are involved in osteoclast activation.",
                    "score_reranked": -1.0731167793273926
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40147673",
                    "text": "Therefore, our method successfully detected and quantified RANK-RANKL binding in living cells.",
                    "score_reranked": -1.1611393690109253
                }
            ]
        },
        {
            "id": "51406e6223fec90375000009",
            "body": "Does metformin interfere thyroxine absorption?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                "http://www.ncbi.nlm.nih.gov/pubmed/21468527",
                "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                "http://www.ncbi.nlm.nih.gov/pubmed/18341376",
                "http://www.ncbi.nlm.nih.gov/pubmed/7713276",
                "http://www.ncbi.nlm.nih.gov/pubmed/16219720",
                "http://www.ncbi.nlm.nih.gov/pubmed/7488863",
                "http://www.ncbi.nlm.nih.gov/pubmed/18341376"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "text": "Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption.",
                    "score_reranked": 0.9840469360351562
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "text": "LT4 absorption is unchanged by concomitant metformin ingestion.",
                    "score_reranked": 0.2708704173564911
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21468527",
                    "text": "[Metformin: one more drug interaction in the treatment of hypothyroidism?].",
                    "score_reranked": 0.1444515883922577
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "text": "It has been hypothesized that metformin may suppress serum thyrotropin (TSH) concentrations by enhancing LT4 absorption or by directly affecting the hypothalamic-pituitary axis.",
                    "score_reranked": 0.12175717949867249
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26191653",
                    "text": "This study examined the effect of metformin ingestion on LT4 absorption, as assessed by serum total thyroxine (TT4) concentrations.",
                    "score_reranked": 0.1194256842136383
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341376",
                    "text": "Altered intestinal absorption of L-thyroxine caused by coffee.",
                    "score_reranked": -0.12683290243148804
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7713276",
                    "text": "In an attempt to clarify the question of an involvement of the inhibition of intestinal glucose absorption in the mechanism of action of Metformin, we used several experimental approaches: 1 glucose/lactate measurement in rat portal blood in vivo and 2 in the venous effluent of an isolated perfused rat intestinal segment; 3 metabolism of freshly isolated enterocytes in vitro and tissue distribution of 3H-labeled Metformin was investigated both in vivo and in vitro.",
                    "score_reranked": -0.2153674066066742
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16219720",
                    "text": "Thyrotropin suppression by metformin.",
                    "score_reranked": -0.5561106204986572
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7488863",
                    "text": "In sum, only the first part of the absorption curve of T4 was shifted to the right (in three of the four women) and this shift was more pronounced and extended to the second part of the curve in the fourth patient; in this last patient absorption peak was 44% at 180 min. Based on these results, we obtained full suppression or normalization of TSH by postponing breakfast for at least 60 min after T4 ingestion.(ABSTRACT",
                    "score_reranked": -0.645390510559082
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341376",
                    "text": "Coffee should be added to the list of interferers of T4 intestinal absorption, and T4 to the list of compounds whose absorption is affected by coffee.",
                    "score_reranked": -0.976719856262207
                }
            ]
        },
        {
            "id": "553fa78b1d53b76422000007",
            "body": "Which miRNAs could be used as potential biomarkers for epithelial ovarian cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38622482",
                "http://www.ncbi.nlm.nih.gov/pubmed/34680550",
                "http://www.ncbi.nlm.nih.gov/pubmed/36603851",
                "http://www.ncbi.nlm.nih.gov/pubmed/34680550",
                "http://www.ncbi.nlm.nih.gov/pubmed/38690293",
                "http://www.ncbi.nlm.nih.gov/pubmed/34692473",
                "http://www.ncbi.nlm.nih.gov/pubmed/37750402",
                "http://www.ncbi.nlm.nih.gov/pubmed/32703147",
                "http://www.ncbi.nlm.nih.gov/pubmed/38690293",
                "http://www.ncbi.nlm.nih.gov/pubmed/32703147"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38622482",
                    "text": "The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis.",
                    "score_reranked": 2.5485386848449707
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680550",
                    "text": "In this review, the potential use of exosomal miRNAs as early detection biomarkers for EOCs and their accuracy are discussed.",
                    "score_reranked": 2.537168025970459
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36603851",
                    "text": "Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma.",
                    "score_reranked": 2.3569083213806152
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34680550",
                    "text": "Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer.",
                    "score_reranked": 2.3162786960601807
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38690293",
                    "text": "Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.",
                    "score_reranked": 2.3016679286956787
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34692473",
                    "text": "MiRNAs are stably present in the circulation and recently have gained an importance to serve as a minimally invasive biomarker for early detection of epithelial ovarian cancer.",
                    "score_reranked": 1.9169464111328125
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37750402",
                    "text": "Identifying Serum Small Extracellular Vesicle MicroRNA as a Noninvasive Diagnostic and Prognostic Biomarker for Ovarian Cancer.",
                    "score_reranked": 1.267930507659912
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703147",
                    "text": "MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.",
                    "score_reranked": 0.6872942447662354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38690293",
                    "text": "Here, we cover our present comprehension of the most up-to-date microRNA-based approaches to detect ovarian cancer, as well as current diagnostic and treatment strategies, the role of microRNAs as oncogenes or tumor suppressor genes, and their significance in ovarian cancer progression, prognosis, and therapy.",
                    "score_reranked": 0.48457029461860657
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32703147",
                    "text": "A comprehensive miRNA expression profiling can help to refine subtype classification in EOC, opening new opportunities for identifying clinically applicable markers for improved stratification and diagnostics of ovarian tumors.",
                    "score_reranked": 0.2119368612766266
                }
            ]
        },
        {
            "id": "5149199dd24251bc05000040",
            "body": "Which acetylcholinesterase inhibitors are used for treatment of myasthenia gravis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                "http://www.ncbi.nlm.nih.gov/pubmed/31593530",
                "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                "http://www.ncbi.nlm.nih.gov/pubmed/39869260",
                "http://www.ncbi.nlm.nih.gov/pubmed/39379218",
                "http://www.ncbi.nlm.nih.gov/pubmed/38212553",
                "http://www.ncbi.nlm.nih.gov/pubmed/40087931",
                "http://www.ncbi.nlm.nih.gov/pubmed/38191918",
                "http://www.ncbi.nlm.nih.gov/pubmed/32337145"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                    "text": "The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.",
                    "score_reranked": 1.8577752113342285
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                    "text": "This article is a summary of the history of the use of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.",
                    "score_reranked": 1.7402154207229614
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31593530",
                    "text": "The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target.",
                    "score_reranked": 1.386488676071167
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32918950",
                    "text": "The beneficial effects of acetylcholinesterase inhibitors for the treatment of myasthenia gravis (MG) was a major discovery that came about through one young physician putting together a string of previous observations.",
                    "score_reranked": 1.382326602935791
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39869260",
                    "text": "Standard treatment has been unchanged for decades and includes symptomatic treatment with acetylcholine-esterase inhibitors and disease-modifying treatment with steroids, steroid-sparing immunosuppressants and thymectomy.",
                    "score_reranked": 1.1012179851531982
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39379218",
                    "text": "New treatment strategies in Myasthenia gravis.",
                    "score_reranked": 0.9551323652267456
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38212553",
                    "text": "Myasthenia Gravis Treatment: From Old Drugs to Innovative Therapies with a Glimpse into the Future.",
                    "score_reranked": 0.5110583305358887
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40087931",
                    "text": "Clinical Spectrum and Therapeutic Outcome of Myasthenia Gravis in a Tertiary Care Hospital: A Retrospective Study.",
                    "score_reranked": 0.4912829101085663
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38191918",
                    "text": "Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.",
                    "score_reranked": 0.11788859963417053
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32337145",
                    "text": "Review Analysis on Thymectomy vs Conservative Medical Management in Myasthenia Gravis.",
                    "score_reranked": -0.21180906891822815
                }
            ]
        },
        {
            "id": "52bf1db603868f1b06000011",
            "body": "Has Denosumab (Prolia) been approved by FDA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
                "http://www.ncbi.nlm.nih.gov/pubmed/39294041",
                "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
                "http://www.ncbi.nlm.nih.gov/pubmed/38027014",
                "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
                "http://www.ncbi.nlm.nih.gov/pubmed/40322084",
                "http://www.ncbi.nlm.nih.gov/pubmed/31820174",
                "http://www.ncbi.nlm.nih.gov/pubmed/39294041",
                "http://www.ncbi.nlm.nih.gov/pubmed/25614274",
                "http://www.ncbi.nlm.nih.gov/pubmed/25614274"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21170699",
                    "text": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis.",
                    "score_reranked": 2.2906911373138428
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39294041",
                    "text": "Sandoz biosimilar denosumab (GP2411 [SDZ-deno]; Jubbonti/Wyost) is approved by the US FDA, EMA and Health Canada for all indications of reference denosumab (REF-deno; Prolia/Xgeva), a fully human IgG2\u03ba monoclonal antibody that binds with high affinity and specificity to receptor activator of nuclear factor kappa-B ligand (RANKL).",
                    "score_reranked": 1.9041931629180908
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
                    "text": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United States and by the European Medicines Agency in Europe since June 2010.",
                    "score_reranked": 0.8668526411056519
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38027014",
                    "text": "Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).",
                    "score_reranked": 0.8466911315917969
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24126422",
                    "text": "Denosumab: recent update in postmenopausal osteoporosis.",
                    "score_reranked": 0.5425772666931152
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40322084",
                    "text": "Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health.",
                    "score_reranked": 0.3639366924762726
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31820174",
                    "text": "The 11 existing FDA-approved osteoporosis drug treatments include hormone replacement therapy, 2 SERMs (raloxifene and bazedoxifene), 5 inhibitors of bone-resorbing osteoclasts (4 bisphosphonates and anti-RANKL denosumab), 2 parathyroid hormone analogues (teriparatide and abaloparatide), and 1 WNT signaling enhancer (romosozumab).",
                    "score_reranked": 0.16246744990348816
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39294041",
                    "text": "The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab.",
                    "score_reranked": 0.08376204967498779
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25614274",
                    "text": "This review covers the pharmacology and major clinical trials with extension/post-marketing follow-up, including trials for all FDA-approved indications of denosumab to date.",
                    "score_reranked": -0.3779354691505432
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25614274",
                    "text": "Denosumab is a novel agent that acts to reduce bone turnover, improve bone mineral density, and reduce fracture risk, offering a favorable efficacy and safety profile.",
                    "score_reranked": -0.47538724541664124
                }
            ]
        },
        {
            "id": "5709e4b2cf1c32585100001c",
            "body": "List the human genes encoding for the dishevelled proteins?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24838524",
                "http://www.ncbi.nlm.nih.gov/pubmed/9192851",
                "http://www.ncbi.nlm.nih.gov/pubmed/11856884",
                "http://www.ncbi.nlm.nih.gov/pubmed/9192851",
                "http://www.ncbi.nlm.nih.gov/pubmed/11803455",
                "http://www.ncbi.nlm.nih.gov/pubmed/10585287",
                "http://www.ncbi.nlm.nih.gov/pubmed/8922524",
                "http://www.ncbi.nlm.nih.gov/pubmed/8922524",
                "http://www.ncbi.nlm.nih.gov/pubmed/15533824",
                "http://www.ncbi.nlm.nih.gov/pubmed/12883684"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24838524",
                    "text": "We are here reviewing the role of the PCP pathway genes in the etiology of human NTDs, updating the list of the rare and deleterious mutations identified so far.",
                    "score_reranked": 1.8128619194030762
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9192851",
                    "text": "Our results indicate that the human dishevelled genes constitute a multigene family and that Dishevelled proteins are highly conserved among metazoans.",
                    "score_reranked": 1.6625466346740723
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11856884",
                    "text": "The gene encodes a protein with high homology to human RGS11 (79.9%), containing conserved DEP (Dishevelled/EGL-10/Pleckstrin) and GGL (G protein gamma-like) domains.",
                    "score_reranked": 1.4032647609710693
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9192851",
                    "text": "Human dishevelled genes constitute a DHR-containing multigene family.",
                    "score_reranked": 0.7995890378952026
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11803455",
                    "text": "Identification of genomic organisation, sequence variants and analysis of the role of the human dishevelled 1 gene in late onset Alzheimer's disease.",
                    "score_reranked": 0.7950646877288818
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10585287",
                    "text": "The Dishevelled (Dvl) gene family encodes cytoplasmic proteins that are implicated in Wnt signal transduction.",
                    "score_reranked": 0.4768035113811493
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8922524",
                    "text": "Utilizing RT-PCR with degenerate primers, we isolated another member of the mouse Dishevelled (Dvl) gene family, Dvl3.",
                    "score_reranked": 0.10887429118156433
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8922524",
                    "text": "The region of highest conservation between all three Dvl coding regions, at 97% identity, is noted at the PDZ domain (also termed the DHR domain or GLGF motif), a motif of 60 amino acids present in all dishevelled encoded proteins and first described in the Drosophila discs large (dlg) tumor suppressor gene.",
                    "score_reranked": 0.08161702752113342
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15533824",
                    "text": "A recently identified member of the Formin family, Daam (Dishevelled--associated activator of morphogenesis), regulates the morphogenetic movements of vertebrate gastrulation in a Wnt-dependent manner through direct interactions with Dsh/Dvl and RhoA.",
                    "score_reranked": -0.3068619668483734
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12883684",
                    "text": "The Dvl-1 gene on chromosome 1p36 belongs to a family of highly conserved secreted proteins which regulates embryonic induction, generation of cell polarity and specification of cell fate through activation of Wnt signaling pathways.",
                    "score_reranked": -0.45679208636283875
                }
            ]
        },
        {
            "id": "56bc751eac7ad10019000013",
            "body": "Name synonym of Acrokeratosis paraneoplastica.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16435144",
                "http://www.ncbi.nlm.nih.gov/pubmed/22146896",
                "http://www.ncbi.nlm.nih.gov/pubmed/16435144",
                "http://www.ncbi.nlm.nih.gov/pubmed/35776037",
                "http://www.ncbi.nlm.nih.gov/pubmed/8638903",
                "http://www.ncbi.nlm.nih.gov/pubmed/22146896",
                "http://www.ncbi.nlm.nih.gov/pubmed/24280364",
                "http://www.ncbi.nlm.nih.gov/pubmed/30264310",
                "http://www.ncbi.nlm.nih.gov/pubmed/28101384",
                "http://www.ncbi.nlm.nih.gov/pubmed/23294970"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16435144",
                    "text": "Obligatory cutaneous paraneoplastic disorders comprising acanthosis nigricans maligna, erythema gyratum repens, paraneoplastic pemphigus, hypertrichosis lanuginosa acquisita, erythema necrolyticum migrans and acrokeratosis paraneoplastica are rare.",
                    "score_reranked": 2.7983920574188232
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146896",
                    "text": "[Paraneoplastic palmoplantar hyperkeratosis. Minor form of acrokeratosis neoplastica Bazex?].",
                    "score_reranked": 2.4748263359069824
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16435144",
                    "text": "Acrokeratosis paraneoplastica (first described by Gougerot and Rupp in 1922) was named after Bazex who had then reported several cases in a French dermatological journal since 1965 (Bazex et al. in Bull Soc Fr Dermatol Syphiligr 72:182, 1965; Bazex and Griffiths in Br J Dermatol 102:301-306, 1980).",
                    "score_reranked": 2.3002257347106934
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35776037",
                    "text": "Acrokeratosis of Bazex as a sign of thyroid cancer: first description and review of thyroid-associated paraneoplastic dermatoses.",
                    "score_reranked": 2.039539098739624
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8638903",
                    "text": "Bazex's acrokeratosis paraneoplastica.",
                    "score_reranked": 1.7555011510849
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22146896",
                    "text": "We diagnosed a minor form of acrokeratosis paraneoplastica Bazex.",
                    "score_reranked": 1.5783792734146118
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24280364",
                    "text": "[Acrokeratosis paraneoplastica of Bazex].",
                    "score_reranked": 1.0866296291351318
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30264310",
                    "text": "[Acrokeratosis paraneoplastica in hemato-oncological disease].",
                    "score_reranked": 1.0682835578918457
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28101384",
                    "text": "Acrokeratosis Paraneoplastica Associated with Cervical Squamous Cell Carcinoma.",
                    "score_reranked": 0.6306084394454956
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23294970",
                    "text": "Bazex acrokeratosis as a paraneoplastic syndrome.",
                    "score_reranked": 0.5012744665145874
                }
            ]
        },
        {
            "id": "54d4e03a3706e89528000001",
            "body": "Which are the classes of anti-arrhythmic drugs according to Vaughan-Williams classification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40033368",
                "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                "http://www.ncbi.nlm.nih.gov/pubmed/40074161",
                "http://www.ncbi.nlm.nih.gov/pubmed/36286872",
                "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                "http://www.ncbi.nlm.nih.gov/pubmed/40000285",
                "http://www.ncbi.nlm.nih.gov/pubmed/39552737",
                "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                "http://www.ncbi.nlm.nih.gov/pubmed/40292507"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40033368",
                    "text": "Patient records were analysed to investigate the nature of the medication such as the number of drugs and distribution according to the anatomical therapeutic code classification and drug-drug interactions in relation to bicycle ergometry performance.",
                    "score_reranked": 0.8798515796661377
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                    "text": "The 1970 landmark Vaughan Williams (VW) classification utilizing known actions of then available antiarrhythmic drugs (AADs) became and remains central to management, but it requires revision in response to extensive subsequent advances.",
                    "score_reranked": 0.8590903282165527
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40074161",
                    "text": "We attempted to clarify the mechanisms by utilizing model drugs classified as biopharmaceutics classification system class II.",
                    "score_reranked": 0.7560817003250122
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36286872",
                    "text": "After reviewing the current definitions and classification of pulmonary hypertension (PH) associated with congenital heart disease (CHD), based on an analysis of 59 clinical trials (of which 14 are randomized controlled trials) drugs registered in the Russian Federation, the evidence base for PH therapy in adults with CHD is provided.",
                    "score_reranked": 0.5642659664154053
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                    "text": "The modernized classification of cardiac antiarrhythmic drugs: Its application to clinical practice.",
                    "score_reranked": 0.32868626713752747
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                    "text": "(4) The simplified scheme remains flexible, permitting drugs to be placed in multiple classes where required, and the addition of classes and subclasses in light of future investigations and clinical approvals.",
                    "score_reranked": 0.3020053207874298
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40000285",
                    "text": "A new class of cardiovascular medications, cardiac myosin inhibitors, has surged to the forefront of HCM treatment in recent years.",
                    "score_reranked": 0.23135784268379211
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39552737",
                    "text": "Flecainide acetate is classified as a class IC antiarrhythmic medication according to the Vaughan-Williams classification, primarily used to manage both ventricular and supraventricular tachycardia.",
                    "score_reranked": 0.08504119515419006
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40187508",
                    "text": "(3) The adopted subclasses within each AAD class parallel clinical practice by including only subclasses containing established AADs, or approved potential off-label drugs, as opposed to those only including INDs.",
                    "score_reranked": 0.006307631731033325
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40292507",
                    "text": "Today, a new class of drugs that inhibit cardiac myosin activity is available for patients with obstructive HCM.In light of the new treatment perspectives, the correct clinical-therapeutic classification of affected patients becomes of fundamental importance for the cardiologist.",
                    "score_reranked": -0.044362276792526245
                }
            ]
        },
        {
            "id": "55072c803b8a5dc045000001",
            "body": "Which are the different isoforms of the mammalian Notch receptor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39932958",
                "http://www.ncbi.nlm.nih.gov/pubmed/8948600",
                "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751380",
                "http://www.ncbi.nlm.nih.gov/pubmed/34341333",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751380",
                "http://www.ncbi.nlm.nih.gov/pubmed/31661545",
                "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751380"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39932958",
                    "text": "Moreover, different Notch receptor/ligand combinations are known to elicit distinct molecular and cellular responses, and together, these phenomena determine the strength, the duration and the specificity of Notch receptor signalling.",
                    "score_reranked": 2.4897682666778564
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8948600",
                    "text": "Our data are consistent with the idea that the diversity of cell types regulated by Notch signaling is a consequence of activation of unique Notch isoforms by different DSL ligands.",
                    "score_reranked": 2.4052093029022217
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                    "text": "To allow the Notch signal to be deployed in numerous contexts, many different mechanisms have evolved to regulate the level, duration and spatial distribution of Notch activity.",
                    "score_reranked": 1.6549084186553955
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                    "text": "Different proteolytically derived isoforms of Notch have also been identified that may be involved in alternative Notch-dependent signals or regulatory mechanisms, and differences between the four mammalian Notch homologues are beginning to be appreciated.",
                    "score_reranked": 1.364209532737732
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751380",
                    "text": "A fundamental question is how the strength of Notch signaling depends on which pathway components are expressed, at what levels, and in which cells.",
                    "score_reranked": 1.0353341102600098
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34341333",
                    "text": "Correction: DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis.",
                    "score_reranked": 0.5991790294647217
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751380",
                    "text": "Diversity in Notch ligand-receptor signaling interactions.",
                    "score_reranked": 0.4205845296382904
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31661545",
                    "text": "Delta-like homolog 1 (DLK1) regulates noncanonical Notch signaling pathway as ligand.",
                    "score_reranked": 0.09478232264518738
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11989820",
                    "text": "Multiple levels of Notch signal regulation (review).",
                    "score_reranked": -0.007464081048965454
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751380",
                    "text": "Each ligand (Dll1, Dll4, Jag1, and Jag2) and receptor variant (Notch1 and Notch2) analyzed here exhibited a unique profile of interactions, Fringe dependence, and signaling outcomes.",
                    "score_reranked": -1.8190670013427734
                }
            ]
        },
        {
            "id": "53061af558348c0f52000002",
            "body": "Which are the major characteristics of cellular senescence?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40149983",
                "http://www.ncbi.nlm.nih.gov/pubmed/34944585",
                "http://www.ncbi.nlm.nih.gov/pubmed/40082352",
                "http://www.ncbi.nlm.nih.gov/pubmed/37371545",
                "http://www.ncbi.nlm.nih.gov/pubmed/38375248",
                "http://www.ncbi.nlm.nih.gov/pubmed/34944585",
                "http://www.ncbi.nlm.nih.gov/pubmed/38481648",
                "http://www.ncbi.nlm.nih.gov/pubmed/38429379",
                "http://www.ncbi.nlm.nih.gov/pubmed/37371545",
                "http://www.ncbi.nlm.nih.gov/pubmed/40149983"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40149983",
                    "text": "In this review, we first introduce the causes and characteristics of induced cellular senescence, analyze the senescence process of immune cells and cancer cells, and then discuss the dual regulatory role of cell senescence on tumor growth and senescence-induced therapies targeting cancer cells.",
                    "score_reranked": 1.5523337125778198
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34944585",
                    "text": "While phenotypically diverse, characteristics of senescence include the expression of the senescence-associated secretory phenotype, cell cycle arrest factors, senescence-associated \u03b2-galactosidase, morphogenesis, and chromatin remodelling.",
                    "score_reranked": 1.101466178894043
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40082352",
                    "text": "The dynamic, context-dependent and ambivalent nature of senescence challenges the identification, characterization, and specific targeting of senescent cells for disease management.",
                    "score_reranked": 0.5074418783187866
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37371545",
                    "text": "The major persisting challenge in developing novel senotherapies is the heterogeneity of senescence phenotypes, causing a lack of universal biomarkers and difficulties in discriminating senescent from non-senescent cells.",
                    "score_reranked": 0.38420143723487854
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38375248",
                    "text": "The senescence-associated secretory phenotype (SASP), an essential cellular senescence hallmark, is an important mechanism connecting cellular senescence to osteoporosis.",
                    "score_reranked": 0.11910012364387512
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34944585",
                    "text": "Cellular Senescence: Mechanisms and Therapeutic Potential.",
                    "score_reranked": 0.10117268562316895
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38481648",
                    "text": "In contrast to physiological aging, premature aging diseases are driven by one or two distinct primary causes of aging, such as genomic instability in the case of Werner syndrome (WS), each displaying other hallmarks of aging to a variable extent.",
                    "score_reranked": -0.1863616406917572
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38429379",
                    "text": "Senescence-like characteristics are observed in both neuronal and glial lineages, but their relative contribution to aging and neurodegeneration remains unclear.",
                    "score_reranked": -0.28439757227897644
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37371545",
                    "text": "Cellular senescence describes a stable cell cycle arrest state with a characteristic phenotype.",
                    "score_reranked": -0.5107740163803101
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40149983",
                    "text": "After senescence, cells cease dividing and exhibit many age-related characteristics.",
                    "score_reranked": -0.6434880495071411
                }
            ]
        },
        {
            "id": "56c1f01def6e394741000045",
            "body": "Orteronel was developed for treatment of which cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                "http://www.ncbi.nlm.nih.gov/pubmed/27482286",
                "http://www.ncbi.nlm.nih.gov/pubmed/28463227"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                    "text": "Orteronel for the treatment of prostate cancer.",
                    "score_reranked": 1.8948109149932861
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                    "text": "Orteronel (also known as TAK-700) is a novel hormonal therapy that is currently in testing for the treatment of prostate cancer.",
                    "score_reranked": 1.0849504470825195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                    "text": "These findings suggest that orteronel may be an effective therapeutic option for diseases where androgen suppression is critical, such as androgen sensitive and CRPC.",
                    "score_reranked": 0.9251877069473267
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                    "text": "However, additional Phase III orteronel trials are ongoing in men with earlier stages of prostate cancer.",
                    "score_reranked": 0.8172855377197266
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                    "text": "In this study, we quantified the inhibitory activity and specificity of orteronel for testicular and adrenal androgen production by evaluating its effects on CYP17A1 enzymatic activity, steroid production in monkey adrenal cells and human adrenal tumor cells, and serum levels of dehydroepiandrosterone (DHEA), cortisol, and testosterone after oral dosing in castrated and intact male cynomolgus monkeys.",
                    "score_reranked": 0.7351187467575073
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24799061",
                    "text": "Orteronel inhibits the 17,20 lyase activity of the enzyme CYP17A1, which is important for androgen synthesis in the testes, adrenal glands and prostate cancer cells.",
                    "score_reranked": 0.61484694480896
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                    "text": "In castrated monkeys treated twice daily with orteronel, suppression of DHEA and testosterone persisted throughout the treatment period.",
                    "score_reranked": 0.34120407700538635
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22249003",
                    "text": "In terms of human CYP17A1 and human adrenal tumor cells, orteronel inhibited 17,20-lyase activity 5.4 times more potently than 17-hydroxylase activity in cell-free enzyme assays and DHEA production 27 times more potently than cortisol production in human adrenal tumor cells, suggesting greater specificity of inhibition between 17,20-lyase and 17-hydroxylase activities in humans vs monkeys.",
                    "score_reranked": -0.11738023161888123
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27482286",
                    "text": "These include VT-464, orteronel, and galeterone.",
                    "score_reranked": -0.5999331474304199
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28463227",
                    "text": "A phase I study recently reported that seviteronel, a CYP17 lyase-selective inhibitor, \u00e6demonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another study showed seviteronel's direct effects on AR function.",
                    "score_reranked": -1.2476089000701904
                }
            ]
        },
        {
            "id": "5313b049e3eabad021000013",
            "body": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17210707",
                "http://www.ncbi.nlm.nih.gov/pubmed/12173324",
                "http://www.ncbi.nlm.nih.gov/pubmed/22977535",
                "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                "http://www.ncbi.nlm.nih.gov/pubmed/19373278",
                "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                "http://www.ncbi.nlm.nih.gov/pubmed/19373278",
                "http://www.ncbi.nlm.nih.gov/pubmed/22505344",
                "http://www.ncbi.nlm.nih.gov/pubmed/16408160"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17210707",
                    "text": "Therefore, the objective of this present study was to assess the efficiency of paclitaxel palmitate-loaded anti-HER2 immunoemulsions, a targeted drug delivery system based on cationic emulsion covalently linked to anti-HER2 monoclonal antibody (Herceptin), in a well-established in vivo pharmacologic model of metastatic prostate cancer that overexpresses the HER2 receptor.",
                    "score_reranked": 3.1197404861450195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12173324",
                    "text": "The authors report the results of HER-2 screening from a Phase II trial of chemotherapy with trastuzumab and docetaxel in patients with HER-2-overexpressing prostate carcinoma.",
                    "score_reranked": 3.1134426593780518
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977535",
                    "text": "Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A\u2033DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines.",
                    "score_reranked": 2.4989984035491943
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                    "text": "Monoclonal antibody therapy for prostate cancer.",
                    "score_reranked": 2.2302727699279785
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                    "text": "The clinical experience with some of the commercialized MAb products points out specific challenges in conducting clinical trials with targeted therapy in PCa.",
                    "score_reranked": 1.9898927211761475
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19373278",
                    "text": "When bound to trastuzumab (Herceptin, Genentech, CA), lentiviruses were able to selectively infect androgen-sensitive LNCaP and castration-resistant C4-2 human prostate cancer cell lines, both of which express high levels of HER-2.",
                    "score_reranked": 1.5945429801940918
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071949",
                    "text": "These properties have fostered interest in the development and clinical evaluation of therapeutic MAbs directed to both well established and newly discovered targets in PCa.",
                    "score_reranked": 1.4632278680801392
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19373278",
                    "text": "In conclusion, we found that although prostate cancers that express high levels of HER-2 are resistant to the killing effects of trastuzumab, they can be targeted for selective gene expression and destruction by viruses with envelope proteins engineered to bind this antibody.",
                    "score_reranked": 1.3113253116607666
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22505344",
                    "text": "Effects of a human compact anti-ErbB2 antibody on prostate cancer.",
                    "score_reranked": 1.1564741134643555
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16408160",
                    "text": "Antibody-based therapeutics: focus on prostate cancer.",
                    "score_reranked": 0.539771556854248
                }
            ]
        },
        {
            "id": "53137541e3eabad021000010",
            "body": "Which are the Yamanaka factors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40059074",
                "http://www.ncbi.nlm.nih.gov/pubmed/39684245",
                "http://www.ncbi.nlm.nih.gov/pubmed/39668101",
                "http://www.ncbi.nlm.nih.gov/pubmed/39426381",
                "http://www.ncbi.nlm.nih.gov/pubmed/40327951",
                "http://www.ncbi.nlm.nih.gov/pubmed/40387991",
                "http://www.ncbi.nlm.nih.gov/pubmed/39642859",
                "http://www.ncbi.nlm.nih.gov/pubmed/39834592",
                "http://www.ncbi.nlm.nih.gov/pubmed/39668101",
                "http://www.ncbi.nlm.nih.gov/pubmed/39834592"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40059074",
                    "text": "An interesting aspect of blastema formation in highly regenerative organisms is the temporary expression of pluripotency factors as known as the Yamanaka factors (YFs), which is a key requirement for reprogramming somatic cells into induced pluripotent stem cells (iPSCs).",
                    "score_reranked": 1.3781523704528809
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39684245",
                    "text": "In the present study, we subjected senescent human endometrial MSCs to partial reprogramming using Sendai virus vectors containing genes encoding Yamanaka transcription factors Oct4, Sox2, Klf4, and c-Myc.",
                    "score_reranked": 1.3592052459716797
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39668101",
                    "text": "The Yamanaka factors (YFs), a set of four transcription factors, are widely studied for their ability to dedifferentiate somatic cells into a pluripotent state.",
                    "score_reranked": 1.0703709125518799
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39426381",
                    "text": "Yamanaka factors (YFs) can reverse some aging features in mammalian tissues, but their effects on the brain remain largely unexplored.",
                    "score_reranked": 0.8513250350952148
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40327951",
                    "text": "The hope for ultimate regeneration was made even more tangible by the observations that partial reprogramming by the Yamanaka factors reverses many hallmarks of aging [76], even though the underlying mechanism remains unclear.",
                    "score_reranked": 0.7769527435302734
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40387991",
                    "text": "Recent studies have demonstrated that human-induced trophoblast stem cells (hiTSCs) can be generated either by overexpressing the pluripotency factors OCT4, SOX2, KLF4, and MYC (OSKM) in fibroblasts or through the transdifferentiation of pluripotent stem cells.",
                    "score_reranked": 0.5722255706787109
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39642859",
                    "text": "In this issue of Cell Stem Cell, Shen et\u00a0al. investigate in\u00a0vivo transient expression of Yamanaka factors (YFs) during embryogenesis and an adult mouse model of Alzheimer's disease (AD)-associated amyloidosis.",
                    "score_reranked": 0.5624345541000366
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39834592",
                    "text": "In addition to iPSC reprogramming, pioneer TFs are pivotal in direct reprogramming or transdifferentiation where somatic cells are converted into different cell types without passing through a pluripotent state.",
                    "score_reranked": 0.5237035751342773
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39668101",
                    "text": "Beyond pluripotency: Yamanaka factors drive brain growth and regeneration.",
                    "score_reranked": 0.29353341460227966
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39834592",
                    "text": "The generation of induced pluripotent stem cells (iPSCs) from differentiated somatic cells by Yamanaka factors, including pioneer transcription factors (TFs), has greatly reshaped our traditional understanding of cell plasticity and demonstrated the remarkable potential of pioneer TFs.",
                    "score_reranked": 0.21882429718971252
                }
            ]
        },
        {
            "id": "515aa0abd24251bc050000a8",
            "body": "What is the aim of the Human Chromosome-centric Proteome Project (C-HPP)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                "http://www.ncbi.nlm.nih.gov/pubmed/39793580",
                "http://www.ncbi.nlm.nih.gov/pubmed/36475733",
                "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                "http://www.ncbi.nlm.nih.gov/pubmed/36475733",
                "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                "http://www.ncbi.nlm.nih.gov/pubmed/36351892",
                "http://www.ncbi.nlm.nih.gov/pubmed/40196523"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                    "text": "\u03c0-HuB: the proteomic navigator of the human body.",
                    "score_reranked": 1.4995059967041016
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39793580",
                    "text": "We utilized the latest large-scale plasma proteomic data from the UK Biobank Pharma Proteomics Project (UKB-PPP) and AD genome-wide association study (GWAS) summary data from the International Genomics of Alzheimer's Project (IGAP).",
                    "score_reranked": 1.3862457275390625
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36475733",
                    "text": "The biology/disease initiative, at Human Proteome Project, is an integrative approach to identify relevant proteins in the human proteome associated with pathologies.",
                    "score_reranked": 1.3334813117980957
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                    "text": "The aim of the \u03c0-HuB project is to (1) generate and harness multimodality proteomic datasets to enhance our understanding of human biology; (2) facilitate disease risk assessment and diagnosis; (3) uncover new drug targets; (4) optimize appropriate therapeutic strategies; and (5) enable intelligent healthcare, thereby ushering in a new era of proteomics-driven phronesis medicine.",
                    "score_reranked": 1.3110766410827637
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                    "text": "Understanding the complexities of the proteome in the context of a human organism and its many potential states is a necessary requirement to understanding human biology, but these complexities can neither be predicted from the genome, nor have they been systematically measurable with available technologies.",
                    "score_reranked": 1.2467446327209473
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                    "text": "Here we introduce a big-science endeavour called \u03c0-HuB (proteomic navigator of the human body).",
                    "score_reranked": 0.9221924543380737
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36475733",
                    "text": "Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project.",
                    "score_reranked": 0.8692835569381714
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39663494",
                    "text": "Recent advances in proteomic technology and computational sciences now provide opportunities to investigate the intricate biology of the human body at unprecedented resolution and scale.",
                    "score_reranked": 0.3964294493198395
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36351892",
                    "text": "Comparative serum proteomic analysis of a selected protein panel in individuals with schizophrenia and bipolar disorder and the impact of genetic risk burden on serum proteomic profiles.",
                    "score_reranked": -0.2671770751476288
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40196523",
                    "text": "QuickProt: A bioinformatics and visualization tool for DIA and PRM mass spectrometry-based proteomics datasets.",
                    "score_reranked": -1.0113918781280518
                }
            ]
        },
        {
            "id": "56af9f130a360a5e45000015",
            "body": "Where is the protein Pannexin1 located?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37492223",
                "http://www.ncbi.nlm.nih.gov/pubmed/39990207",
                "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                "http://www.ncbi.nlm.nih.gov/pubmed/24911976",
                "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                "http://www.ncbi.nlm.nih.gov/pubmed/19570022",
                "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                "http://www.ncbi.nlm.nih.gov/pubmed/38897345",
                "http://www.ncbi.nlm.nih.gov/pubmed/37130457",
                "http://www.ncbi.nlm.nih.gov/pubmed/35663270"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37492223",
                    "text": "Pannexin1 proteins form communication channels at the cell plasma membrane surface, which allow the transfer of small molecules and ions between the intracellular compartment and extracellular environment.",
                    "score_reranked": 0.6418501138687134
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39990207",
                    "text": "Pannexin1 (Panx1) is a glycoprotein, ubiquitously expressed throughout vertebrate tissues.",
                    "score_reranked": 0.5282677412033081
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                    "text": "Moreover, the pannexin1-targeting nanobodies were found to block pannexin1 channel-mediated release of adenosine triphosphate.",
                    "score_reranked": -0.301120787858963
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24911976",
                    "text": "The Pannexin-1 (Panx1) channel is known to become activated under a variety of physiological conditions resulting in the release of medium-sized molecules such as ATP and amino acids from the cell.",
                    "score_reranked": -0.41913357377052307
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                    "text": "Pannexin1-targeting nanobodies were developed as potential new pannexin1 channel inhibitors.",
                    "score_reranked": -0.5696367025375366
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19570022",
                    "text": "Our previous studies have shown that the pore-forming P2X7R (P2X7 receptor) contributes to the amplification of ICW spread by providing sites of ATP release through Panx1 (Pannexin1) channels.",
                    "score_reranked": -0.6007099151611328
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37821897",
                    "text": "The pannexin1-targeting nanobodies were also demonstrated to display anti-inflammatory effects in vitro through reduction of interleukin 1 beta amounts.",
                    "score_reranked": -0.7351508140563965
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38897345",
                    "text": "Pannexin-1 (PANX1) is a hemichannel that releases ATP upon opening, initiating inflammation, cell proliferation, and migration.",
                    "score_reranked": -1.013464331626892
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37130457",
                    "text": "Carboxyl terminus of Pannexin-1 plays a crucial role in P2X7 receptor-mediated signaling.",
                    "score_reranked": -1.0762161016464233
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35663270",
                    "text": "Altogether, existing studies indicated that probenecid can alleviate inflammation by blocking Pannexin-1 channels to inhibit the expression of caspase-1 and IL-1\u03b2, which in turn restores the balance of immune cell subsets and exerts neuroprotective effects in rats with SCI.",
                    "score_reranked": -1.0881202220916748
                }
            ]
        },
        {
            "id": "5718bbb37de986d80d00000b",
            "body": "Which currently known mitochondrial diseases have been attributed to POLG mutations?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20818731",
                "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                "http://www.ncbi.nlm.nih.gov/pubmed/35289132",
                "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                "http://www.ncbi.nlm.nih.gov/pubmed/38943319",
                "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                "http://www.ncbi.nlm.nih.gov/pubmed/32502631"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20818731",
                    "text": "The most common group of mitochondrial disease is due to mutations within the mitochondrial DNA polymerase, polymerase gamma 1 (POLG).",
                    "score_reranked": 0.4857201874256134
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                    "text": "Mutations in POLG, the gene encoding the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase gamma (Pol-\u03b3), lead to diseases driven by defective mtDNA maintenance.",
                    "score_reranked": 0.2791194021701813
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35289132",
                    "text": "The POLG gene is the most common disease-causing gene in this group of PEO patients with multiple mtDNA deletions.",
                    "score_reranked": 0.03329238295555115
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                    "text": "As a consequence, POLG mutations can cause disease through impaired replication of mitochondrial DNA.",
                    "score_reranked": -0.2580440938472748
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                    "text": "POLG mutations in Australian patients with mitochondrial disease.",
                    "score_reranked": -0.3255000412464142
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22647225",
                    "text": "The aim of this study was to determine the prevalence of POLG mutations in an adult population of Australian patients with mitochondrial disease, displaying symptoms commonly associated with POLG-related diseases.",
                    "score_reranked": -0.34195438027381897
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38943319",
                    "text": "Mutations in several nuclear-encoded genes (ie, POLG, TWNK, SPG7, and OPA1) and, more rarely, mtDNA mutations, are responsible for mitochondrial parkinsonism.",
                    "score_reranked": -0.5548975467681885
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                    "text": "Despite being the most prevalent cause of mitochondrial disease, treatments for POLG-related disorders remain elusive.",
                    "score_reranked": -0.6591482162475586
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37584631",
                    "text": "In this study, we used POLG patient-induced pluripotent stem cell (iPSC)-derived neural stem cells (iNSCs), one homozygous for the POLG mutation c.2243G>C and one compound heterozygous with c.2243G>C and c.1399G>A, and treated these iNSCs with ethidium bromide (EtBr) to study the rate of depletion and repopulation of mtDNA.",
                    "score_reranked": -1.0518718957901
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32502631",
                    "text": "We conducted a chart review of blood pressure and hemodynamics in patients with either mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS, n\u00a0=\u00a036) or individuals with variants in the mitochondrial DNA polymerase gamma (POLG, n\u00a0=\u00a026).",
                    "score_reranked": -1.7340493202209473
                }
            ]
        },
        {
            "id": "532f062ad6d3ac6a34000027",
            "body": "What is the effect of ivabradine in heart failure after myocardial infarction?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40248252",
                "http://www.ncbi.nlm.nih.gov/pubmed/28423233",
                "http://www.ncbi.nlm.nih.gov/pubmed/22416440",
                "http://www.ncbi.nlm.nih.gov/pubmed/24440004",
                "http://www.ncbi.nlm.nih.gov/pubmed/19514618",
                "http://www.ncbi.nlm.nih.gov/pubmed/25102753",
                "http://www.ncbi.nlm.nih.gov/pubmed/37024594",
                "http://www.ncbi.nlm.nih.gov/pubmed/19720635",
                "http://www.ncbi.nlm.nih.gov/pubmed/37024594",
                "http://www.ncbi.nlm.nih.gov/pubmed/22416440"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40248252",
                    "text": "Efficacy of ivabradine in patients with poor heart rate control after beta-blocker use in acute myocardial infarction: a pragmatic randomized controlled trial.",
                    "score_reranked": 0.7052053213119507
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28423233",
                    "text": "Ivabradine is well tolerated and equally effective as metoprolol in acute inferior wall ST elevation myocardial infarction patients for lowering the heart rate with lesser risk of AV blocks.",
                    "score_reranked": 0.6782251596450806
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416440",
                    "text": "To study effects of ivabradin on clinicohemodynamic and prognostic parameters in patients after myocardial infarction (MI) with systolic chronic cardiac failure (SCCF).",
                    "score_reranked": 0.4784795343875885
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24440004",
                    "text": "Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.",
                    "score_reranked": 0.2692422568798065
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19514618",
                    "text": "[Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].",
                    "score_reranked": 0.22805872559547424
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25102753",
                    "text": "[Ivabradine in acute myocardial infarction].",
                    "score_reranked": 0.03678816556930542
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37024594",
                    "text": "Ivabradine in patients with acute ST-elevation myocardial infarction: a meta-analysis of randomized controlled trials.",
                    "score_reranked": -0.0899871289730072
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19720635",
                    "text": "Ivabradine was associated with a 24% reduction in the primary endpoint (cardiovascular mortality or hospitalization for fatal and non-fatal myocardial infarction [MI] or heart failure) (HR, 0.76; 95% CI, 0.58-1.00) and a 42% reduction in hospitalization for MI (HR, 0.58, 95% CI, 0.37-0.92).",
                    "score_reranked": -0.2061907947063446
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37024594",
                    "text": "However, Ivabradine had no impact on all-cause mortality [OR 0.76; 95%CI 0.35, 1.67], heart failure incidence [OR 0.61; 95%CI 0.21, 1.80], and recurrent angina pectoris",
                    "score_reranked": -0.48676449060440063
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22416440",
                    "text": "Addition of ivabradin to standard treatment of SCCF after MI promoted less frequency of hospitalizations, recurrent non-fatal MI, fatal cardiovascular events.",
                    "score_reranked": -0.941948652267456
                }
            ]
        },
        {
            "id": "52bf1b0a03868f1b06000009",
            "body": "What is the mode of inheritance of Wilson's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                "http://www.ncbi.nlm.nih.gov/pubmed/16932613",
                "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                "http://www.ncbi.nlm.nih.gov/pubmed/16932613",
                "http://www.ncbi.nlm.nih.gov/pubmed/26253413",
                "http://www.ncbi.nlm.nih.gov/pubmed/39267050",
                "http://www.ncbi.nlm.nih.gov/pubmed/39559689",
                "http://www.ncbi.nlm.nih.gov/pubmed/28717664",
                "http://www.ncbi.nlm.nih.gov/pubmed/39267050"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                    "text": "The autosomal recessive mode of inheritance strongly suggests that mutation of a single gene causes the impairment of both caeruloplasmin synthesis and biliary copper excretion.",
                    "score_reranked": 1.2258601188659668
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                    "text": "Is Wilson's disease caused by a controller gene mutation resulting in perpetuation of the fetal mode of copper metabolism into childhood?",
                    "score_reranked": 0.7717605829238892
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16932613",
                    "text": "The disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain.",
                    "score_reranked": 0.7305335998535156
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6109943",
                    "text": "It is suggested that mutation of a controller rather than a structural gene underlies the pathogenesis of Wilson's disease and that the disease results from failure to switch from the positive copper balance of the fetus to the normal copper balance of the child.",
                    "score_reranked": 0.5001661777496338
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16932613",
                    "text": "Wilson's disease (WD) is an inborn error of copper metabolism caused by a mutation to the copper-transporting gene ATP7B.",
                    "score_reranked": 0.318637877702713
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253413",
                    "text": "Wilson's disease (WD) is an autosomal recessive genetic disorder of copper metabolism, caused by mutations in the ATP7B gene, resulting in copper accumulation in the liver, brain, kidney, and cornea and leading to significant disability or death if untreated.",
                    "score_reranked": -0.05981072783470154
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39267050",
                    "text": "Phenotypic and genetic characterization of children with Wilson Disease from Northeast China.",
                    "score_reranked": -0.34681931138038635
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39559689",
                    "text": "Introduction Wilson disease (WD) is a rare inherited autosomal recessive disorder caused by a mutation in the",
                    "score_reranked": -0.6535999774932861
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28717664",
                    "text": "Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by allelic variants in  All Latvian patients with clinically confirmed WD were screened for the most common mutation p.H1069Q",
                    "score_reranked": -0.7698893547058105
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39267050",
                    "text": "Wilson disease (WD) is an autosomal recessive inherited disease caused by ATP7B variants and characterized by copper metabolism defects.",
                    "score_reranked": -1.2894184589385986
                }
            ]
        },
        {
            "id": "517395b98ed59a060a00001a",
            "body": "Are transcription and splicing connected?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38773325",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                "http://www.ncbi.nlm.nih.gov/pubmed/40287942",
                "http://www.ncbi.nlm.nih.gov/pubmed/39968360",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                "http://www.ncbi.nlm.nih.gov/pubmed/38762032",
                "http://www.ncbi.nlm.nih.gov/pubmed/39131822",
                "http://www.ncbi.nlm.nih.gov/pubmed/38762032"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38773325",
                    "text": "In the second part, we focus on the spatial connection between splicing regulation and nuclear MLOs such as transcriptional condensates, splicing condensates and nuclear speckles.",
                    "score_reranked": 1.6759430170059204
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                    "text": "Overall, our findings unveil the intricate regulatory landscape of hybrid exons and reveal stronger connections between transcription initiation and RNA splicing than previously acknowledged.",
                    "score_reranked": 1.5340914726257324
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40287942",
                    "text": "TAF2 condensation in nuclear speckles links basal transcription factor TFIID to RNA splicing factors.",
                    "score_reranked": 1.2205238342285156
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39968360",
                    "text": "Further analysis using transcription factor databases and ChIP-seq data identified ETS1 as a key regulator of splicing factor expression.",
                    "score_reranked": 1.155824899673462
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                    "text": "Here, we employ an interpretable deep learning pipeline to dissect the sequence features governing the co-regulation of transcription initiation and splicing in hybrid exons.",
                    "score_reranked": 1.1296030282974243
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                    "text": "Interestingly, transcription start sites of hybrid exons are typically centered at the 3' splice site, suggesting tight coupling between splicing and transcription initiation.",
                    "score_reranked": 1.071889877319336
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39739742",
                    "text": "Hybrid exons evolved by coupling transcription initiation and splicing at the nucleotide level.",
                    "score_reranked": 0.8719092607498169
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38762032",
                    "text": "In the context of RNA splicing, early evidence suggested a loose connection between the chromatin landscape and splicing.",
                    "score_reranked": -0.033840298652648926
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39131822",
                    "text": "Alternative splicing (AS) is emerging as an important regulatory process for complex biological processes.",
                    "score_reranked": -0.12350627779960632
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38762032",
                    "text": "More recently, it has been shown that splicing occurs in a co-transcriptional manner, meaning that the splicing process occurs in the context of chromatin.",
                    "score_reranked": -0.40146416425704956
                }
            ]
        },
        {
            "id": "52bf19c503868f1b06000001",
            "body": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21567298",
                "http://www.ncbi.nlm.nih.gov/pubmed/22551571",
                "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
                "http://www.ncbi.nlm.nih.gov/pubmed/33776777",
                "http://www.ncbi.nlm.nih.gov/pubmed/12561087",
                "http://www.ncbi.nlm.nih.gov/pubmed/17986494",
                "http://www.ncbi.nlm.nih.gov/pubmed/12561087",
                "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
                "http://www.ncbi.nlm.nih.gov/pubmed/28915324",
                "http://www.ncbi.nlm.nih.gov/pubmed/21567298"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298",
                    "text": "The classic phenotype of the facioscapulohumeral muscular dystrophy (FSHD) includes an initially restricted pattern of asymmetric weakness of facial and shoulder girdle muscles.",
                    "score_reranked": 2.2574400901794434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22551571",
                    "text": "Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disease, characterized by an autosomal dominant mode of inheritance, facial involvement, and selectivity and asymmetry of muscle involvement.",
                    "score_reranked": 2.1764609813690186
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23143600",
                    "text": "Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2.",
                    "score_reranked": 1.680092215538025
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33776777",
                    "text": "Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disorder characterized by progressive, asymmetric muscle weakness at the face, shoulders, and upper limbs, which spreads to the lower body with age.",
                    "score_reranked": 1.2522212266921997
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12561087",
                    "text": "[An ambiguous pedigree of facioscapulohumeral muscular dystrophy which showed double EcoRI/BlnI resistant short fragments].",
                    "score_reranked": 1.0728312730789185
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17986494",
                    "text": "Facioscapulohumeral dystrophy (FSHD) is the third most common inherited muscular dystrophy after Duchenne dystrophy and myotonic dystrophy.",
                    "score_reranked": 0.9251445531845093
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12561087",
                    "text": "We report a facioscapulohumeral muscular dystrophy (FSHD) pedigree having double short (25 kb and 33 kb)",
                    "score_reranked": 0.6104996204376221
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34559225",
                    "text": "Facioscapulohumeral muscular dystrophy (FSHD) is an inherited myopathy clinically characterized by weakness in the facial, shoulder girdle and upper a muscles.",
                    "score_reranked": 0.41557934880256653
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28915324",
                    "text": "While typically inherited as autosomal dominant, facioscapulohumeral muscular dystrophy (FSHD) has a complex genetic and epigenetic etiology that has only recently been well described.",
                    "score_reranked": -0.16471335291862488
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567298",
                    "text": "[Facioscapulohumeral muscular dystrophy. Clinical picture, atypical forms, diagnostics, genetics].",
                    "score_reranked": -0.23358026146888733
                }
            ]
        },
        {
            "id": "54db1d580f63c58e6e000005",
            "body": "Is Alu hypomethylation associated with breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                "http://www.ncbi.nlm.nih.gov/pubmed/36340456",
                "http://www.ncbi.nlm.nih.gov/pubmed/23513484",
                "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                "http://www.ncbi.nlm.nih.gov/pubmed/36340456",
                "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                "http://www.ncbi.nlm.nih.gov/pubmed/24971511"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                    "text": "Alu and LINE-1 hypomethylation is associated with HER2 enriched subtype of breast cancer.",
                    "score_reranked": 1.9679911136627197
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36340456",
                    "text": "Breast Cancer Sera Changes in Alu Element Methylation Predict Metastatic Disease Progression.",
                    "score_reranked": 1.1221776008605957
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23513484",
                    "text": "[Utility of chromosome banding with ALU I enzyme for identifying methylated areas in breast cancer].",
                    "score_reranked": 0.8526883125305176
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                    "text": "In the current study, DNA methylation levels of LINE-1 and Alu repeats were analyzed in tumoral tissues of invasive breast cancer in a Tunisian cohort and its association with the clinicopathological features of patients was defined.",
                    "score_reranked": 0.5279691219329834
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                    "text": "This study was designed to evaluate the changes of Alu and LINE-1 hypomethylation during breast cancer progression from normal to pre-invasive lesions and invasive breast cancer (IBC), and their relationship with characteristics of IBC.",
                    "score_reranked": 0.3214193880558014
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36340456",
                    "text": "These warrant the use of Alu element methylation changes for diagnostic and therapeutic purposes in breast cancer.",
                    "score_reranked": 0.20450535416603088
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                    "text": "To the best of our knowledge, the current study is the first study regarding DNA methylation of LINE-1 and Alu repeats element in breast cancer of the Tunisian population.",
                    "score_reranked": 0.17025044560432434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32724446",
                    "text": "DNA methylation of LINE-1 and Alu repeats were analyzed using pyrosequencing in 61 invasive breast cancers.",
                    "score_reranked": -0.3790213465690613
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                    "text": "Alu and LINE-1 methylation status was significantly different between breast cancer subtypes, and the HER2 enriched subtype had lowest methylation levels.",
                    "score_reranked": -0.4670813977718353
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24971511",
                    "text": "Alu methylation showed no significant changes during multistep progression of breast cancer, although it tended to decrease during the transition from DCIS to IBC.",
                    "score_reranked": -0.5621459484100342
                }
            ]
        },
        {
            "id": "54f9d3eedd3fc62544000004",
            "body": "Which proteins participate in the formation of the ryanodine receptor quaternary macromolecular complex?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9287354",
                "http://www.ncbi.nlm.nih.gov/pubmed/15731387",
                "http://www.ncbi.nlm.nih.gov/pubmed/36189802",
                "http://www.ncbi.nlm.nih.gov/pubmed/15276012",
                "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                "http://www.ncbi.nlm.nih.gov/pubmed/15276012",
                "http://www.ncbi.nlm.nih.gov/pubmed/9287354",
                "http://www.ncbi.nlm.nih.gov/pubmed/12871170",
                "http://www.ncbi.nlm.nih.gov/pubmed/15731387",
                "http://www.ncbi.nlm.nih.gov/pubmed/25470059"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9287354",
                    "text": "Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane.",
                    "score_reranked": 2.6543350219726562
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15731387",
                    "text": "Calsequestrin, the major calcium sequestering protein in the sarcoplasmic reticulum of muscle, forms a quaternary complex with the ryanodine receptor calcium release channel and the intrinsic membrane proteins triadin and junctin.",
                    "score_reranked": 2.392103433609009
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36189802",
                    "text": "Clusters of ryanodine receptor calcium channels (RyRs) form the primary molecular machinery of intracellular calcium signalling in cardiomyocytes.",
                    "score_reranked": 2.1671085357666016
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15276012",
                    "text": "The RyR is also the center of a massive macromolecular complex which includes numerous regulatory proteins which can modulate RyR function.",
                    "score_reranked": 1.8424110412597656
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                    "text": "Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle.",
                    "score_reranked": 1.4664961099624634
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15276012",
                    "text": "Macromolecular complexes regulating cardiac ryanodine receptor function.",
                    "score_reranked": 1.2382677793502808
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9287354",
                    "text": "Taken together, these results suggest that junctin, calsequestrin, triadin, and the ryanodine receptor form a quaternary complex that may be required for normal operation of Ca2+ release.",
                    "score_reranked": 1.1458858251571655
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12871170",
                    "text": "The 565 kDa RyR protein forms a tetrameric channel that is part of a macromolecular signaling complex that also includes four FK506 binding proteins (FKBPs).",
                    "score_reranked": 0.3803183138370514
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15731387",
                    "text": "These data suggest that the quaternary complex is intact in vivo, and provides further evidence that calsequestrin is involved in the sarcoplasmic reticulum calcium signaling pathway and has a role as a luminal calcium sensor for the ryanodine receptor.",
                    "score_reranked": 0.1598081886768341
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25470059",
                    "text": "We show that the cytoplasmic moiety of RyR1 contains two large \u03b1-solenoid domains and several smaller domains, with folds suggestive of participation in protein-protein interactions.",
                    "score_reranked": -0.22721049189567566
                }
            ]
        },
        {
            "id": "5505edac8e1671127b000005",
            "body": "What kind of chromatography is HILIC?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17920606",
                "http://www.ncbi.nlm.nih.gov/pubmed/40311268",
                "http://www.ncbi.nlm.nih.gov/pubmed/39876571",
                "http://www.ncbi.nlm.nih.gov/pubmed/39613506",
                "http://www.ncbi.nlm.nih.gov/pubmed/39611213",
                "http://www.ncbi.nlm.nih.gov/pubmed/40142102",
                "http://www.ncbi.nlm.nih.gov/pubmed/39972614",
                "http://www.ncbi.nlm.nih.gov/pubmed/39969575",
                "http://www.ncbi.nlm.nih.gov/pubmed/40028593",
                "http://www.ncbi.nlm.nih.gov/pubmed/40028593"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17920606",
                    "text": "This is a kind of on-line, two-dimensional (2D) separation approach in hydrophilic-interaction chromatography (called the 2D-HILIC method), analogous to that of coupling cation- (or anion-, or mixed ion-) exchange and reversed-phase columns in hydrophobic interaction (reversed-phase) chromatography.",
                    "score_reranked": 1.281878113746643
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40311268",
                    "text": "We investigated the contribution of nucleotide (nt) type and modifications on the retention and resolution of 22-24 nt long oligonucleotides in ion-pairing reversed-phase (IP RP) liquid chromatography (LC) and hydrophilic interaction chromatography (HILIC) methods.",
                    "score_reranked": 1.0738221406936646
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39876571",
                    "text": "Consequently, there is a growing interest in exploring alternative strategies with hydrophilic interaction chromatography (HILIC) emerging as one of the most promising options.",
                    "score_reranked": 0.9073177576065063
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39613506",
                    "text": "Hydrophilic Interaction Liquid Chromatography (HILIC) and Mixed-Mode Chromatography (MMC) excel in separating polar, hydrophilic, and charged analytes due to unique hydrophilic or mixed-mode retention mechanisms.",
                    "score_reranked": 0.8149127960205078
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39611213",
                    "text": "Recently, hydrophilic interaction chromatography (HILIC) has been proposed as a reasonable alternative to ion-pair reversed phase separations of oligonucleotides prior to MS.",
                    "score_reranked": 0.6891858577728271
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40142102",
                    "text": "This study examines the influence of ionic strength and organic modifier selection on the separation of fluorescently labeled dextran ladders in Hydrophilic Interaction Liquid Chromatography (HILIC).",
                    "score_reranked": 0.2551913559436798
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39972614",
                    "text": "From Reverse Phase Chromatography to HILIC: Graph Transformers Power Method-Independent Machine Learning of Retention Times.",
                    "score_reranked": 0.189019113779068
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39969575",
                    "text": "Carbon quantum dots (CQDs) were synthesized from brominated 1-hexadecyl-3-vinylimidazolium and citric acid, and a mixed-mode chromatographic (MMC) stationary phase, which can be used in the RPLC/HILIC/IEC chromatographic modes with a good separation efficiency, was successfully synthesized by click-chemistry bonding to a sulfhydryl-modified silica surface.",
                    "score_reranked": -0.20411905646324158
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40028593",
                    "text": "HILIC can be an obvious choice, but C18 is still used with suitable analytes.",
                    "score_reranked": -0.26748016476631165
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40028593",
                    "text": "In this paper, nine columns with different stationary phases, from reversed-phase to hydrophilic interaction, are compared and ranked in gradient elution.",
                    "score_reranked": -0.382276326417923
                }
            ]
        },
        {
            "id": "5160193d298dcd4e51000039",
            "body": "What is the effect of TRH on myocardial contractility?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1979356",
                "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                "http://www.ncbi.nlm.nih.gov/pubmed/21158078",
                "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                "http://www.ncbi.nlm.nih.gov/pubmed/9159025",
                "http://www.ncbi.nlm.nih.gov/pubmed/21158078"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1979356",
                    "text": "Thyrotropin-releasing hormone (TRH) could improve mean arterial pressure (MAP), myocardial contractile parameters (+/- dp/dtmax, Vpm and Vmax) and increase plasma epinephrine level significantly at 10 min after TRH administration in hemorrhagic shock rabbits, but the action of TRH on MAP and the myocardial contractility did not appear in rabbits pre-treated with reserpine (4 mg/kg, 24 h pre-treatment, i.v.).",
                    "score_reranked": 1.6635217666625977
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                    "text": "TRH in the range of 0.1-10 mumol/l was found to exert a positive inotropic effect on cardiac contractility, which however qualitatively differed at lower vs. higher concentrations of the hormone: at 1 mumol/l, TRH was found to significantly enhance the rate of contraction as well as that of relaxation (by 23.2 +/- 3.7 and 27.8 +/- 7.7%, respectively), which culminated in an increased peak contractile force.",
                    "score_reranked": 1.333728313446045
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                    "text": "The inotropic effect of the physiological level of TRH on isolated guinea pig cardiac muscle was studied using a force transducer and standard microelectrode techniques.",
                    "score_reranked": 1.2912092208862305
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                    "text": "The effects of thyrotropin releasing hormone (TRH) on the contractility of electrically stimulated and perfused isolated rat hearts were investigated.",
                    "score_reranked": 1.1910902261734009
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                    "text": "The positive inotropic effect of TRH was associated with an augmentation of slow action potentials in high K+ solution and was reduced in the presence of diltiazem, verapamil, and manganese.",
                    "score_reranked": 0.930391788482666
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2848686",
                    "text": "TRH increased the contractile force even in the myocardium of reserpinized guinea pig.",
                    "score_reranked": 0.8696534633636475
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21158078",
                    "text": "[Effects and mechanism of hypothalamic TRH on cardiac function in rats].",
                    "score_reranked": 0.8315792083740234
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9088928",
                    "text": "However, at 10 mumol/l, the positive inotropic effect of TRH (i.e. the increase in peak contractile force) was smaller than at 1 mumol/l, which apparently was due to both a reduced TRH-induced elevation in the rate of contraction (12.4 +/- 3.2%) and a TRH-induced decrease in relaxation rate (11.1 +/- 8.1%).",
                    "score_reranked": 0.34717538952827454
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9159025",
                    "text": "Cardiac contractility was stimulated after intracoronary administration of TRH.",
                    "score_reranked": 0.19242772459983826
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21158078",
                    "text": "(1) Hypothalamic TRH can produce positive inotropic and chronotropic response to myocardium.",
                    "score_reranked": -0.33852729201316833
                }
            ]
        },
        {
            "id": "51593dc8d24251bc05000099",
            "body": "Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                "http://www.ncbi.nlm.nih.gov/pubmed/20363779",
                "http://www.ncbi.nlm.nih.gov/pubmed/20363779",
                "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                "http://www.ncbi.nlm.nih.gov/pubmed/27016195",
                "http://www.ncbi.nlm.nih.gov/pubmed/27412985",
                "http://www.ncbi.nlm.nih.gov/pubmed/34325393",
                "http://www.ncbi.nlm.nih.gov/pubmed/19714879",
                "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                "http://www.ncbi.nlm.nih.gov/pubmed/19714879"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                    "text": "Here, for the first time, we report the comparative transcriptomic and proteomic study of Arthrobacter cells to elucidate the higher productivity of cAMP under high oxygen supply.",
                    "score_reranked": 1.9823997020721436
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20363779",
                    "text": "Bioinformatic tools that provide bacterial classification were used to evaluate the proteomic approach.",
                    "score_reranked": 0.14461210370063782
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20363779",
                    "text": "Double-blind characterization of non-genome-sequenced bacteria by mass spectrometry-based proteomics.",
                    "score_reranked": 0.05996277928352356
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                    "text": "We finally obtained 14.1% and 19.3% of the Arthrobacter genome genes which were up-regulated and down-regulated notably, respectively, with high oxygen supply, and identified 54 differently expressed proteins.",
                    "score_reranked": -0.04227516055107117
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27016195",
                    "text": "Whole genome phylogeny as well as whole proteome comparisons using all available complete genomes in Thermococcales clearly showed that the species belongs to the Pyrococcus genus.",
                    "score_reranked": -0.13297030329704285
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27412985",
                    "text": "Genomic comparison of the Thermus sp. NMX2.A1 and T. scotoductus SA-01, as well as other closely related Thermus strains, revealed a high degree of synteny at both the genomic and proteomic level, with processes such as denitrification and natural cell competence appearing to be conserved.",
                    "score_reranked": -0.3236980140209198
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34325393",
                    "text": "Biodegradation of isoprene by Arthrobacter sp. strain BHU FT2: Genomics-proteomics enabled novel insights.",
                    "score_reranked": -0.7538241147994995
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19714879",
                    "text": "A label-free workflow employing spectral counting identified 3749 proteins across all growth conditions, representing over 70% of the predicted genome and 739 of these proteins form the core proteome.",
                    "score_reranked": -0.7942988872528076
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29352122",
                    "text": "Comparative transcriptomic and proteomic analysis of Arthrobacter sp. CGMCC 3584 responding to dissolved oxygen for cAMP production.",
                    "score_reranked": -1.2831735610961914
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19714879",
                    "text": "We compared the Arthrobacter chlorophenolicus proteome during growth on 4-chlorophenol, 4-nitrophenol, or phenol at 5 and 28 degrees C, both for the wild-type and a mutant strain with mass spectrometry based proteomics.",
                    "score_reranked": -3.4563260078430176
                }
            ]
        },
        {
            "id": "56e2cec751531f7e33000015",
            "body": "What is the structural fold of bromodomain proteins?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                "http://www.ncbi.nlm.nih.gov/pubmed/39572658",
                "http://www.ncbi.nlm.nih.gov/pubmed/29902720",
                "http://www.ncbi.nlm.nih.gov/pubmed/37967462",
                "http://www.ncbi.nlm.nih.gov/pubmed/32787145",
                "http://www.ncbi.nlm.nih.gov/pubmed/33138352",
                "http://www.ncbi.nlm.nih.gov/pubmed/30385738",
                "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                "http://www.ncbi.nlm.nih.gov/pubmed/17848202"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                    "text": "Although the overall fold resembles the bromodomains from other proteins, significant differences can be found in loop regions, especially in the ZA loop in which a two amino acids insertion is involved in an uncommon pi-helix, termed piD. The helix piD forms a portion of the acetyl-lysine binding site, which could be a structural characteristic of Brd2 BD2 and other BET bromodomains.",
                    "score_reranked": 1.4794793128967285
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                    "text": "Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.",
                    "score_reranked": 0.4852786958217621
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39572658",
                    "text": "Here, we summarize the different families of KATs and BrDs, discuss their functions and structures, and highlight key advances in the design and development of chemical agents that show promise in blocking the action of these chromatin proteins for disease treatment.",
                    "score_reranked": 0.33430221676826477
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29902720",
                    "text": "Structure-based discovery of selective BRPF1 bromodomain inhibitors.",
                    "score_reranked": 0.32917508482933044
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37967462",
                    "text": "Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.",
                    "score_reranked": 0.202871173620224
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32787145",
                    "text": "The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains.",
                    "score_reranked": 0.03915068507194519
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33138352",
                    "text": "To support the bromodomain inhibitor discovery process, here we report the first application of protein-observed fluorine (PrOF) NMR to the tandem bromodomains of BRD4 and BRDT to quantify the selectivity of their interactions with acetylated histones as well as small molecules.",
                    "score_reranked": -0.016713589429855347
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30385738",
                    "text": "Among them, compound BDF-1253 showed an approximately four-fold improvement in BRD4 inhibition compared with the prototype Nitroxoline and had good selectivity for BET proteins against other bromodomain proteins or epi-enzymes in biochemical assays.",
                    "score_reranked": -0.46635565161705017
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                    "text": "Although the crystal structure of Brd2 BD1 is reported, no structure features have been characterized for Brd2 BD2 and its interaction with acetylated histones.",
                    "score_reranked": -0.49942341446876526
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848202",
                    "text": "The structure basis of Brd2 BD2 will help to further characterize the functions of Brd2 and its BET members.",
                    "score_reranked": -0.5806738138198853
                }
            ]
        },
        {
            "id": "515deafd298dcd4e51000025",
            "body": "List the endoscopic diagnoses that have been reported in children with autism",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22607127",
                "http://www.ncbi.nlm.nih.gov/pubmed/38619780",
                "http://www.ncbi.nlm.nih.gov/pubmed/38619780",
                "http://www.ncbi.nlm.nih.gov/pubmed/22607127",
                "http://www.ncbi.nlm.nih.gov/pubmed/32404744",
                "http://www.ncbi.nlm.nih.gov/pubmed/37722553",
                "http://www.ncbi.nlm.nih.gov/pubmed/37722553",
                "http://www.ncbi.nlm.nih.gov/pubmed/11694674",
                "http://www.ncbi.nlm.nih.gov/pubmed/23776121",
                "http://www.ncbi.nlm.nih.gov/pubmed/11694674"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22607127",
                    "text": "We report our experience with three cases of autistic children we recently treated for esophageal achalasia.",
                    "score_reranked": 0.47897955775260925
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38619780",
                    "text": "Characterization of Initial Gastrointestinal Evaluation of Children with Autism Spectrum Disorder: A Descriptive Study.",
                    "score_reranked": 0.021627873182296753
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38619780",
                    "text": "In this retrospective, descriptive study, we identified 131 patients with diagnosis of autism spectrum disorder who presented for initial evaluation by pediatric gastroenterology at the Baystate Children's Specialty Center.",
                    "score_reranked": 0.01690700650215149
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22607127",
                    "text": "Autism and esophageal achalasia in childhood: a possible correlation? Report on three cases.",
                    "score_reranked": -0.17891284823417664
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32404744",
                    "text": "We report 3 patients with RFBI: a 16-year-old, African American boy with 22 admissions and 27 endoscopic procedures for FBI removal; a 4-year-old, African American boy with autism spectrum disorder admitted twice after delayed presentation of ingestion of magnets; and a 15-year-old Caucasian girl with a complex mental health history who presented twice after intentional ingestion to self-harm.",
                    "score_reranked": -0.36170169711112976
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37722553",
                    "text": "Comparing Gastrointestinal Endoscopy Findings in Children with Autism, Developmental Delay, or Typical Development.",
                    "score_reranked": -0.39174461364746094
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37722553",
                    "text": "To compare endoscopic and histologic upper endoscopy (esophagogastroduodenoscopy [EGD]) findings in children with autism spectrum disorders (ASD) to age- and gender-matched controls with developmental delay (DD) or with typical development (TD).",
                    "score_reranked": -0.46843358874320984
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11694674",
                    "text": "A recently published case series describes 3 autistic children with gastrointestinal symptoms who underwent endoscopy and intravenous administration of secretin and were subsequently noted by their parents to demonstrate improved language skills over a 5-week period.",
                    "score_reranked": -1.1731348037719727
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776121",
                    "text": "We identified patients ages 2 to 21 years with an International Classification of Diseases, Ninth Revision code of autism (299.0) seen from 2000 to 2011 at a major academic health center by using a research patient data repository and determined rates of specialty provider visits and procedures by race.",
                    "score_reranked": -1.3982014656066895
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11694674",
                    "text": "Inclusion criteria for study participation included age (3-6 years), confirmed diagnosis of autism, and reported gastrointestinal symptoms (16 had chronic diarrhea, 2 had gastroesophageal reflux, and 2 had chronic constipation).",
                    "score_reranked": -1.5172213315963745
                }
            ]
        },
        {
            "id": "532624ae600967d132000005",
            "body": "What are the outcomes of Renal sympathetic denervation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38588936",
                "http://www.ncbi.nlm.nih.gov/pubmed/36991064",
                "http://www.ncbi.nlm.nih.gov/pubmed/39493034",
                "http://www.ncbi.nlm.nih.gov/pubmed/39493034",
                "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                "http://www.ncbi.nlm.nih.gov/pubmed/40177507",
                "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                "http://www.ncbi.nlm.nih.gov/pubmed/37804153",
                "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                "http://www.ncbi.nlm.nih.gov/pubmed/38046011"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38588936",
                    "text": "Recently, catheter-based percutaneous renal denervation emerged as a method for ablating renal sympathetic nerves for difficult-to-control hypertension.",
                    "score_reranked": 1.817600965499878
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36991064",
                    "text": "Whether the ablation site is sympathetic dominant or parasympathetic dominant, and afferent dominant or efferent dominant, would in turn determine the final output of renal denervation.",
                    "score_reranked": 1.4697151184082031
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39493034",
                    "text": "The study aims to compare the outcomes of different renal denervation (RDN) procedures in the treatment of uncontrolled hypertension.",
                    "score_reranked": 0.9796816110610962
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39493034",
                    "text": "Comparing the Efficacy of Renal Artery Denervation in Uncontrolled Hypertension: A Systematic Review and Network Meta-Analysis.",
                    "score_reranked": 0.8767868280410767
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                    "text": "Renal denervation is a recognized adjunct therapy for hypertension with clinically significant blood pressure (BP)-lowering effects.",
                    "score_reranked": 0.5926659107208252
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40177507",
                    "text": "Efficacy and safety of renal denervation therapy in hypertension: a meta-analysis.",
                    "score_reranked": 0.40886738896369934
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                    "text": "We sought to analyze study-level data and quantify the ambulatory BP reduction of renal denervation across contemporary randomized sham-controlled trials and available long-term follow-up data up to 10 years from observational studies.",
                    "score_reranked": 0.28786006569862366
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37804153",
                    "text": "Long-term efficacy and safety of renal denervation: an update from registries and randomised trials.",
                    "score_reranked": 0.1714554727077484
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38506059",
                    "text": "Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis.",
                    "score_reranked": 0.07678338885307312
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38046011",
                    "text": "Following second-generation randomized trials, there is evidence that renal denervation (RDN) decreases blood pressure (BP), although to a lesser extent than suggested in the initial controlled and observational studies.",
                    "score_reranked": -0.29764243960380554
                }
            ]
        },
        {
            "id": "5518e7da622b194345000004",
            "body": "Which MAP kinase phosphorylates the transcription factor c-jun?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39930412",
                "http://www.ncbi.nlm.nih.gov/pubmed/39607740",
                "http://www.ncbi.nlm.nih.gov/pubmed/40368139",
                "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                "http://www.ncbi.nlm.nih.gov/pubmed/39596517",
                "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                "http://www.ncbi.nlm.nih.gov/pubmed/39596517",
                "http://www.ncbi.nlm.nih.gov/pubmed/39930412",
                "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                "http://www.ncbi.nlm.nih.gov/pubmed/40120870"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39930412",
                    "text": "Transcription factor XBP1s promotes endometritis-induced epithelial-mesenchymal transition by targeting MAP3K2, a key gene in the MAPK/ERK pathway.",
                    "score_reranked": 1.8227131366729736
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39607740",
                    "text": "Mitogen-activated protein kinase (MAPK) phosphatases (MKPs) constitute members of the dual-specificity family of protein phosphatases that dephosphorylate the MAPKs.",
                    "score_reranked": 1.7692809104919434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40368139",
                    "text": "A pivotal finding is the parasite's manipulation of the MAPK pathway via sustained ERK1/2 activation, which regulates the phosphorylation of critical transcription factors like RUNX3, FOSL2, BCL6, c-JUN, JUNB, and c-MYC.",
                    "score_reranked": 1.0114555358886719
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                    "text": "Western blotting analysis of the phosphorylation of signaling factors revealed that IL-1\u03b1 significantly stimulated the phosphorylation of ERK1/2, RSK, JNK, p38, MSK1, NFkB, c-Jun, ATF-2, CREB, and STAT3.",
                    "score_reranked": 0.8380377292633057
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596517",
                    "text": "Probenecid Inhibits Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase Mitogen-Activated Protein Kinase Pathways in Regulating Respiratory Syncytial Virus Response.",
                    "score_reranked": 0.7957262992858887
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                    "text": "Analysis using various signaling inhibitors demonstrated that inhibiting ERK and JNK but not p38, MSK1, NFkB, or STAT3 significantly abrogated the IL-1\u03b1 stimulated expression of neprilysin at the mRNA, protein, and enzyme activity levels.",
                    "score_reranked": 0.6811392307281494
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39596517",
                    "text": "The probenecid inhibition of JNK and ERK phosphorylation involves the MAPK pathway that precludes virus replication.",
                    "score_reranked": 0.6509948968887329
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39930412",
                    "text": "and MAP3K2 significantly promoted phosphorylation of p38 and ERK, activating the MAPK/ERK pathway.",
                    "score_reranked": 0.373131662607193
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39482861",
                    "text": "The interleukin-1\u03b1 stimulated expression of the wrinkle-inducing elastase neprilysin in adult human dermal fibroblasts is mediated via the intracellular signaling axis of ERK/JNK/c-Jun/c-Fos/AP-1.",
                    "score_reranked": 0.3639196455478668
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40120870",
                    "text": "Moreover, we discovered that TF and TFRC might regulate cellular oxidative phosphorylation via the JNK signaling pathway.",
                    "score_reranked": 0.3196277320384979
                }
            ]
        },
        {
            "id": "530a5117970c65fa6b000007",
            "body": "What is the meaning of the acronym \"TAILS\" used in protein N-terminomics?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                "http://www.ncbi.nlm.nih.gov/pubmed/39540736",
                "http://www.ncbi.nlm.nih.gov/pubmed/34666940",
                "http://www.ncbi.nlm.nih.gov/pubmed/34713496",
                "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                "http://www.ncbi.nlm.nih.gov/pubmed/40318628",
                "http://www.ncbi.nlm.nih.gov/pubmed/39540736",
                "http://www.ncbi.nlm.nih.gov/pubmed/8484021",
                "http://www.ncbi.nlm.nih.gov/pubmed/39896498"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                    "text": "Here, we report the results of the MS characterization of the peptides and proteins harvested by the EVA technology applied to three letters written in 1457 and 1475 by the voivode of Wallachia, Vlad III, also known as Vlad the Impaler, or Vlad Dracula.",
                    "score_reranked": 2.6864964962005615
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                    "text": "In addition, the identification of many human peptides and proteins harvested from the letters allowed us to uncover more about Vlad Dracula the Impaler.",
                    "score_reranked": 2.3312149047851562
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540736",
                    "text": "Previous methods mainly focused on protein sequence features, overlooking the semantic meaning of protein labels.",
                    "score_reranked": 1.9624946117401123
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34666940",
                    "text": "We have named this subclass of protein hormones caudamins, from the Latin word cauda meaning 'tail'.",
                    "score_reranked": 1.874114751815796
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34713496",
                    "text": "On the contrary, the truncated form of the mitoribosome exit tunnel protein uL24 (N) yields a partially functional mitoribosome.",
                    "score_reranked": 1.5814698934555054
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37552208",
                    "text": "The data have been deposited to the ProteomeXchange with the identifier \u27e8PXD041350\u27e9.",
                    "score_reranked": 1.3642960786819458
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40318628",
                    "text": "Furthermore, we identified two distinct tail conformations in the mature podophage N4.",
                    "score_reranked": 0.945296049118042
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39540736",
                    "text": "Assigning accurate property labels to proteins, like functional terms and catalytic activity, is challenging, especially for proteins without homologs and \"tail labels\" with few known examples.",
                    "score_reranked": 0.6393674612045288
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8484021",
                    "text": "In order to overcome many of the problems arising from current nomenclature, a standardised classification scheme for peptidic messengers is proposed which utilises an alphanumeric code string analogous to EC enzyme classification to convey information on origin, chemistry and relatedness to other similar molecules.",
                    "score_reranked": 0.08095553517341614
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39896498",
                    "text": "Next, we focus on the H2B tail, one of the least studied tails.",
                    "score_reranked": 0.04809346795082092
                }
            ]
        },
        {
            "id": "56bf365eef6e39474100000e",
            "body": "Do mutations of AKT1 occur in meningiomas?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26826201",
                "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
                "http://www.ncbi.nlm.nih.gov/pubmed/27550858",
                "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
                "http://www.ncbi.nlm.nih.gov/pubmed/26826201",
                "http://www.ncbi.nlm.nih.gov/pubmed/27624470",
                "http://www.ncbi.nlm.nih.gov/pubmed/28482067",
                "http://www.ncbi.nlm.nih.gov/pubmed/28482067",
                "http://www.ncbi.nlm.nih.gov/pubmed/28082415",
                "http://www.ncbi.nlm.nih.gov/pubmed/28482067"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26826201",
                    "text": "Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.",
                    "score_reranked": 1.4887937307357788
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
                    "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas.",
                    "score_reranked": 1.4063830375671387
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27550858",
                    "text": "Cranial hyperostosis and meningiomas are common in patients with Proteus syndrome, which is caused by a somatic activating mutation in AKT1 c.49G>A.",
                    "score_reranked": 1.236728549003601
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
                    "text": "AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors.",
                    "score_reranked": 1.2326793670654297
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26826201",
                    "text": "Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients.",
                    "score_reranked": 0.6570630073547363
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27624470",
                    "text": "Clinicopathologically, tumors with mutations in TRAF7/AKT1 and SMO shared specific features: they were located in the anterior fossa, median middle fossa, or anterior calvarium, and most of them were meningothelial or transitional meningiomas.",
                    "score_reranked": 0.6450271606445312
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28482067",
                    "text": "AKT1E17K mutation is frequent in skull base meningiomas, results in activation of the mTOR and ERK1/2 signaling pathways, and has negative impact on tumor recurrence.",
                    "score_reranked": 0.5205169916152954
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28482067",
                    "text": "Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.",
                    "score_reranked": 0.49081531167030334
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28082415",
                    "text": "Meningiomas in the SMO-mutant group had an overall 36% recurrence rate, significantly higher than in the AKT1-mutant group (16%) and in the \"SMO and AKT1 wildtype\" group (11%) (\u03c72 test, P = .04).",
                    "score_reranked": 0.4422430098056793
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28482067",
                    "text": "Patients with skull base meningiomas with AKT1E17K mutation might benefit from additional treatment targeting the mTOR pathway.",
                    "score_reranked": -0.02278074622154236
                }
            ]
        },
        {
            "id": "52bf202003868f1b06000018",
            "body": "What are the main indications of lacosamide?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37647825",
                "http://www.ncbi.nlm.nih.gov/pubmed/29053136",
                "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                "http://www.ncbi.nlm.nih.gov/pubmed/35397759",
                "http://www.ncbi.nlm.nih.gov/pubmed/37582688",
                "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                "http://www.ncbi.nlm.nih.gov/pubmed/20687785",
                "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                "http://www.ncbi.nlm.nih.gov/pubmed/26916326"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37647825",
                    "text": "The use of newer second-line ASMs (levetiracetam and lacosamide) was frequent in our study population.",
                    "score_reranked": 0.2565425932407379
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29053136",
                    "text": "[Lacosamide (vimpat). Prospects for clinical application].",
                    "score_reranked": 0.1393463909626007
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                    "text": "This retrospective cohort study was conducted to gain insight into the use of lacosamide in a large number of patients with epilepsy in real-life clinical practice with less restrictive selection criteria compared with clinical trial participants.",
                    "score_reranked": -0.03149792551994324
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                    "text": "Overall, results suggest that the lacosamide use is driven predominantly by age and that there is substantial use of lacosamide monotherapy (16.8%), despite lack of indication at the time of the study.",
                    "score_reranked": -0.2206457555294037
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35397759",
                    "text": "Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged\u2009\u2265\u20094.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE).",
                    "score_reranked": -0.2255452573299408
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37582688",
                    "text": "Among residents with seizures, ASMs without alternative indications were more common (59%), with marked reductions in phenobarbital and phenytoin but significant increases in levetiracetam and lacosamide use observed.",
                    "score_reranked": -0.24369260668754578
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                    "text": "Information on the use of lacosamide and concomitant antiepileptic and non-antiepileptic drugs (non-AEDs) is available from clinical trials and observational studies with small sample sizes.",
                    "score_reranked": -0.26927217841148376
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20687785",
                    "text": "The majority of the published human data relate to the use of lacosamide for the treatment of painful diabetic neuropathy where the extent of pain relief produced has not been deemed sufficient to warrant an application for a product license for this indication.",
                    "score_reranked": -0.31262001395225525
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28575767",
                    "text": "Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study.",
                    "score_reranked": -0.3777402639389038
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26916326",
                    "text": "Treatment with lacosamide in neuropathic pain of various etiologies could be considered as an effective alternative for patients who do not respond or not tolerate standard treatments.",
                    "score_reranked": -0.960688591003418
                }
            ]
        },
        {
            "id": "552fac4fbc4f83e828000006",
            "body": "Which fusion protein is involved in the development of Ewing sarcoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24082883",
                "http://www.ncbi.nlm.nih.gov/pubmed/31756779",
                "http://www.ncbi.nlm.nih.gov/pubmed/23329308",
                "http://www.ncbi.nlm.nih.gov/pubmed/24082883",
                "http://www.ncbi.nlm.nih.gov/pubmed/39622389",
                "http://www.ncbi.nlm.nih.gov/pubmed/40225989",
                "http://www.ncbi.nlm.nih.gov/pubmed/34465585",
                "http://www.ncbi.nlm.nih.gov/pubmed/36672331",
                "http://www.ncbi.nlm.nih.gov/pubmed/31756779",
                "http://www.ncbi.nlm.nih.gov/pubmed/40205020"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24082883",
                    "text": "The EWS-FLI1 gene fusion is the prototypical translocation that encodes the aberrant, chimeric transcription factor, which is a landmark of Ewing tumors.",
                    "score_reranked": 1.6239615678787231
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31756779",
                    "text": "The molecular hallmark of Ewing sarcoma (ES) is a fusion involving the EWSR1 gene and a member of the ETS family of transcription factors.",
                    "score_reranked": 1.608337640762329
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23329308",
                    "text": "We describe the different fusion partners of EWSR1, the molecular pathways in which is involved and the main molecular biology techniques for the identification of fusion transcripts and for their inhibition.",
                    "score_reranked": 1.3768329620361328
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24082883",
                    "text": "The Ewing sarcoma protein (EWS) is a well-known player in cancer biology for the specific translocations occurring in sarcomas.",
                    "score_reranked": 1.1954375505447388
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39622389",
                    "text": "Here, we provide a comprehensive review of Ewing sarcoma, including fusion proteins, various signaling pathways, pivotal pathogenetic molecules implicated in its development, and associated targeted therapies and immunotherapies.",
                    "score_reranked": 0.9613115787506104
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40225989",
                    "text": "It is distinguished by a characteristic chromosomal translocation between the Ewing sarcoma breakpoint region 1 (EWS) gene and the erythroblast transformation-specific (ETS) family of genes, most commonly resulting in the EWS-friend leukemia integration 1 (EWS-FLI1) fusion gene.",
                    "score_reranked": 0.4782622158527374
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34465585",
                    "text": "Ewing sarcoma is a pediatric bone cancer defined by a chromosomal translocation fusing one of the FET family members to an ETS transcription factor.",
                    "score_reranked": 0.38009944558143616
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36672331",
                    "text": "Genetically, Ewing sarcoma is driven by a fusion oncoprotein that results from one of a small number of chromosomal translocations composed of a FET gene and a gene encoding an ETS family transcription factor, with ~85% of tumors expressing the EWSR1::FLI1 fusion.",
                    "score_reranked": 0.145936518907547
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31756779",
                    "text": "Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.",
                    "score_reranked": -0.3178977072238922
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40205020",
                    "text": "As is known, many soft tissue tumors harbor gene fusion events, and while it was initially thought that individual entities would be defined by single, specific fusions, it quickly became clear that some entities could be caused by several different fusion events (e.g., EWSR1::FLI1, EWSR1::ERG, EWSR1:FEV and others in Ewing sarcoma).",
                    "score_reranked": -0.778878927230835
                }
            ]
        },
        {
            "id": "56be0da3ef6e394741000007",
            "body": "List Hemolytic Uremic Syndrome Triad.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34034793",
                "http://www.ncbi.nlm.nih.gov/pubmed/31245222",
                "http://www.ncbi.nlm.nih.gov/pubmed/30454746",
                "http://www.ncbi.nlm.nih.gov/pubmed/36880929",
                "http://www.ncbi.nlm.nih.gov/pubmed/20090363",
                "http://www.ncbi.nlm.nih.gov/pubmed/30454746",
                "http://www.ncbi.nlm.nih.gov/pubmed/31461583",
                "http://www.ncbi.nlm.nih.gov/pubmed/27297224",
                "http://www.ncbi.nlm.nih.gov/pubmed/36272423",
                "http://www.ncbi.nlm.nih.gov/pubmed/27296266"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34034793",
                    "text": "Hemolytic uremic syndrome (HUS) is a rare condition which diagnosed with the triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal injury.",
                    "score_reranked": 1.087194561958313
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31245222",
                    "text": "Hemolytic uremic syndrome (HUS) is a type of thrombotic microangiopathy syndrome\u00a0(TMA) defined as a triad of non-immune microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury.",
                    "score_reranked": 1.0507043600082397
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30454746",
                    "text": "Hemolytic uremic syndrome (HUS) is the clinical triad of thrombocytopenia, anemia, and acute kidney injury.",
                    "score_reranked": 1.0288550853729248
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36880929",
                    "text": "Hemolytic uremic syndrome is characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney failure.",
                    "score_reranked": 0.8568931818008423
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20090363",
                    "text": "Atypical hemolytic uremic syndrome: update on the complement system and what is new.",
                    "score_reranked": 0.7766740322113037
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30454746",
                    "text": "Hemolytic Uremic Syndrome.",
                    "score_reranked": 0.5981711149215698
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31461583",
                    "text": "The term hemolytic uremic syndrome (HUS) refers to a heterogenous group of disorders arising from an initial endothelial cell injury with fibrin and platelet thrombi formation in the vasculature, leading to severe organ damage resulting in the well-known triad of microangiopathic hemolytic anemia, thrombocytopenia and kidney disease.",
                    "score_reranked": 0.5168907642364502
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27297224",
                    "text": "Hemolytic-uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, impaired renal function and thrombocytopenia, primarily affecting pre-school-aged children.",
                    "score_reranked": 0.49489298462867737
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36272423",
                    "text": "Haemolytic uraemic syndrome (HUS) is a heterogeneous group of diseases that result in a common pathology, thrombotic microangiopathy, which is classically characterised by the triad of non-immune microangiopathic haemolytic anaemia, thrombocytopenia, and acute kidney injury.",
                    "score_reranked": -0.2680334746837616
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27296266",
                    "text": "The described case illustrates difficulties in diagnosing atypical hemolytic-uremic syndrome (aHUS) in incomplete thrombotic microangiopathy (TMA) in the absence of thrombocytopenia, one of the signs of the classic triad of aHUS, which has resulted in the delayed verification of its diagnosis and in progressive kidney injury.",
                    "score_reranked": -0.40945252776145935
                }
            ]
        },
        {
            "id": "5158644cd24251bc0500008e",
            "body": "Does physical activity influence gut hormones?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39683426",
                "http://www.ncbi.nlm.nih.gov/pubmed/27924137",
                "http://www.ncbi.nlm.nih.gov/pubmed/38511400",
                "http://www.ncbi.nlm.nih.gov/pubmed/34945630",
                "http://www.ncbi.nlm.nih.gov/pubmed/34945630",
                "http://www.ncbi.nlm.nih.gov/pubmed/27090792",
                "http://www.ncbi.nlm.nih.gov/pubmed/38511400",
                "http://www.ncbi.nlm.nih.gov/pubmed/33238373",
                "http://www.ncbi.nlm.nih.gov/pubmed/33238373",
                "http://www.ncbi.nlm.nih.gov/pubmed/33238373"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39683426",
                    "text": "Muscle activity, particularly exercise, alters the gut microbial composition, promoting beneficial species, while gut-derived metabolites like short-chain fatty acids (SCFAs) impact muscle metabolism, mitochondrial function, and insulin sensitivity.",
                    "score_reranked": 0.5988408327102661
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924137",
                    "text": "Exercise-induced stress behavior, gut-microbiota-brain axis and diet: a systematic review for athletes.",
                    "score_reranked": 0.35485556721687317
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38511400",
                    "text": "Environmental factors including meal schedule, food contents and quality, type of exercise, and sleep deprivation also play a role in the influence of gut hormone on appetite, weight change, and obesity.",
                    "score_reranked": 0.32416191697120667
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34945630",
                    "text": "Among the external causes, nutrition as well as physical activity appear to be potential drivers of microbial diversity, both at the taxonomic and functional level, likely also influencing endocrine system, and acting as endocrine organ itself.",
                    "score_reranked": 0.321895569562912
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34945630",
                    "text": "In this review, we evaluate and summarize the current knowledge regarding the interaction and cross-talks among hormonal modifications, physical performance, and microbiota content and function.",
                    "score_reranked": 0.10048988461494446
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27090792",
                    "text": "An acute bout of aerobic exercise suppresses appetite by decreasing ghrelin plasma levels, and increasing gut hormones.",
                    "score_reranked": -0.308664470911026
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38511400",
                    "text": "Recent human studies have revealed that gut hormones act differently in various systems, including adipose tissue, beyond appetite and energy intake, and even involve in high-order thinking.",
                    "score_reranked": -0.4757479727268219
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33238373",
                    "text": "Effect of Acute Sprint Exercise on Myokines and Food Intake Hormones in Young Healthy Men.",
                    "score_reranked": -0.6702326536178589
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33238373",
                    "text": "Physical exercise is known to influence hormonal mediators of appetite, but the effect of short-term maximal intensity exercise on plasma levels of appetite hormones and cytokines has been little studied.",
                    "score_reranked": -0.7030518054962158
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33238373",
                    "text": "We postulate that this physiological response involves exercise-induced alterations in plasma hormones and the release of myokines such as irisin and IL-6, and supports the notion of existence of the skeletal muscle-brain-gut axis.",
                    "score_reranked": -1.0808829069137573
                }
            ]
        },
        {
            "id": "515a7ffdd24251bc050000a5",
            "body": "What are the effects of depleting protein  km23-1 (DYNLRB1)  in a cell?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/32088381",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/19711352",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                "http://www.ncbi.nlm.nih.gov/pubmed/17965411"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "Here, we show that a significant fraction of km23-1/DYNLRB1 and RRas wase co-localized at the protruding edges of migrating HCT116 cells, suggesting an important role for the km23-1/DYNLRB1-R-Ras complex in CRC invasion.",
                    "score_reranked": 1.1235766410827637
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "Furthermore, we show that CRISPR-Cas9 knock-out (KO) of km23-1/DYNLRB1 reduced cell migration in two additional CRC models, HCT116 and DLD-1.",
                    "score_reranked": 0.9465986490249634
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088381",
                    "text": "Furthermore, heterozygous or adult knockdown animals display reduced neuronal growth, and selective depletion of Dynlrb1 in proprioceptive neurons compromises their survival.",
                    "score_reranked": 0.3096499741077423
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "km23-1/DYNLRB1 regulation of MEK/ERK signaling and R-Ras in invasive human colorectal cancer cells.",
                    "score_reranked": 0.20099487900733948
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711352",
                    "text": "Here we describe another member of the km23/DYNLRB/LC7/robl family of DLCs, termed km23-2, which is also involved in TGFbeta signaling.",
                    "score_reranked": 0.032287389039993286
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "Furthermore, sucrose gradient fractionation of cell lysates from both HCT116 and CBS CRC cells demonstrated that km23-1/DYNLRB1 co-sedimented with Ras, p-ERK, and ERK in fractions that did not contain components of holo-dynein.",
                    "score_reranked": -0.3570002019405365
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "Thus, km23-1/DYNLRB1 may be associated with activated Ras/ERK signaling complexes in cell compartments that do not contain the dynein holoprotein complex, suggesting dynein-independent km23-1/DYNLRB1 functions in Ras/ERK signaling.",
                    "score_reranked": -0.3987102210521698
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "We previously found that km23-1/DYNLRB1 is required for transforming growth factor-\u03b2 (TGF\u03b2) production through Ras/ERK pathways in TGF\u03b2-sensitive epithelial cells and in human colorectal cancer (CRC) cells.",
                    "score_reranked": -0.4197321832180023
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31393067",
                    "text": "Here we demonstrate that km23-1/DYNLRB1 is required for mitogen-activated protein kinase kinase (MEK) activation in human CRC cells, detected by km23-1/DYNLRB1-siRNA inhibition of phospho-(p)-MEK immunostaining in RKO cells.",
                    "score_reranked": -0.43819460272789
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17965411",
                    "text": "Co-immunoprecipitation using DYNLT-specific antibodies reveals that dynein complexes with DYNLT light chains also contain the DYNLL and DYNLRB light chains.",
                    "score_reranked": -0.6630151271820068
                }
            ]
        },
        {
            "id": "54cf7051f693c3b16b000013",
            "body": "Treatment of which disease was investigated in the MR CLEAN study?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/34872339",
                "http://www.ncbi.nlm.nih.gov/pubmed/34078103",
                "http://www.ncbi.nlm.nih.gov/pubmed/29581124",
                "http://www.ncbi.nlm.nih.gov/pubmed/32279619",
                "http://www.ncbi.nlm.nih.gov/pubmed/35017306",
                "http://www.ncbi.nlm.nih.gov/pubmed/36478761",
                "http://www.ncbi.nlm.nih.gov/pubmed/38102770",
                "http://www.ncbi.nlm.nih.gov/pubmed/32279619",
                "http://www.ncbi.nlm.nih.gov/pubmed/34078103",
                "http://www.ncbi.nlm.nih.gov/pubmed/35017306"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34872339",
                    "text": "We used data (March 2014 until November 2017) of patients with an anterior circulation large vessel occlusion stroke from the MR CLEAN (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry, a nationwide, prospective study on endovascular thrombectomy in the Netherlands.",
                    "score_reranked": 2.173947334289551
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078103",
                    "text": "We analyzed data from the MR CLEAN Registry (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischaemic Stroke in the Netherlands)\u2014a prospective, multicenter, observational cohort study of patients treated with endovascular treatment in the Netherlands.",
                    "score_reranked": 1.8116838932037354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29581124",
                    "text": "The MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands) is an ongoing, prospective, observational study in all centers that perform EVT in The Netherlands.",
                    "score_reranked": 1.2943768501281738
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32279619",
                    "text": "Patients included in the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; n=500) and MR CLEAN Registry (n=1488) were studied.",
                    "score_reranked": 1.221851110458374
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35017306",
                    "text": "Clinical Outcome After Endovascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR CLEAN Registry Substudy.",
                    "score_reranked": 0.8955198526382446
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36478761",
                    "text": "We retrospectively analyzed data from the Dutch MR CLEAN trial and MR CLEAN Registry.",
                    "score_reranked": 0.4004357159137726
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38102770",
                    "text": "We report data from the MR CLEAN Registry: a prospective, observational study on all stroke patients who underwent EVT in the Netherlands (March 2014-November 2017).",
                    "score_reranked": 0.37342706322669983
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32279619",
                    "text": "Clinical and Imaging Determinants of Collateral Status in Patients With Acute Ischemic Stroke in MR CLEAN Trial and Registry.",
                    "score_reranked": 0.10718837380409241
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078103",
                    "text": "White Matter Lesions and Outcomes After Endovascular Treatment for Acute Ischemic Stroke: MR CLEAN Registry Results.",
                    "score_reranked": -0.08954522013664246
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35017306",
                    "text": "Using data from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry, we compared patients with active cancer (defined as cancer diagnosed within 12 months before stroke, metastatic disease, or current cancer treatment) to patients without cancer.",
                    "score_reranked": -0.4864109456539154
                }
            ]
        },
        {
            "id": "56a92be0a17756b72f000009",
            "body": "Which factors activate zygotic gene expression during the maternal-to-zygotic transition in zebrafish?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24056933",
                "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                "http://www.ncbi.nlm.nih.gov/pubmed/24056933",
                "http://www.ncbi.nlm.nih.gov/pubmed/27235108",
                "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                "http://www.ncbi.nlm.nih.gov/pubmed/27235108",
                "http://www.ncbi.nlm.nih.gov/pubmed/23950494",
                "http://www.ncbi.nlm.nih.gov/pubmed/39302832",
                "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                "http://www.ncbi.nlm.nih.gov/pubmed/29229769"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24056933",
                    "text": "Nanog, Pou5f1 and SoxB1 activate zygotic gene expression during the maternal-to-zygotic transition.",
                    "score_reranked": 2.328592538833618
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                    "text": "The activation of the zygotic genome occurs during the so-called maternal to zygotic transition and prepares the embryo for zygotic takeover from maternal factors, in the control of the development of cellular lineages during differentiation.",
                    "score_reranked": 2.109097719192505
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24056933",
                    "text": "After fertilization, maternal factors direct development and trigger zygotic genome activation (ZGA) at the maternal-to-zygotic transition (MZT).",
                    "score_reranked": 1.8420698642730713
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27235108",
                    "text": "Upon fertilization, maternal factors direct development and trigger zygotic genome activation at the maternal-to-zygotic transition (MZT).",
                    "score_reranked": 1.7458440065383911
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                    "text": "Transcriptional Regulation During Zygotic Genome Activation in Zebrafish and Other Anamniote Embryos.",
                    "score_reranked": 1.5898593664169312
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27235108",
                    "text": "However, the factors that activate the zygotic program in vertebrates are not well defined.",
                    "score_reranked": 1.1838762760162354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23950494",
                    "text": "During the maternal-to-zygotic transition, transcription of zygotic genes commences, and developmental control starts to be regulated by zygotic gene products.",
                    "score_reranked": 1.112908124923706
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39302832",
                    "text": "The maternal-to-zygotic transition is crucial in embryonic development, marked by the degradation of maternally provided mRNAs and initiation of zygotic gene expression.",
                    "score_reranked": 0.9262850284576416
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27503357",
                    "text": "Zygotic genome activation in zebrafish occurs 10 cell cycles after fertilization and provides an ideal experimental platform for elucidating the temporal sequence and dynamics of establishment of a transcriptionally active chromatin state and helps in identifying the determinants of transcription activation at polymerase II transcribed gene promoters.",
                    "score_reranked": 0.8731999397277832
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29229769",
                    "text": "In the earliest stages of animal development following fertilization, maternally deposited mRNAs direct biological processes to the point of zygotic genome activation (ZGA).",
                    "score_reranked": 0.17740705609321594
                }
            ]
        },
        {
            "id": "54f08d4a94afd61504000016",
            "body": "Is irritable bowel syndrome more common in women with endometriosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15618831",
                "http://www.ncbi.nlm.nih.gov/pubmed/35957857",
                "http://www.ncbi.nlm.nih.gov/pubmed/37400789",
                "http://www.ncbi.nlm.nih.gov/pubmed/19694698",
                "http://www.ncbi.nlm.nih.gov/pubmed/35957857",
                "http://www.ncbi.nlm.nih.gov/pubmed/25916604",
                "http://www.ncbi.nlm.nih.gov/pubmed/35713579",
                "http://www.ncbi.nlm.nih.gov/pubmed/30326376",
                "http://www.ncbi.nlm.nih.gov/pubmed/15618831",
                "http://www.ncbi.nlm.nih.gov/pubmed/35713579"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15618831",
                    "text": "A symptom questionnaire was administered to 50 women with irritable bowel syndrome and 51 gynaecological patients (30 patients with endometriosis, 21 patients with chronic pelvic inflammatory disease).",
                    "score_reranked": 2.5609230995178223
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35957857",
                    "text": "The pooled prevalence of irritable bowel syndrome in women with endometriosis was 23.4% (95% confidence interval, 9.7 - 37.2).",
                    "score_reranked": 2.4964547157287598
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37400789",
                    "text": "Associations and gastrointestinal symptoms in women with endometriosis in comparison to women with irritable bowel syndrome: a study based on a population cohort.",
                    "score_reranked": 2.4294230937957764
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19694698",
                    "text": "Seventy-six women (21.4%) had previously been diagnosed with irritable bowel syndrome and 79% of them had endometriosis confirmed.",
                    "score_reranked": 2.2294647693634033
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35957857",
                    "text": "Patients with endometriosis have an approximately threefold increased risk of developing irritable bowel syndrome.",
                    "score_reranked": 1.63340425491333
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25916604",
                    "text": "The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study.",
                    "score_reranked": 1.5796732902526855
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713579",
                    "text": "Do the spectrum and prevalence of comorbidities of endometriosis and irritable bowel syndrome (IBS) overlap?",
                    "score_reranked": 1.5444996356964111
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30326376",
                    "text": "Is endometriosis associated with irritable bowel syndrome? A cross-sectional study.",
                    "score_reranked": 1.1745033264160156
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15618831",
                    "text": "Irritable bowel syndrome, chronic pelvic inflammatory disease and endometriosis: a comparison of symptomatology.",
                    "score_reranked": 0.9884531497955322
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35713579",
                    "text": "Endometriosis and irritable bowel syndrome: similarities and differences in the spectrum of comorbidities.",
                    "score_reranked": 0.7096647024154663
                }
            ]
        },
        {
            "id": "54f49995d0d681a040000002",
            "body": "What is evaluated using the EORTC QLQ \u2013 INFO25 questionnaire?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39960712",
                "http://www.ncbi.nlm.nih.gov/pubmed/39450833",
                "http://www.ncbi.nlm.nih.gov/pubmed/38716910",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751734",
                "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                "http://www.ncbi.nlm.nih.gov/pubmed/25101146",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751734",
                "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751734"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39960712",
                    "text": "QoL assessment was done with EORTC QOL-C15-PAL, EORTC QOL-BN20 module and Barthel index for Activities of Daily Living.",
                    "score_reranked": 2.7418577671051025
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39450833",
                    "text": "The adapted version of the EORTC QLQ-INFO25 questionnaire presents adequate psychometric properties and, therefore, is a reliable tool for Chilean patients.",
                    "score_reranked": 2.452950954437256
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38716910",
                    "text": "Sociodemographic and clinical instruments, EORTC QLQ-C30, EORTC QLQ-INFO25 and Supportive Care Needs Survey - Short Form 34 were used.",
                    "score_reranked": 2.35081148147583
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751734",
                    "text": "This study aims to validate the Sinhala translation of the EORTC QLQ-INFO25, a module that assesses the quality of patient information, for use among Sri Lankans with cancer.",
                    "score_reranked": 2.3446314334869385
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                    "text": "The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients.",
                    "score_reranked": 2.159884214401245
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25101146",
                    "text": "The intermediate version of the INFO25 was pilot-tested together with the general questionnaire of quality of life (EORTC QLQ-C30).",
                    "score_reranked": 1.7301907539367676
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751734",
                    "text": "The Sinhala translation of EORTC QLQ-INFO25 demonstrates satisfactory reliability, validity, reproducibility, and compliance for assessing information provision in cancer care among patients in Sri Lanka.",
                    "score_reranked": 1.5863091945648193
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                    "text": "The EORTC QLQ-INFO25 evaluates the information received by cancer patients.",
                    "score_reranked": 1.2761725187301636
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21680301",
                    "text": "The EORTC QLQ-INFO 25 is a reliable and valid instrument when applied to a sample of Spanish cancer patients.",
                    "score_reranked": 1.1700432300567627
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751734",
                    "text": "EORTC QLQ-INFO25, an information module developed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group, is aimed at assessing cancer patients' perception of information received during different phases of care.",
                    "score_reranked": 0.4251098930835724
                }
            ]
        },
        {
            "id": "531d2aa5267d7dd053000003",
            "body": "Does BNP increase after intensive exercise in athletes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                "http://www.ncbi.nlm.nih.gov/pubmed/25755058",
                "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                "http://www.ncbi.nlm.nih.gov/pubmed/25828341",
                "http://www.ncbi.nlm.nih.gov/pubmed/23419987",
                "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783700",
                "http://www.ncbi.nlm.nih.gov/pubmed/21263409",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783700",
                "http://www.ncbi.nlm.nih.gov/pubmed/26783700"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                    "text": "Serum BNP concentrations were measured in 191 participants (60\u00b112yrs) of the Nijmegen Marches before (baseline) and immediately after 4 consecutive days of walking exercise (30-50km/day).",
                    "score_reranked": 0.6276558637619019
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25755058",
                    "text": "Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls.",
                    "score_reranked": 0.5095624923706055
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                    "text": "Endurance exercise-induced changes in BNP concentrations in cardiovascular patients versus healthy controls.",
                    "score_reranked": 0.2423149049282074
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25828341",
                    "text": "Letter regarding the article: Changes in BNP and cardiac troponin I after high-intensity interval and endurance exercise in heart failure patients and healthy controls.",
                    "score_reranked": 0.09453567862510681
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419987",
                    "text": "In all groups, NT-pro-BNP decreased from rest to the beginning phase, increased in maximal effort and stayed unchanged in recovery.",
                    "score_reranked": -0.09679433703422546
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27847152",
                    "text": "BNP increases were small, and did not accumulate across consecutive days of exercise.",
                    "score_reranked": -0.23655226826667786
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783700",
                    "text": "LV systolic and diastolic functions may deteriorate, and proBNP levels could be elevated even by a single bout of treadmill exercise in untrained young subjects.",
                    "score_reranked": -0.35365328192710876
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21263409",
                    "text": "The workload consisting of 40-minutes long swimming session is not sufficient to provoke BNP release from myocardium in rats.",
                    "score_reranked": -0.4302699863910675
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783700",
                    "text": "Dynamic change in LV diastolic function is a major stimulus to NT-proBNP release following exercise in men but not in women.",
                    "score_reranked": -0.5829197764396667
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26783700",
                    "text": "To examine the impact of a single bout of exercise on cardiac function and the blood level of brain natriuretic peptide (BNP) in healthy subjects.",
                    "score_reranked": -0.9458798170089722
                }
            ]
        },
        {
            "id": "56bf3a79ef6e39474100000f",
            "body": "What is the association of estrogen replacement therapy and intracranial meningioma risk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17580362",
                "http://www.ncbi.nlm.nih.gov/pubmed/20738039",
                "http://www.ncbi.nlm.nih.gov/pubmed/23800670",
                "http://www.ncbi.nlm.nih.gov/pubmed/20738039",
                "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                "http://www.ncbi.nlm.nih.gov/pubmed/20802020",
                "http://www.ncbi.nlm.nih.gov/pubmed/23800670",
                "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                "http://www.ncbi.nlm.nih.gov/pubmed/17580362"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17580362",
                    "text": "Although not definitive, available data suggest an association between the use of hormone replacement therapy and increased meningioma risk.",
                    "score_reranked": 1.7619094848632812
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20738039",
                    "text": "Postmenopausal hormone replacement therapy and meningioma.",
                    "score_reranked": 1.5685756206512451
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23800670",
                    "text": "Hormone replacement therapy increases the risk of cranial meningioma.",
                    "score_reranked": 1.2953050136566162
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20738039",
                    "text": "A retrospective study including more than 350,000 women, about 1400 of whom had developed meningioma, showed that the risk of meningioma was about twice as high in users of postmenopausal hormone replacement therapy as in non-users.",
                    "score_reranked": 1.0934394598007202
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                    "text": "Ever use of estradiol-only therapy was associated with an increased risk of meningioma (standardized incidence ratio = 1.29, 95% confidence interval: 1.15, 1.44).",
                    "score_reranked": 1.0757379531860352
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                    "text": "Estradiol-only therapy was accompanied with a slightly increased risk of meningioma.",
                    "score_reranked": 0.8268530368804932
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20802020",
                    "text": "A higher risk of meningioma was observed among postmenopausal women who were current users of hormone replacement therapy (HR, 1.79; 95% CI, 1.18-2.71) compared with never users.",
                    "score_reranked": 0.7573415040969849
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23800670",
                    "text": "Long-term HRT use, particularly of combined oestrogen-progestagen therapy, may increase the risk of meningioma.",
                    "score_reranked": 0.44959917664527893
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287638",
                    "text": "Women who had used postmenopausal hormone therapy were identified from the medical reimbursement register of the Social Insurance Institution (131,480 estradiol users and 131,248 estradiol-progestin users), and meningioma cases were identified from the Finnish Cancer Registry.",
                    "score_reranked": 0.2786915600299835
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17580362",
                    "text": "Further evaluation of exogenous hormone use in women with meningioma is needed with particular attention to stratification by hormone (ie, estrogen and/or progesterone) composition, duration of and age at use as well as tumor receptor subtype.",
                    "score_reranked": -0.4013877809047699
                }
            ]
        },
        {
            "id": "54fefff26ad7dcbc1200000b",
            "body": "Are there web based self management strategies for chronic pain ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                "http://www.ncbi.nlm.nih.gov/pubmed/23859438",
                "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                "http://www.ncbi.nlm.nih.gov/pubmed/38701440",
                "http://www.ncbi.nlm.nih.gov/pubmed/32320936",
                "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                "http://www.ncbi.nlm.nih.gov/pubmed/23859438",
                "http://www.ncbi.nlm.nih.gov/pubmed/38701440",
                "http://www.ncbi.nlm.nih.gov/pubmed/23328333",
                "http://www.ncbi.nlm.nih.gov/pubmed/38701440"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                    "text": "While there are emerging web-based self-management programs for children and adolescents with chronic pain, there is currently not an integrated web- and smartphone-based app that specifically addresses the needs of adolescents with chronic pain.",
                    "score_reranked": 0.7538697719573975
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859438",
                    "text": "Results suggest the potential value of self-management for chronic pain patients and the potential acceptability of web-based delivery of intervention content.",
                    "score_reranked": 0.5493507385253906
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                    "text": "iCanCope with Pain\u2122: User-centred design of a web- and mobile-based self-management program for youth with chronic pain based on identified health care needs.",
                    "score_reranked": 0.38354137539863586
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38701440",
                    "text": "Aiming to meet the demand for accessible, fully automated resources for individuals with chronic noncancer pain, we developed a French web- and evidence-based self-management program, Agir pour moi (APM).",
                    "score_reranked": 0.3560068905353546
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32320936",
                    "text": "To assess the efficacy on pain intensity and disability of e-Health based self-management programs on chronic low back pain.",
                    "score_reranked": 0.3052773177623749
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25000507",
                    "text": "The proposed iCanCope with Pain\u2122 program aims to address the self-management needs of adolescents with chronic pain by improving access to disease information, strategies to manage symptoms and social support.",
                    "score_reranked": 0.2910297214984894
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23859438",
                    "text": "Patients as collaborators: using focus groups and feedback sessions to develop an interactive, web-based self-management intervention for chronic pain.",
                    "score_reranked": 0.09708556532859802
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38701440",
                    "text": "Web-based self-management programs cost-effectively increase access to pain management and can improve several aspects of physical and emotional functioning.",
                    "score_reranked": -0.10470804572105408
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23328333",
                    "text": "To qualitatively explore the information and service needs of young adults (YAs) with chronic pain to inform the development of a web-based chronic pain self-management program.",
                    "score_reranked": -0.3765306770801544
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38701440",
                    "text": "Assessing the Feasibility and Preliminary Effects of a Web-Based Self-Management Program for Chronic Noncancer Pain: Mixed Methods Study.",
                    "score_reranked": -0.9336098432540894
                }
            ]
        },
        {
            "id": "571f34ac0fd6f91b68000005",
            "body": "Is Weaver syndrome similar to Sotos?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16010674",
                "http://www.ncbi.nlm.nih.gov/pubmed/22287508",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                "http://www.ncbi.nlm.nih.gov/pubmed/24214728",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                "http://www.ncbi.nlm.nih.gov/pubmed/24852293",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                "http://www.ncbi.nlm.nih.gov/pubmed/27834868"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16010674",
                    "text": "Two groups are distinguished: group I corresponding to patients with recognizable overgrowth syndromes (Sotos syndrome (SS), Weaver syndrome (WS), Beckwith-Wiedemann syndrome, Simpson-Golabi-Behmel syndrome (SGBS), and del(22)(qter) syndrome) (60 cases) and group II corresponding to unclassified cases (15 patients).",
                    "score_reranked": 2.519662618637085
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22287508",
                    "text": "Clinically, Weaver syndrome is closely related to Sotos syndrome, which is frequently caused by mutations in NSD1.",
                    "score_reranked": 2.3926055431365967
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                    "text": "The syndromes of Sotos and Weaver are paradigmatic of the daily nosologic difficulties faced by clinical geneticists attempting to diagnose and counsel, and to give accurate prognoses in cases of extensive phenotypic overlap between molecularly undefined entities.",
                    "score_reranked": 1.2443795204162598
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24214728",
                    "text": "Considerable phenotypic overlap between Sotos and Weaver syndromes is also evident.",
                    "score_reranked": 1.1725678443908691
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                    "text": "In Weaver syndrome there are more conspicuous contractures and a facial appearance that experts find convincingly different from that of Sotos individuals.",
                    "score_reranked": 0.9082397222518921
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                    "text": "On the other hand, the Sotos syndrome may be a cancer syndrome, the Weaver syndrome not (though a neuroblastoma was reported in the latter); in the former there is also remarkably advanced dental maturation rarely commented on in the latter.",
                    "score_reranked": 0.6477186679840088
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24852293",
                    "text": "Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively.",
                    "score_reranked": 0.4724786579608917
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                    "text": "Thus, it is not surprising that prenatal overgrowth occurs in several syndromes, including the Sotos and Weaver syndromes.",
                    "score_reranked": 0.26735520362854004
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9781911",
                    "text": "The syndromes of Sotos and Weaver: reports and review.",
                    "score_reranked": 0.029993385076522827
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27834868",
                    "text": "Mutations of the SET domains were reported to cause intellectual disability syndromes such as Sotos, Weaver, or Kabuki syndromes.",
                    "score_reranked": -0.2511352598667145
                }
            ]
        },
        {
            "id": "54e0d1491388e8454a000014",
            "body": "Which enzyme is targeted by Evolocumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39947256",
                "http://www.ncbi.nlm.nih.gov/pubmed/30629143",
                "http://www.ncbi.nlm.nih.gov/pubmed/37055909",
                "http://www.ncbi.nlm.nih.gov/pubmed/39751968",
                "http://www.ncbi.nlm.nih.gov/pubmed/37939861",
                "http://www.ncbi.nlm.nih.gov/pubmed/39679827",
                "http://www.ncbi.nlm.nih.gov/pubmed/30629143",
                "http://www.ncbi.nlm.nih.gov/pubmed/30701731",
                "http://www.ncbi.nlm.nih.gov/pubmed/39947256",
                "http://www.ncbi.nlm.nih.gov/pubmed/35339752"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39947256",
                    "text": "The PCSK9 inhibitors, alirocumab and evolocumab, are human monoclonal antibodies (mAbs) that act outside the cell by complexing circulating PCSK9 and thus preventing its binding to the LDLR.",
                    "score_reranked": 0.13991603255271912
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30629143",
                    "text": "Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.",
                    "score_reranked": -0.08458197116851807
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37055909",
                    "text": "Approved PCSK9i are the monoclonal antibodies (Mabs), evolocumab and alirocumab, targeting PCSK9, and inclisiran, a small interfering RNA inhibiting PSCK9 synthesis.",
                    "score_reranked": -0.26014992594718933
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39751968",
                    "text": "Novel LDLR dependent therapies that reduce proprotein subtilisin kexin type 9 levels include monoclonal antibodies (alirocumab and evolocumab) and a small inhibitory RNA (inclisiran).",
                    "score_reranked": -0.38448724150657654
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37939861",
                    "text": "The clinical use of two monoclonal antibodies (alirocumab and evolocumab, approved in 2015) and one small interfering RNA (inclisiran, approved in 2020) which can inhibit PCSK9 function proved that they are very effective in lowering low density lipoprotein cholesterol (LDL-C).",
                    "score_reranked": -0.46905168890953064
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39679827",
                    "text": "Approaches to inhibit this effect have centered on monoclonal antibodies (mAbs) (alirocumab, evolocumab) targeting PCSK9 functionality and small interfering RNA (siRNA) therapies (inclisiran) targeting the hepatic synthesis of PCSK9.",
                    "score_reranked": -0.678918719291687
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30629143",
                    "text": "Other strategies under consideration include: (i) antibodies targeting the C-terminal domain of PCSK9, thereby inhibiting the trafficking of PCSK9-LDLR to lysosomes; (ii) small molecules that either prevent PCSK9 binding to the LDLR, its trafficking to lysosomes or its secretion from cells; (iii) complete silencing of PCSK9 by CRISPR-Cas9 strategies; (iv) PCSK9 vaccines that inhibit the activity of circulating PCSK9.",
                    "score_reranked": -0.7700744867324829
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30701731",
                    "text": "Since the target cholesterol levels of low-density lipoprotein cholesterol (LDL-C) were not achieved during the statin therapy, patients were prescribed lipid-lowering therapy with the inclusion of the inhibitor PCSK9-emocoucumab from Amgen 420 mg once a month.",
                    "score_reranked": -0.8767502307891846
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39947256",
                    "text": "This review critically appraises pharmacological strategies to target PCSK9 either inside or outside the cell.",
                    "score_reranked": -0.9687761068344116
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35339752",
                    "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9), a negative regulator of LDLR, has emerged as an important target for the treatment of hypercholesterolemic cardiovascular disease, and monoclonal antibodies alirocumab and evolocumab against it have been widely used in clinical practice.",
                    "score_reranked": -1.4657161235809326
                }
            ]
        },
        {
            "id": "553a8d78f321868558000003",
            "body": "Are ultraconserved elements often transcribed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                "http://www.ncbi.nlm.nih.gov/pubmed/28729024",
                "http://www.ncbi.nlm.nih.gov/pubmed/20202189",
                "http://www.ncbi.nlm.nih.gov/pubmed/20202189",
                "http://www.ncbi.nlm.nih.gov/pubmed/36622962",
                "http://www.ncbi.nlm.nih.gov/pubmed/24953281",
                "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                "http://www.ncbi.nlm.nih.gov/pubmed/35978878"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                    "text": "Transcribed ultraconserved region (T-UCR) transcripts are a novel class of lncRNAs transcribed from ultraconserved regions (UCRs).",
                    "score_reranked": 1.0252461433410645
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28729024",
                    "text": "Transcribed ultraconserved regions (T-UCRs) are genomic regions conserved across large evolutionary distances, which encode for noncoding RNAs that serve as regulators of gene expression.",
                    "score_reranked": 0.9272234439849854
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20202189",
                    "text": "Ultraconserved elements (UCEs) are highly constrained elements of mammalian genomes, whose functional role has not been completely elucidated yet.",
                    "score_reranked": 0.82676100730896
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20202189",
                    "text": "Promiscuity of enhancer, coding and non-coding transcription functions in ultraconserved elements.",
                    "score_reranked": 0.8014523983001709
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36622962",
                    "text": "Transcribed Ultraconserved Regions: New regulators in cancer signaling and potential biomarkers.",
                    "score_reranked": 0.5150519609451294
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24953281",
                    "text": "These transcribed ultraconserved regions (T-UCRs) are thought to control the essential regulatory functions basic for life in rodents and mammals.",
                    "score_reranked": 0.35144129395484924
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                    "text": "Transcribed ultraconserved regions are putative lncRNA molecules that are transcribed from DNA that is 100% conserved in human, mouse, and rat genomes.",
                    "score_reranked": 0.2821187973022461
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                    "text": "Transcribed Ultraconserved Regions in Cancer.",
                    "score_reranked": 0.0843835175037384
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                    "text": "Transcribed ultraconserved region in human cancers.",
                    "score_reranked": 0.026541396975517273
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978878",
                    "text": "Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.",
                    "score_reranked": -0.20223557949066162
                }
            ]
        },
        {
            "id": "51404dd723fec90375000002",
            "body": "What is the methyl donor of DNA (cytosine-5)-methyltransferases?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                "http://www.ncbi.nlm.nih.gov/pubmed/39941901",
                "http://www.ncbi.nlm.nih.gov/pubmed/39239102",
                "http://www.ncbi.nlm.nih.gov/pubmed/39239102",
                "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                "http://www.ncbi.nlm.nih.gov/pubmed/40367161",
                "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                "http://www.ncbi.nlm.nih.gov/pubmed/39762254",
                "http://www.ncbi.nlm.nih.gov/pubmed/39375179",
                "http://www.ncbi.nlm.nih.gov/pubmed/39214851"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                    "text": "Here, the utility of an N-mustard analog designed to mimic the native methyl donor, S-adenosyl-L-methionine (SAM), was explored with the DNA methyltransferase 3A catalytic domain (DNMT3AC).",
                    "score_reranked": 1.2450816631317139
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39941901",
                    "text": "S-adenosylmethionine (SAMe) is a key methyl donor that plays a critical role in a variety of cellular processes, such as DNA, RNA and protein methylation, essential for maintaining genomic stability, regulating gene expression and maintaining cellular homeostasis.",
                    "score_reranked": 1.1272119283676147
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39239102",
                    "text": "SAM serves as the sole methyl group donor for DNA and histone methyltransferases, making it a crucial metabolite for chromatin modifications.",
                    "score_reranked": 1.088503122329712
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39239102",
                    "text": "Together, these cycles generate S-adenosylmethionine (SAM), the universal methyl donor essential for DNA and histone methylation.",
                    "score_reranked": 1.025572657585144
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                    "text": "DNA methylation, an important epigenetic modification, is catalyzed by DNA methyltransferases and is essential in the regulation of gene expression.",
                    "score_reranked": 0.5275173187255859
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40367161",
                    "text": "Introducing the \"other\" type of DNA methylation.",
                    "score_reranked": 0.45949587225914
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                    "text": "Irreversible Inhibition of DNMT3A by an N-Mustard Analog of S-Adenosyl-L-Methionine.",
                    "score_reranked": 0.41389021277427673
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39762254",
                    "text": "Moreover, Met accelerates the conversion to S-adenosyl-L-methionine, an essential methyl donor, thereby enhancing 5mC methylation modification in the promoter region of tet(X4) gene and reducing its expression.",
                    "score_reranked": 0.15243437886238098
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39375179",
                    "text": "Given that certain micronutrients can either donate methyl groups within one-carbon metabolism pathways or serve as cofactors for enzymes involved in the DNA methylation process, this randomised, double-blind, placebo-controlled trial aims to investigate whether a 3-month supplementation of folic acid and vitamin B Patients will be classified according to their nutritional status by body mass index in normal weight or excess body weight.",
                    "score_reranked": -0.028179973363876343
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39214851",
                    "text": "In lieu of the expected analog transfer to DNA, methyltransferase activity was instead inhibited in a concentration dependent manner.",
                    "score_reranked": -0.20272186398506165
                }
            ]
        },
        {
            "id": "552fa6f5bc4f83e828000002",
            "body": "Is peripheral neuroepithelioma related to Ewing sarcoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7771924",
                "http://www.ncbi.nlm.nih.gov/pubmed/1786632",
                "http://www.ncbi.nlm.nih.gov/pubmed/1659113",
                "http://www.ncbi.nlm.nih.gov/pubmed/8204006",
                "http://www.ncbi.nlm.nih.gov/pubmed/1659113",
                "http://www.ncbi.nlm.nih.gov/pubmed/8204006",
                "http://www.ncbi.nlm.nih.gov/pubmed/2551479",
                "http://www.ncbi.nlm.nih.gov/pubmed/7487413",
                "http://www.ncbi.nlm.nih.gov/pubmed/1985713",
                "http://www.ncbi.nlm.nih.gov/pubmed/3113717"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7771924",
                    "text": "Peripheral neuroepithelioma, Ewing tumour, primitive neuroectodermal tumour (PNET), Askin tumour belong to these neoplasms.",
                    "score_reranked": 0.7583003044128418
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1786632",
                    "text": "The pediatric peripheral neuroectodermal tumors which include neuroblastoma, peripheral neuroepithelioma and Ewing's sarcoma may correspond to distinct neural crest cell lineages or tumors arrested at different stages of neural crest development.",
                    "score_reranked": 0.680813193321228
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1659113",
                    "text": "Recently, primitive neuroectodermal tumors (PNETs) have been shown to cover a wide spectrum of small round cell sarcomas, probably including some Ewing's sarcomas (ESs) and extraskeletal Ewing's sarcomas (EESs), in addition to classical peripheral neuroepitheliomas (PNs).",
                    "score_reranked": 0.629900336265564
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006",
                    "text": "Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms.",
                    "score_reranked": 0.49763599038124084
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1659113",
                    "text": "Atypical primitive neuroectodermal tumors. Comparative light and electron microscopic and immunohistochemical studies on peripheral neuroepitheliomas and Ewing's sarcomas.",
                    "score_reranked": 0.48648515343666077
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8204006",
                    "text": "Ewing's sarcoma of bone (ESB) and peripheral neuroepithelioma (PN) are frequently considered to be different tumors.",
                    "score_reranked": 0.3769548237323761
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2551479",
                    "text": "Peripheral primitive neuroectodermal tumor (peripheral neuroepithelioma) in children. A review of the St. Jude experience and controversies in diagnosis and management.",
                    "score_reranked": 0.27779561281204224
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7487413",
                    "text": "Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma.",
                    "score_reranked": 0.18248876929283142
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1985713",
                    "text": "Histologically, the tumors were categorized, based on recent pathologic criteria, into three diagnostic groups: (1) typical Ewing's sarcoma, (2) atypical Ewing's sarcoma, and (3) other (predominantly peripheral neuroepithelioma [PN]).",
                    "score_reranked": 0.14831534028053284
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3113717",
                    "text": "Ewing's sarcoma (ES) of bone may occasionally display rosette-like textures mimicking Homer-Wright ones, as seen in neuroectodermic neoplasms (neuroblastoma, peripheral neuroepithelioma).",
                    "score_reranked": -0.1686767041683197
                }
            ]
        },
        {
            "id": "56d0451c3975bb303a00000e",
            "body": "Which signaling pathway does sonidegib inhibit?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29943836",
                "http://www.ncbi.nlm.nih.gov/pubmed/29315702",
                "http://www.ncbi.nlm.nih.gov/pubmed/28577129",
                "http://www.ncbi.nlm.nih.gov/pubmed/29315702",
                "http://www.ncbi.nlm.nih.gov/pubmed/27095306",
                "http://www.ncbi.nlm.nih.gov/pubmed/27095306",
                "http://www.ncbi.nlm.nih.gov/pubmed/36332550",
                "http://www.ncbi.nlm.nih.gov/pubmed/31362788",
                "http://www.ncbi.nlm.nih.gov/pubmed/31035664",
                "http://www.ncbi.nlm.nih.gov/pubmed/31724562"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29943836",
                    "text": "Inhibiting hedgehog pathway with sonidegib decreased FoxR2-induced migration and lung metastasis of OC cells, establishing the critical role of hedgehog signaling in mediating the effects of FoxR2 expression.",
                    "score_reranked": 1.8420355319976807
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315702",
                    "text": "The clinical success of vismodegib and sonidegib provided strong support for the development of Hh signaling pathway inhibitors via targeting the smoothened (Smo) receptor.",
                    "score_reranked": 1.6659181118011475
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28577129",
                    "text": "Sonidegib is a potent, selective and orally bioavailable inhibitor of the Hedgehog signaling pathway, primarily metabolized by the liver.",
                    "score_reranked": 1.3239760398864746
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29315702",
                    "text": "Vismodegib, a first-in-class Hh signaling pathway inhibitor was approved by the US Food and Drug Administration in 2012, and sonidegib, another potent Hh pathway inhibitor, received FDA's approval in 2015 as a new treatment of locally advanced or metastatic basal cell carcinoma.",
                    "score_reranked": 0.9914071559906006
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27095306",
                    "text": "Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.",
                    "score_reranked": 0.9827163219451904
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27095306",
                    "text": "Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway-dependent tumors, and has recently been approved in the indication of locally advanced basal cell carcinoma.",
                    "score_reranked": 0.7075585126876831
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36332550",
                    "text": "The development of inhibitors targeting Hedgehog pathway has attracted significant interests in cancer therapy and led to the discovery of three drugs Vismodegib, Sonidegib and Glasdegib.",
                    "score_reranked": 0.652904748916626
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31362788",
                    "text": "SMO inhibitors, sonidegib and vismodegib, have been used as selective antagonist of the hedgehog pathway that acts by binding to SMO, and inhibits activation of the downstream hedgehog target genes.",
                    "score_reranked": 0.4264737665653229
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31035664",
                    "text": "We review agents blocking both the ligand-dependent and ligand-independent cascades, and discuss the clinical evidence, which has led to the FDA approval of Hedgehog receptor Smoothened inhibitors, vismodegib, and sonidegib, in different malignancies.",
                    "score_reranked": 0.3139486610889435
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31724562",
                    "text": "Sonidegib, a Smoothened Inhibitor, Promotes Apoptosis and Suppresses Proliferation of Natural Killer/T-Cell Lymphoma.",
                    "score_reranked": -0.6999191045761108
                }
            ]
        },
        {
            "id": "54ede8c594afd61504000009",
            "body": "In which phase of the cell cycle arrest is impaired in Fanconi anemia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11749045",
                "http://www.ncbi.nlm.nih.gov/pubmed/7518042",
                "http://www.ncbi.nlm.nih.gov/pubmed/7518042",
                "http://www.ncbi.nlm.nih.gov/pubmed/16738325",
                "http://www.ncbi.nlm.nih.gov/pubmed/4050789",
                "http://www.ncbi.nlm.nih.gov/pubmed/9414295",
                "http://www.ncbi.nlm.nih.gov/pubmed/9414295",
                "http://www.ncbi.nlm.nih.gov/pubmed/8822951",
                "http://www.ncbi.nlm.nih.gov/pubmed/26385365",
                "http://www.ncbi.nlm.nih.gov/pubmed/16738325"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11749045",
                    "text": "The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.",
                    "score_reranked": 2.728132963180542
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7518042",
                    "text": "The effect of caffeine on the endogenous G2 phase cell cycle blockage of Fanconi anemia (FA) cells was compared with the effect of caffeine on the G2 phase blockage induced in control cells by X-irradiation.",
                    "score_reranked": 2.581143617630005
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7518042",
                    "text": "Modulation of the spontaneous G2 phase blockage in Fanconi anemia cells by caffeine: differences from cells arrested by X-irradiation.",
                    "score_reranked": 1.917280912399292
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738325",
                    "text": "The G2/M checkpoint-mediated arrest of the cell cycle is critical for the prevention of both apoptosis and the accumulation of cells with rereplicated DNA, because the loss of ATR, BRCA1, or FANCA promotes apoptosis and suppresses the accumulation.",
                    "score_reranked": 1.742103099822998
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4050789",
                    "text": "Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent edomitosis in Fanconi anemia cells.",
                    "score_reranked": 1.5611594915390015
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9414295",
                    "text": "Cells from individuals with Fanconi anemia (FA) arrest excessively in the G2/M cell cycle compartment after exposure to low doses of DNA cross-linking agents.",
                    "score_reranked": 1.39650559425354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9414295",
                    "text": "DNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function.",
                    "score_reranked": 1.1107890605926514
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8822951",
                    "text": "Fanconi anemia (FA) cells are hypersensitive to cytotoxicity, cell cycle arrest, and chromosomal aberrations induced by DNA cross-linking agents, such as mitomycin C (MMC) and nitrogen mustard (HN2).",
                    "score_reranked": 0.48084500432014465
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26385365",
                    "text": "Fanconi anemia cells with unrepaired DNA damage activate components of the checkpoint recovery process.",
                    "score_reranked": -0.20618936419487
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16738325",
                    "text": "An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication.",
                    "score_reranked": -0.8356505632400513
                }
            ]
        },
        {
            "id": "56c3327c50c68dd41600000c",
            "body": "Which DNA sequences are more prone for the formation of R-loops?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38110032",
                "http://www.ncbi.nlm.nih.gov/pubmed/39772743",
                "http://www.ncbi.nlm.nih.gov/pubmed/40382323",
                "http://www.ncbi.nlm.nih.gov/pubmed/39779919",
                "http://www.ncbi.nlm.nih.gov/pubmed/40377216",
                "http://www.ncbi.nlm.nih.gov/pubmed/40382323",
                "http://www.ncbi.nlm.nih.gov/pubmed/39988315",
                "http://www.ncbi.nlm.nih.gov/pubmed/39019869",
                "http://www.ncbi.nlm.nih.gov/pubmed/39019869",
                "http://www.ncbi.nlm.nih.gov/pubmed/40377216"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38110032",
                    "text": "We recently reported that FXS patient cells lacking FMRP sustain higher level of DNA double-strand breaks (DSBs) than normal cells, specifically at sequences prone to forming R-loops, a phenotype further exacerbated by DNA replication stress.",
                    "score_reranked": 0.7082260847091675
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39772743",
                    "text": "Expansion-prone CAG/CTG repeats are actively transcribed and prone to forming stable R-loops with hairpin structures forming on the displaced single-stranded DNA (S-loops).",
                    "score_reranked": 0.18726912140846252
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40382323",
                    "text": "Oncogene-induced replicative stress (RS) drives tumor progression by disrupting genome stability, primarily through transcription-replication conflicts (TRCs), which promote R-loop accumulation and trigger the DNA damage response (DDR).",
                    "score_reranked": -0.020559638738632202
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39779919",
                    "text": "We found that core RNAP in the PTC can unwind DNA and initiate RNA synthesis but is prone to producing R-loops.",
                    "score_reranked": -0.06618198752403259
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40377216",
                    "text": "During recombinase-mediated homology recognition RecQ helicases inhibit formation of toxic long-lived D-loops that could promote genomic instability.",
                    "score_reranked": -0.14734312891960144
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40382323",
                    "text": "In this study, we investigate the role of chromatin regulators in exacerbating TRCs and R-loop accumulation in cancer.",
                    "score_reranked": -0.21379926800727844
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39988315",
                    "text": "Here, we engineered an inducible TRC reporter system using a genome-integrated R-loop-prone sequence and characterized the dynamic changes of the local chromatin structure inflicted by TRCs, leading to reduced nucleosome occupancy and replication fork blockage.",
                    "score_reranked": -0.4145924746990204
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39019869",
                    "text": "Cockayne Syndrome Linked to Elevated R-Loops Induced by Stalled RNA Polymerase II during Transcription Elongation.",
                    "score_reranked": -0.5243148803710938
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39019869",
                    "text": "Consequently, CSB deficiency retards RNAPII elongation in these regions, and when coupled with G-rich sequences upstream, exacerbates genome instability by promoting R-loop formation.",
                    "score_reranked": -0.6133456230163574
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40377216",
                    "text": "Thus, RecQ does not reduce genomic instability by discriminating against incorrect D-loops.",
                    "score_reranked": -0.7628105878829956
                }
            ]
        },
        {
            "id": "551c23bc6b348bb82c00000b",
            "body": "Mutation of which gene is implicated in the familial isolated pituitary adenoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37149543",
                "http://www.ncbi.nlm.nih.gov/pubmed/20506337",
                "http://www.ncbi.nlm.nih.gov/pubmed/17993773",
                "http://www.ncbi.nlm.nih.gov/pubmed/28427099",
                "http://www.ncbi.nlm.nih.gov/pubmed/38590848",
                "http://www.ncbi.nlm.nih.gov/pubmed/38590848",
                "http://www.ncbi.nlm.nih.gov/pubmed/17993773",
                "http://www.ncbi.nlm.nih.gov/pubmed/32604740",
                "http://www.ncbi.nlm.nih.gov/pubmed/31588533",
                "http://www.ncbi.nlm.nih.gov/pubmed/20506337"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37149543",
                    "text": "Mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene cause familial isolated pituitary adenomas (FIPA).",
                    "score_reranked": 1.859191656112671
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20506337",
                    "text": "Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families.",
                    "score_reranked": 1.792212724685669
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17993773",
                    "text": "Recently, some cases of familial isolated somatotropinoma have been associated with germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.",
                    "score_reranked": 1.7316951751708984
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28427099",
                    "text": "Familial isolated pituitary adenoma (FIPA) is caused in about 20% of cases by loss-of-function germline mutations in the",
                    "score_reranked": 1.6569472551345825
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38590848",
                    "text": "Human familial isolated pituitary adenoma (FIPA) has been linked to germline heterozygous mutations in the gene encoding the aryl hydrocarbon receptor-interacting protein (AIP, also known as ARA9, XAP2, FKBP16, or FKBP37).",
                    "score_reranked": 1.1404789686203003
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38590848",
                    "text": "Familial isolated pituitary adenoma is independent of",
                    "score_reranked": 0.8359255790710449
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17993773",
                    "text": "The most frequently described forms of familial isolated pituitary adenoma (FIPA) are familial somatotropinomas or prolactinomas.",
                    "score_reranked": 0.4573211967945099
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32604740",
                    "text": "Familial isolated pituitary adenomas (FIPA) are one of the most important inherited settings for pituitary adenomas and the most frequent genetic cause is a germline mutation in the",
                    "score_reranked": 0.3126573860645294
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31588533",
                    "text": "Pituitary tumours can also develop secondary to germline mutations as part of a complex syndrome or as familial isolated pituitary adenomas.",
                    "score_reranked": 0.19213584065437317
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20506337",
                    "text": "Familial isolated pituitary adenoma (FIPA) is an autosomal dominant condition with variable genetic background and incomplete penetrance.",
                    "score_reranked": 0.020045965909957886
                }
            ]
        },
        {
            "id": "5314a7a4dae131f847000003",
            "body": "which mutations of troponin C gene have been found to cause hypertrophic cardiomyopathy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10806205",
                "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                "http://www.ncbi.nlm.nih.gov/pubmed/14575308",
                "http://www.ncbi.nlm.nih.gov/pubmed/11735257",
                "http://www.ncbi.nlm.nih.gov/pubmed/28056232",
                "http://www.ncbi.nlm.nih.gov/pubmed/9241277",
                "http://www.ncbi.nlm.nih.gov/pubmed/32885985",
                "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                "http://www.ncbi.nlm.nih.gov/pubmed/15698845"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10806205",
                    "text": "Recently, specific missense mutations of the cTnI gene (TNNI3) have been shown to cause familial hypertrophic cardiomyopathy (HCM).",
                    "score_reranked": 3.9472100734710693
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                    "text": "Mutations in the Troponin C gene (TNNC1) are a rare genetic cause of hypertrophic cardiomyopathy.",
                    "score_reranked": 3.144514322280884
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14575308",
                    "text": "The mechanism by which mutations of the cardiac troponin I (cTnI) gene evoke familial hypertrophic cardiomyopathy (fHCM) is unknown.",
                    "score_reranked": 2.4967401027679443
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11735257",
                    "text": "Functional consequences of the mutations in human cardiac troponin I gene found in familial hypertrophic cardiomyopathy.",
                    "score_reranked": 1.9162259101867676
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28056232",
                    "text": "[Analysis of cardiac troponin C gene TNNC1 c. G175C mutation in a Chinese pedigree with familial hypertrophic cardiomyopathy and the correlation between genotype and phenotype].",
                    "score_reranked": 1.7497544288635254
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9241277",
                    "text": "Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy.",
                    "score_reranked": 1.2208293676376343
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32885985",
                    "text": "Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy.",
                    "score_reranked": 1.0589596033096313
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                    "text": "We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family.",
                    "score_reranked": 0.9701616764068604
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21262074",
                    "text": "We describe a novel type of mutation (c.363dupG) in Troponin C, a rare form of hypertrophic cardiomyopathy.",
                    "score_reranked": 0.8575596809387207
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15698845",
                    "text": "Cardiac troponin I mutations in Australian families with hypertrophic cardiomyopathy: clinical, genetic and functional consequences.",
                    "score_reranked": 0.4026665985584259
                }
            ]
        },
        {
            "id": "535d78137d100faa09000005",
            "body": "What is known about the effect of acupuncture in smoking cessation ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29933532",
                "http://www.ncbi.nlm.nih.gov/pubmed/36316847",
                "http://www.ncbi.nlm.nih.gov/pubmed/24459016",
                "http://www.ncbi.nlm.nih.gov/pubmed/26124197",
                "http://www.ncbi.nlm.nih.gov/pubmed/26182598",
                "http://www.ncbi.nlm.nih.gov/pubmed/24459016",
                "http://www.ncbi.nlm.nih.gov/pubmed/25030215",
                "http://www.ncbi.nlm.nih.gov/pubmed/32416946",
                "http://www.ncbi.nlm.nih.gov/pubmed/32416946",
                "http://www.ncbi.nlm.nih.gov/pubmed/29933532"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29933532",
                    "text": "To analyze the characteristics of smokers treated with acupuncture for smoking cessation in Hong Kong.",
                    "score_reranked": 1.43752121925354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36316847",
                    "text": "Acupuncture is an alternative option with proven effects on smoking cessation.",
                    "score_reranked": 0.4947530925273895
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24459016",
                    "text": "Acupuncture and related interventions for smoking cessation.",
                    "score_reranked": 0.481416255235672
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26124197",
                    "text": "Trial of intensive acupuncture for smoking cessation: a pilot study.",
                    "score_reranked": 0.3784835636615753
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26182598",
                    "text": "Acupuncture and related interventions for smoking.",
                    "score_reranked": 0.31258848309516907
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24459016",
                    "text": "Acupuncture and related techniques are promoted as a treatment for smoking cessation in the belief that they may reduce nicotine withdrawal symptoms.",
                    "score_reranked": 0.1824648678302765
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030215",
                    "text": "Acupuncture for smoking cessation: where now?",
                    "score_reranked": 0.022365421056747437
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32416946",
                    "text": "Acupuncture is proposed as an aid to stopping smoking.",
                    "score_reranked": -0.032346516847610474
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32416946",
                    "text": "[Acupuncture and smoking cessation, a review of the literature].",
                    "score_reranked": -0.09391209483146667
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29933532",
                    "text": "The effectiveness of acupuncture-smoking cessation was most significant in the smokers over 60.",
                    "score_reranked": -0.17048385739326477
                }
            ]
        },
        {
            "id": "56c6dd275795f9a73e000008",
            "body": "Which post-translational histone modifications are characteristic of constitutive heterochromatin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31103921",
                "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                "http://www.ncbi.nlm.nih.gov/pubmed/37178005",
                "http://www.ncbi.nlm.nih.gov/pubmed/32017156",
                "http://www.ncbi.nlm.nih.gov/pubmed/28636597",
                "http://www.ncbi.nlm.nih.gov/pubmed/27940208",
                "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                "http://www.ncbi.nlm.nih.gov/pubmed/32017156",
                "http://www.ncbi.nlm.nih.gov/pubmed/37178005"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31103921",
                    "text": "Among the different histone post-translational modifications (PTMs) associated with heterochromatin, tri-methylation of lysine 9 on histone H3 (H3K9me3) is gaining increased attention.",
                    "score_reranked": 1.6340913772583008
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                    "text": "Two types of heterochromatin exist: constitutive heterochromatin is primarily associated with trimethylation of histone H3 at lysine 9 (H3K9me3), and facultative heterochromatin with trimethylation of H3 at lysine 27 (H3K27me3).",
                    "score_reranked": 1.5583478212356567
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37178005",
                    "text": "Histone H3 lysine 9 trimethylation (H3K9me3) and lysine 27 trimethylation (H3K27me3) are two major epigenetic modifications that enrich constitutive and facultative heterochromatin, respectively.",
                    "score_reranked": 1.532570481300354
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32017156",
                    "text": "Establishment and evolution of heterochromatin.",
                    "score_reranked": 0.3701591193675995
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28636597",
                    "text": "Heterochromatin is highly enriched for repetitive sequences, and is defined epigenetically by methylation of histone H3 at lysine 9 and recruitment of its binding partner heterochromatin protein 1 (HP1).",
                    "score_reranked": 0.3432622253894806
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940208",
                    "text": "This histone modification is a feature of facultative heterochromatin in many eukaryotes and maintains transcriptional repression established during early development.",
                    "score_reranked": 0.33044102787971497
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                    "text": "Heterochromatin regulation is primarily achieved by controlling histone modifications.",
                    "score_reranked": 0.30486467480659485
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31198932",
                    "text": "Heterochromatin is a condensed and transcriptionally silent chromatin structure and that plays important roles in epigenetic regulation of the genome.",
                    "score_reranked": 0.04737958312034607
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32017156",
                    "text": "We summarize here the ever-changing characteristics of heterochromatin and propose models and principles for the evolutionary transitions of heterochromatin that have been mainly learned from studies of Drosophila and yeast.",
                    "score_reranked": -0.16206297278404236
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37178005",
                    "text": "In the mammalian nucleus, heterochromatin segregates from transcriptionally active genomic regions and exists in large, condensed, and inactive nuclear compartments.",
                    "score_reranked": -0.6792187690734863
                }
            ]
        },
        {
            "id": "56c1f02cef6e39474100004c",
            "body": "GV1001 vaccine targets which enzyme?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20822343",
                "http://www.ncbi.nlm.nih.gov/pubmed/36183673",
                "http://www.ncbi.nlm.nih.gov/pubmed/21377838",
                "http://www.ncbi.nlm.nih.gov/pubmed/21377838",
                "http://www.ncbi.nlm.nih.gov/pubmed/23827187",
                "http://www.ncbi.nlm.nih.gov/pubmed/22841437",
                "http://www.ncbi.nlm.nih.gov/pubmed/27363520",
                "http://www.ncbi.nlm.nih.gov/pubmed/20822343",
                "http://www.ncbi.nlm.nih.gov/pubmed/22934259",
                "http://www.ncbi.nlm.nih.gov/pubmed/20822343"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343",
                    "text": "GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development.",
                    "score_reranked": 1.5450119972229004
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36183673",
                    "text": "GV1001, a human telomerase reverse transcriptase catalytic subunit-derived 16-mer peptide, has been developed as a novel anticancer vaccine against various cancers including pancreatic cancer.",
                    "score_reranked": 1.23952317237854
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21377838",
                    "text": "The telomerase-specific peptide vaccination GV1001 has shown promising results in previous studies.",
                    "score_reranked": 0.9847633838653564
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21377838",
                    "text": "Since telomerase is expressed in malignant cells of CTCL, GV1001 vaccination in CTCL is a promising new therapeutic approach.",
                    "score_reranked": 0.832648515701294
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23827187",
                    "text": "A reverse-transcriptase-subunit of telomerase (hTERT) derived peptide, GV1001, has been developed as a vaccine against various cancers.",
                    "score_reranked": 0.7013964653015137
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22841437",
                    "text": "Based on this review, the most promising current telomerase targeting therapeutics are the antisense oligonucleotide inhibitor GRN163L and immunotherapies that use dendritic cells (GRVAC1), hTERT peptide (GV1001) or cryptic peptides (Vx-001).",
                    "score_reranked": 0.6066738367080688
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27363520",
                    "text": "A peptide vaccine designed to induce T-cell immunity to telomerase, GV1001, has been shown to modulate cellular signaling pathways and confer a direct anti-cancer effect through the interaction with heat shock protein (HSP) 90 and 70.",
                    "score_reranked": 0.5606676340103149
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343",
                    "text": "It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.",
                    "score_reranked": 0.4665985405445099
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934259",
                    "text": "Extensive characterization of CD4+ T-cell clones specific for GV1001 generated from a lung cancer patient in complete remission after vaccination demonstrated a very broad immune response to this single peptide vaccine with differences in fine specificity, HLA restriction, affinity and function.",
                    "score_reranked": 0.07003822922706604
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20822343",
                    "text": "Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.",
                    "score_reranked": 0.0031431615352630615
                }
            ]
        },
        {
            "id": "550af222c2af5d5b7000000b",
            "body": "Which is the E3 ubiquitin ligase which ubiquitinates IkB leading to its proteasomal degradation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35373703",
                "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                "http://www.ncbi.nlm.nih.gov/pubmed/22496598",
                "http://www.ncbi.nlm.nih.gov/pubmed/22496598",
                "http://www.ncbi.nlm.nih.gov/pubmed/21496385",
                "http://www.ncbi.nlm.nih.gov/pubmed/10455908",
                "http://www.ncbi.nlm.nih.gov/pubmed/16490171",
                "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                "http://www.ncbi.nlm.nih.gov/pubmed/22708077"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35373703",
                    "text": "Moreover, LINC01605 recruited IGF2BP2 to stabilize ubiquitin-specific protease 3 (USP3) mRNA and thereby enhanced the stability of IkB subunit beta (IKK\u03b2) protein.",
                    "score_reranked": 2.145117998123169
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                    "text": "Thus, new approaches to modulating NF-kB activation, and as a consequence inflammatory or metastatic processes, may take advantage of the selectivity of the ubiquitination and ATP-dependent proteolytic processes leading to IkB turnover.",
                    "score_reranked": 1.1563398838043213
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                    "text": "Phosphorylation targets IkB for ubiquitination and degradation by the 26S proteasome thus leading to NF-kB nuclear translocation.",
                    "score_reranked": 0.8080518245697021
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496598",
                    "text": "In the adhered tissue an increased values of ubiquitin and the 20S proteasome subunit, NFkB, IL-6, TNF-\u03b1 and decreased values of IkB-beta were found.",
                    "score_reranked": 0.583418607711792
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22496598",
                    "text": "In contrast, bortezomib-treated rats showed a decreased number of peritoneal adhesions, decreased values of ubiquitin and the 20S proteasome, NFkB, IL-6, TNF-\u03b1, and increased levels of IkB-beta in the adhered peritoneal tissue.",
                    "score_reranked": 0.4345240890979767
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21496385",
                    "text": "The purpose of this study is to investigate the effects of blocking the actions of NFkB, through inhibition of the ubiquitin-proteasome system (UPS) or IkB kinase (IKK), in a murine model of asthma.",
                    "score_reranked": 0.3731551468372345
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10455908",
                    "text": "Nuclear translocation of NF-kB requires degradation of ubiquitinated phospho-IkB-a by the 26S proteasome.",
                    "score_reranked": 0.2680110037326813
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16490171",
                    "text": "PDTC prevents the degradation of IkappaB alpha via the ubiquitylation-proteasome proteolytic pathway.",
                    "score_reranked": 0.23997178673744202
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11467077",
                    "text": "The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB).",
                    "score_reranked": 0.19686177372932434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22708077",
                    "text": "Here, we report that, unlike other IkBs, ubiquitination and destruction of NFkB2 are governed by SCF(Fbw7) in a GSK3-dependent manner.",
                    "score_reranked": -0.15356633067131042
                }
            ]
        },
        {
            "id": "5318a955b166e2b806000020",
            "body": "Is c-met involved in the activation of the Akt pathway?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40339768",
                "http://www.ncbi.nlm.nih.gov/pubmed/40378957",
                "http://www.ncbi.nlm.nih.gov/pubmed/40295046",
                "http://www.ncbi.nlm.nih.gov/pubmed/40339768",
                "http://www.ncbi.nlm.nih.gov/pubmed/40386723",
                "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                "http://www.ncbi.nlm.nih.gov/pubmed/40386723",
                "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                "http://www.ncbi.nlm.nih.gov/pubmed/40360533"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40339768",
                    "text": "Critical pathways, such as c-Met and PTEN/AKT, play crucial roles within the regulatory network of miR-206 in CRC and impact various cellular processes involved in CRC pathogenesis, metastasis, and treatment response.",
                    "score_reranked": 0.8021825551986694
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40378957",
                    "text": "These proteins are involved in regulating key signaling proteins and pathways that are often dysregulated in cancer, such as EGFR, PI3K/AKT, c-Met, and the Wnt pathway.",
                    "score_reranked": 0.6030411720275879
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40295046",
                    "text": "Immunohistochemical analysis was conducted to evaluate the expression of PTEN and phosphorylated AKT (P-AKT/PKB), a key component of the PI3K/AKT pathway regulated by PTEN.",
                    "score_reranked": 0.4378310739994049
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40339768",
                    "text": "Understanding the complex interactions between miR-206 and key signaling pathways like c-Met and PTEN/AKT is crucial for understanding the underlying mechanisms driving CRC initiation and progression.",
                    "score_reranked": 0.30195608735084534
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40386723",
                    "text": "The mesenchymal-epithelial transition factor (MET) proto-oncogene plays an important role in the development of non-small cell lung cancer (NSCLC).",
                    "score_reranked": 0.03488364815711975
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                    "text": "TRIB3 recruits and stabilizes CARM1 to confer chemoresistance by activating Akt signalling in clear cell renal cancer cells.",
                    "score_reranked": -0.06644752621650696
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                    "text": "Our findings uncovering a novel TRIB3-CARM1-Akt axis as a central driver of sunitinib resistance.",
                    "score_reranked": -0.42628857493400574
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40386723",
                    "text": "MET tyrosine kinase inhibitors (TKIs) have shown promising antitumor activity in patients with NSCLC harboring MET alterations.",
                    "score_reranked": -0.5674573183059692
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40286768",
                    "text": "Elevated CARM1 further exacerbates therapeutic resistance, establishing a feedforward loop that sustains Akt activation.",
                    "score_reranked": -1.272681474685669
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40360533",
                    "text": "This complex activates MAPK/AKT signaling, Src/PI3K/AKT, and Smad2/3 pathways which is a reason for tumor proliferation.",
                    "score_reranked": -1.5553171634674072
                }
            ]
        },
        {
            "id": "531a3fe3b166e2b806000038",
            "body": "Is pregnancy an additional risk during during H1N1 infection?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19444154",
                "http://www.ncbi.nlm.nih.gov/pubmed/19940421",
                "http://www.ncbi.nlm.nih.gov/pubmed/32029047",
                "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                "http://www.ncbi.nlm.nih.gov/pubmed/20100064",
                "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                "http://www.ncbi.nlm.nih.gov/pubmed/22272853",
                "http://www.ncbi.nlm.nih.gov/pubmed/33449966",
                "http://www.ncbi.nlm.nih.gov/pubmed/33274169"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19444154",
                    "text": "During seasonal influenza epidemics and previous pandemics, pregnant women have been at increased risk for complications related to influenza infection.",
                    "score_reranked": 0.6942414045333862
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19940421",
                    "text": "During pregnancy both mother and baby are at increased risk when infected with either pandemic or seasonal influenza.",
                    "score_reranked": 0.619316816329956
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029047",
                    "text": "Pregnancy has increased susceptibility to H1N1 influenza virus infection.",
                    "score_reranked": 0.47466757893562317
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                    "text": "Pregnant women with H1N1 infection are at higher risk of pneumonia and death than other women in the reproductive period.",
                    "score_reranked": -0.01952698826789856
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20100064",
                    "text": "Pregnant women have been identified as a group at risk of increased morbidity and mortality associated with the pandemic H1N1 influenza A 2009 (H1N1/09) outbreak.",
                    "score_reranked": -0.03714224696159363
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                    "text": "Pregnant women are at higher risk of developing severe influenza.",
                    "score_reranked": -0.09000912308692932
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31865302",
                    "text": "Our aim was to analyze clinical course and risk factors for fatal outcome in pregnant women with influenza (H1N1) infection.",
                    "score_reranked": -0.10365989804267883
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22272853",
                    "text": "Pregnancy, with or without additional complications, constitutes a high-risk condition for complications of influenza infection and warrants early intervention with neuraminidase inhibitors such as oseltamivir, if influenza is suspected.",
                    "score_reranked": -0.4393826425075531
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33449966",
                    "text": "Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study.",
                    "score_reranked": -0.44027838110923767
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33274169",
                    "text": "Evaluation of Pregnancy, Younger Age, and Old Age as Independent Risk Factors for Poor Hospitalization Outcomes in Influenza A (H1N1)pdm09 Virus a Decade After the Pandemic.",
                    "score_reranked": -0.8096482753753662
                }
            ]
        },
        {
            "id": "51757bbb8ed59a060a00002e",
            "body": "Are long non coding RNAs as conserved in sequence as protein coding genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30400819",
                "http://www.ncbi.nlm.nih.gov/pubmed/33575549",
                "http://www.ncbi.nlm.nih.gov/pubmed/37260771",
                "http://www.ncbi.nlm.nih.gov/pubmed/31405016",
                "http://www.ncbi.nlm.nih.gov/pubmed/34506887",
                "http://www.ncbi.nlm.nih.gov/pubmed/32156600",
                "http://www.ncbi.nlm.nih.gov/pubmed/31454122",
                "http://www.ncbi.nlm.nih.gov/pubmed/33575549",
                "http://www.ncbi.nlm.nih.gov/pubmed/32156600",
                "http://www.ncbi.nlm.nih.gov/pubmed/33575549"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30400819",
                    "text": "However, unlike protein coding genes the poor sequence conservation of long non-coding genes makes the identification of their homologs a challenging task.",
                    "score_reranked": 2.098665714263916
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33575549",
                    "text": "Conserved regions in long non-coding RNAs contain abundant translation and protein-RNA interaction signatures.",
                    "score_reranked": 1.3775027990341187
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37260771",
                    "text": "Functional inference of long non-coding RNAs through exploration of highly conserved regions.",
                    "score_reranked": 1.2612950801849365
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31405016",
                    "text": "Long non-coding RNAs (lncRNAs) are a diverse class of transcripts that structurally resemble mRNAs",
                    "score_reranked": 1.2501671314239502
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34506887",
                    "text": "Here, we used RNA sequencing to determine differentially expressed protein coding (PC) and long non-coding (lncRNA) transcripts within the heart chambers across seven vertebrate species and identified evolutionarily conserved chamber specific genes, lncRNAs and pathways.",
                    "score_reranked": 1.1949635744094849
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32156600",
                    "text": "Evolution of new proteins from translated sORFs in long non-coding RNAs.",
                    "score_reranked": 1.0339528322219849
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31454122",
                    "text": "lncRNAs, genes transcribed but not translated, longer than 200 nucleotides, are classified as a separate class of nonprotein coding genes.",
                    "score_reranked": 0.964630126953125
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33575549",
                    "text": "The study also reveals that conserved regions in intergenic lncRNAs are significantly enriched in protein-RNA interaction signatures when compared to non-conserved ones; this includes sites in well-characterized lncRNAs, such as",
                    "score_reranked": 0.5895365476608276
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32156600",
                    "text": "Unlike canonical protein-coding genes, lncRNAs do not contain long open reading frames (ORFs) and tend to be poorly conserved across species.",
                    "score_reranked": 0.256615549325943
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33575549",
                    "text": "We find that lncRNA-conserved regions contain three times more ORFs with translation evidence than non-conserved ones, and identify nine cases that display significant sequence constraints at the amino acid sequence level.",
                    "score_reranked": -1.6559479236602783
                }
            ]
        },
        {
            "id": "56c1f03bef6e394741000053",
            "body": "Mutation of which gene is implicated in the Brain-lung-thyroid syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40033291",
                "http://www.ncbi.nlm.nih.gov/pubmed/39905544",
                "http://www.ncbi.nlm.nih.gov/pubmed/40350738",
                "http://www.ncbi.nlm.nih.gov/pubmed/39905544",
                "http://www.ncbi.nlm.nih.gov/pubmed/40350738",
                "http://www.ncbi.nlm.nih.gov/pubmed/40291819",
                "http://www.ncbi.nlm.nih.gov/pubmed/40038168",
                "http://www.ncbi.nlm.nih.gov/pubmed/40291819",
                "http://www.ncbi.nlm.nih.gov/pubmed/40387751",
                "http://www.ncbi.nlm.nih.gov/pubmed/40038168"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40033291",
                    "text": "The deleted region is predicted to include multiple transcription factor binding sites, such as Stat2, Zic1, Zic2, and FOXD3, which are crucial for the neurodevelopmental process, as well as a regulatory element including an eQTL (rs1263181) that is implicated in the tissue-specific regulation of SLC16A2 expression, notably in skeletal muscle and thyroid tissues.",
                    "score_reranked": 1.4106760025024414
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39905544",
                    "text": "A previously identified missense variant (c.221C\u2009>\u2009T) in the SOX5 gene was determined to be the underlying cause of intellectual disability in a Chinese family.",
                    "score_reranked": 0.41561630368232727
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40350738",
                    "text": "Contiguous gene syndromes (CGS) arise from microdeletions and other aberrations of a chromosome region containing several gene loci.",
                    "score_reranked": 0.23726025223731995
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39905544",
                    "text": "A missense variant in the SOX5 gene (c.221C\u2009>\u2009T) is associated with intellectual disability.",
                    "score_reranked": 0.2293476164340973
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40350738",
                    "text": "The child's mother was diagnosed with the same mutation, including 11 genes in the imbalance region.",
                    "score_reranked": 0.162704199552536
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40291819",
                    "text": "Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked neurodevelopmental disorder caused by mutations in the solute carrier family 16-member 2 ( A blood specimen was collected from a one-year-old child with delayed development and abnormal thyroid function and this was followed by whole-exome sequencing (WES) was performed on the proband to identify potential genetic mutations.",
                    "score_reranked": 0.12017300724983215
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40038168",
                    "text": "Variants in multiple genes in the 22q11.2 region, especially the TBX1 and DGCR8 genes, have been linked to the clinical phenotypes of 22q11.2 DS and 22q11.2 DupS. Variations in genes on the non-deleted homologous chromosome in the critical 22q11.2 region can further influence phenotypes by revealing recessive diseases.",
                    "score_reranked": 0.09773114323616028
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40291819",
                    "text": "The proband, who presented with developmental delay, thyroid dysfunction, and abnormal brain development, was found to have a novel hemizygous frameshift mutation, c.513_538del (p.Ile172Cysfs*60), in the  This study identified a novel frameshift mutation in the",
                    "score_reranked": -0.03596588969230652
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40387751",
                    "text": "An NGS panel targeting 155 genes related to inborn errors of metabolism, hearing loss, severe combined immunodeficiency, congenital hypothyroidism, and other actionable genetic diseases, was designed.",
                    "score_reranked": -0.3202113211154938
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40038168",
                    "text": "22q11.2 deletion and duplication syndromes are complex genetic syndromes composed of a wide spectrum of clinical manifestations, mostly affecting cardiovascular, endocrine, neurodevelopmental, and immune functioning.",
                    "score_reranked": -0.6081879138946533
                }
            ]
        },
        {
            "id": "52d946c798d023950500000a",
            "body": "What is clathrin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                "http://www.ncbi.nlm.nih.gov/pubmed/40305091",
                "http://www.ncbi.nlm.nih.gov/pubmed/39978713",
                "http://www.ncbi.nlm.nih.gov/pubmed/40112806",
                "http://www.ncbi.nlm.nih.gov/pubmed/40112806",
                "http://www.ncbi.nlm.nih.gov/pubmed/40062769",
                "http://www.ncbi.nlm.nih.gov/pubmed/40062769",
                "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                "http://www.ncbi.nlm.nih.gov/pubmed/39973445"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                    "text": "Clathrin is a key protein involved in receptor-mediated endocytosis (RME), which is also known as clathrin-mediated endocytosis (CME).",
                    "score_reranked": 0.6022673845291138
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40305091",
                    "text": "Clathrin-mediated endocytosis involves the remodeling of membranes via the initiation, maturation, and scission of clathrin-coated pits (CCPs).",
                    "score_reranked": -0.005367785692214966
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39978713",
                    "text": "Although several endocytic pathways, such as clathrin-mediated and caveolin-mediated endocytosis, are well-characterized, other endocytic pathways remain poorly understood.",
                    "score_reranked": -0.15563218295574188
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40112806",
                    "text": "Next-generation small molecule inhibitors of clathrin function acutely inhibit endocytosis.",
                    "score_reranked": -0.290270060300827
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40112806",
                    "text": "Clathrin-mediated endocytosis (CME) is the predominant endocytic pathway in eukaryotic cells and a major regulator of cell physiology as it facilitates the internalization of receptors, channels, and transporters and viral entry.",
                    "score_reranked": -0.2916509509086609
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40062769",
                    "text": "Beyond Clathrin: Decoding the Mechanism of Ultrafast Endocytosis.",
                    "score_reranked": -0.3338845670223236
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40062769",
                    "text": "In this review, we compare the mechanisms of protein recruitment during clathrin-mediated endocytosis in non-neuronal cells and ultrafast endocytosis in neurons and discuss how endocytosis can complete within 100 milliseconds.",
                    "score_reranked": -0.3728257417678833
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                    "text": "In this study, we clarified the unknown roles of clathrin during intracellular trafficking.",
                    "score_reranked": -0.39851975440979004
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                    "text": "Clathrin functions in intracellular sorting during receptor-mediated endocytosis.",
                    "score_reranked": -0.4061247706413269
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39973445",
                    "text": "This suggests that clathrin contributes to the recycling and exocytosis of endocytosed molecules.",
                    "score_reranked": -0.42593345046043396
                }
            ]
        },
        {
            "id": "5322d9339b2d7acc7e000011",
            "body": "What are the main results of PRKAR1A Knockdown?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27995993",
                "http://www.ncbi.nlm.nih.gov/pubmed/24506536",
                "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                "http://www.ncbi.nlm.nih.gov/pubmed/27995993",
                "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                "http://www.ncbi.nlm.nih.gov/pubmed/32738126",
                "http://www.ncbi.nlm.nih.gov/pubmed/32738126",
                "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                "http://www.ncbi.nlm.nih.gov/pubmed/23480756",
                "http://www.ncbi.nlm.nih.gov/pubmed/24506536"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995993",
                    "text": "The re-expression of PRKAR1A in H1299 cells suppressed the tumor cell proliferation and migration; stable knockdown (KD) of PRKAR1A in A549 cells enhanced this function both in vitro and in vivo.",
                    "score_reranked": 0.9741485118865967
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506536",
                    "text": "Knockdown of PRKAR1A, the gene responsible for Carney complex, interferes with differentiation in osteoblastic cells.",
                    "score_reranked": 0.740383505821228
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                    "text": "Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells.",
                    "score_reranked": 0.6420001983642578
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995993",
                    "text": "Loss of PRKAR1A was frequently observed in endocrine neoplasia and stromal cell tumors.",
                    "score_reranked": 0.4821617901325226
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                    "text": "The aim of this study was to compare the effects of PRKAR1A and PRKAR2B depletion on cell proliferation, apoptosis, cell signaling pathways, and cell cycle regulation.",
                    "score_reranked": 0.3889552056789398
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32738126",
                    "text": "Knockdown of PKA's catalytic subunit (PRKACA) by siRNA reduced c-KIT levels.",
                    "score_reranked": 0.3009026348590851
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32738126",
                    "text": "PRKAR1A-deficient CAR47 cells expressed c-KIT; this was enhanced by forskolin and lowered by PRKAR1A reintroduction.",
                    "score_reranked": 0.29154714941978455
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25268545",
                    "text": "We previously showed that PRKAR1A and PRKAR2B inactivation have anti-apoptotic effects on the adrenocortical carcinoma cell line H295R.",
                    "score_reranked": 0.26066622138023376
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23480756",
                    "text": "The results revealed that PRKAR1A suppressed CCA cell lines demonstrated enhanced sensitivity to some chemotherapeutic drugs when compared to control cells.",
                    "score_reranked": 0.2536579668521881
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24506536",
                    "text": "To validate this hypothesis, we generated stable Prkar1a knockdown in both mouse and human cells.",
                    "score_reranked": -0.4878182113170624
                }
            ]
        },
        {
            "id": "535d75ab7d100faa09000004",
            "body": "Is TENS machine effective in pain?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17333874",
                "http://www.ncbi.nlm.nih.gov/pubmed/17338424",
                "http://www.ncbi.nlm.nih.gov/pubmed/17333874",
                "http://www.ncbi.nlm.nih.gov/pubmed/7885874",
                "http://www.ncbi.nlm.nih.gov/pubmed/6600517",
                "http://www.ncbi.nlm.nih.gov/pubmed/31014125",
                "http://www.ncbi.nlm.nih.gov/pubmed/6600517",
                "http://www.ncbi.nlm.nih.gov/pubmed/17338424",
                "http://www.ncbi.nlm.nih.gov/pubmed/31014125",
                "http://www.ncbi.nlm.nih.gov/pubmed/3266072"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333874",
                    "text": "This article, the second in a two-part series, outlines how to set up and use a TENS machine to achieve the most effective results.",
                    "score_reranked": 0.9294698238372803
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17338424",
                    "text": "Use of tens in pain management. Part One: How TENS works.",
                    "score_reranked": 0.8939781188964844
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17333874",
                    "text": "Use of tens in pain management: part two--how to use tens.",
                    "score_reranked": 0.7811353206634521
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7885874",
                    "text": "Pain control: TENS machines.",
                    "score_reranked": 0.5152831077575684
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6600517",
                    "text": "Seventy-five patients who underwent laparotomy and received TENS at the most comfortable machine settings were compared by chart review to 75 patients who had undergone similar surgical procedures performed by the same surgeon before TENS postoperative pain management had been instituted.",
                    "score_reranked": 0.4523700773715973
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31014125",
                    "text": "This is a different theoretical mechanism than the traditional electric stimulation of A-Beta fibers to produce paresthesia and/or block the conduction of nerve fibers to produce an analgesic effect, that is, via TENS (transcutaneous electrical nerve stimulation) machines.",
                    "score_reranked": 0.4040488302707672
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6600517",
                    "text": "The TENS was applied for an average of five days; machine settings of intensity, frequency, and pulse width tended to be midrange.",
                    "score_reranked": 0.3082943260669708
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17338424",
                    "text": "Transcutaneous electrical nerve stimulation machines are widely available and used to treat many painful conditions.",
                    "score_reranked": -0.21424870193004608
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31014125",
                    "text": "Scrambler therapy (ST) is an electro-analgesia therapy for the noninvasive treatment of chronic neuropathic and cancer pain based on a new generation of medical device that uses 5 artificial neurons and is based on a novel theoretical model the differs from gate control theory.",
                    "score_reranked": -0.9807356595993042
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3266072",
                    "text": "Each patient served as her own control by switching off the machine for 2 contractions every hour and then recording the intensity of pain.",
                    "score_reranked": -1.0852216482162476
                }
            ]
        },
        {
            "id": "56d1d14567f0cb3d66000003",
            "body": "Is there any algorithm for enhancer identification from chromatin state?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40170155",
                "http://www.ncbi.nlm.nih.gov/pubmed/20453004",
                "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                "http://www.ncbi.nlm.nih.gov/pubmed/28056037",
                "http://www.ncbi.nlm.nih.gov/pubmed/28056037",
                "http://www.ncbi.nlm.nih.gov/pubmed/20453004",
                "http://www.ncbi.nlm.nih.gov/pubmed/23771147",
                "http://www.ncbi.nlm.nih.gov/pubmed/27582178",
                "http://www.ncbi.nlm.nih.gov/pubmed/27582178",
                "http://www.ncbi.nlm.nih.gov/pubmed/20453004"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40170155",
                    "text": "Accurate identification of chromatin loops is essential for understanding the regulatory mechanisms in disease.",
                    "score_reranked": 0.7821950912475586
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20453004",
                    "text": "We implemented our framework in a software tool CSI-ANN (chromatin signature identification by artificial neural network).",
                    "score_reranked": 0.45473888516426086
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26091399",
                    "text": "DELTA: A Distal Enhancer Locating Tool Based on AdaBoost Algorithm and Shape Features of Chromatin Modifications.",
                    "score_reranked": 0.4529680907726288
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28056037",
                    "text": "Accurate Promoter and Enhancer Identification in 127 ENCODE and Roadmap Epigenomics Cell Types and Tissues by GenoSTAN.",
                    "score_reranked": 0.42918047308921814
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28056037",
                    "text": "Promoters and enhancers are usually mapped by integration of chromatin assays charting histone modifications, DNA accessibility, and transcription factor binding.",
                    "score_reranked": 0.31008681654930115
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20453004",
                    "text": "We introduce a new computational framework for identifying functional DNA elements using chromatin signatures.",
                    "score_reranked": 0.2797801196575165
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771147",
                    "text": "We have recently developed a novel computational methodology, which uses a support vector machine (SVM) with kmer sequence features (kmer-SVM) to identify predictive combinations of short transcription factor-binding sites, which determine the tissue specificity of these genomic assays (Lee, Karchin and Beer, Discriminative prediction of mammalian enhancers from DNA sequence.",
                    "score_reranked": -0.2523549497127533
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582178",
                    "text": "However, enhancers are difficult to identify because they generally do not have fixed positions or consensus sequence features, and biological experiments for enhancer identification are costly in terms of labor and expense.",
                    "score_reranked": -0.45522424578666687
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27582178",
                    "text": "In silico identification of enhancers on the basis of a combination of transcription factor binding motif occurrences.",
                    "score_reranked": -0.48713240027427673
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20453004",
                    "text": "Discover regulatory DNA elements using chromatin signatures and artificial neural network.",
                    "score_reranked": -0.8364627361297607
                }
            ]
        },
        {
            "id": "532498959b2d7acc7e000017",
            "body": "Which enzyme is targeted by the drug Imetelstat?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26479411",
                "http://www.ncbi.nlm.nih.gov/pubmed/30389730",
                "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
                "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
                "http://www.ncbi.nlm.nih.gov/pubmed/32571117",
                "http://www.ncbi.nlm.nih.gov/pubmed/27213497",
                "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
                "http://www.ncbi.nlm.nih.gov/pubmed/30389730",
                "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
                "http://www.ncbi.nlm.nih.gov/pubmed/37216228"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26479411",
                    "text": "Furthermore, calculated IC50-values for the oligonucleotide delivered by CPPs into HeLa cells are more than 20 times lower than telomerase inhibitor Imetelstat, currently undergoing clinical trials.",
                    "score_reranked": 1.1940487623214722
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30389730",
                    "text": "Imetelstat, a 13-base oligonucleotide (5'-TAGGGTTAGACAA-3'), is a potent, investigational telomerase inhibitor in clinical development for the treatment of hematologic myeloid malignancies.",
                    "score_reranked": 1.0778770446777344
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
                    "text": "Imetelstat (GRN163L) is a potent and specific telomerase inhibitor and so far the only drug of its class in clinical trials.",
                    "score_reranked": 0.6786383390426636
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
                    "text": "imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3'\u2192P5' thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit.",
                    "score_reranked": 0.4846058189868927
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32571117",
                    "text": "Imetelstat is a specific and competitive inhibitor of telomerase enzymatic activity.",
                    "score_reranked": 0.21488913893699646
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27213497",
                    "text": "Preclinical and clinical studies have shown that imetelstat, a competitive inhibitor of telomerase, has activity in certain hematologic malignancies, in particular the myeloproliferative neoplasms and acute myeloid leukemia.",
                    "score_reranked": 0.007691413164138794
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23545855",
                    "text": "Imetelstat (a telomerase antagonist) exerts off\u2011target effects on the cytoskeleton.",
                    "score_reranked": 0.006662517786026001
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30389730",
                    "text": "Characterization of the In Vitro Inhibitory Potential of the Oligonucleotide Imetelstat on Human Cytochrome P450 Enzymes with Predictions of In Vivo Drug-Drug Interactions.",
                    "score_reranked": -0.43935999274253845
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20072842",
                    "text": "Here, we report on the structure and the mechanism of action of imetelstat as well as about the preclinical and clinical data and future prospects using imetelstat in cancer therapy.",
                    "score_reranked": -0.9472787380218506
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37216228",
                    "text": "We overview all mechanisms of targeting telomerase that are currently in development, with a particular focus on imetelstat, an oligonucleotide with direct telomerase inhibitory properties that has advanced the furthest in clinical development and has demonstrated promising data in multiple myeloid malignancies.",
                    "score_reranked": -1.1231064796447754
                }
            ]
        },
        {
            "id": "56c1f005ef6e39474100003a",
            "body": "Which interleukins are inhibited by Dupilumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35746582",
                "http://www.ncbi.nlm.nih.gov/pubmed/40161158",
                "http://www.ncbi.nlm.nih.gov/pubmed/36988167",
                "http://www.ncbi.nlm.nih.gov/pubmed/38141197",
                "http://www.ncbi.nlm.nih.gov/pubmed/36219538",
                "http://www.ncbi.nlm.nih.gov/pubmed/35414583",
                "http://www.ncbi.nlm.nih.gov/pubmed/34572281",
                "http://www.ncbi.nlm.nih.gov/pubmed/36894196",
                "http://www.ncbi.nlm.nih.gov/pubmed/34572281",
                "http://www.ncbi.nlm.nih.gov/pubmed/35394682"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35746582",
                    "text": "The fully human IgG4 monoclonal antibody dupilumab binds to IL-4R\u03b1, thereby preventing its interactions with both IL-4 and IL-13.",
                    "score_reranked": 0.7023084163665771
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40161158",
                    "text": "Dupilumab, a monoclonal antibody, acts as a dual-action inhibitor that effectively suppresses interleukin-4 (IL-4) and interleukin-13 (IL-13) secretion, which plays an important role in type 2 inflammation.",
                    "score_reranked": 0.6753919124603271
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36988167",
                    "text": "Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor inhibiting the signaling of interleukin-4 and interleukin-13, two major cytokines in type 2 inflammatory diseases such as atopic dermatitis, asthma and nasosinusal polyposis.",
                    "score_reranked": 0.6104439496994019
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38141197",
                    "text": "Dupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases.",
                    "score_reranked": 0.6053028106689453
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36219538",
                    "text": "Dupilumab, as one of the most widely applied Th2 cytokine inhibitors, could block the bioactivity of IL-14/IL-13 via competitively binding to the common IL-4R\u03b1 subunit shared by IL-4 and IL-13 receptors.",
                    "score_reranked": 0.5468331575393677
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35414583",
                    "text": "She had previously failed treatments and was started on dupilumab (which binds to the interleukin-4 [IL4] receptor and inhibits both IL-4 and IL-13).",
                    "score_reranked": 0.10168817639350891
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572281",
                    "text": "Dupilumab is a fully humanized monoclonal antibody, capable of inhibiting intracellular signaling of both interleukin (IL)-4 and IL-13.",
                    "score_reranked": 0.0181979238986969
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36894196",
                    "text": "Dupilumab (DUP) is a monoclonal antibody that acts on the interleukin (IL)-4 receptor alpha, which inhibits IL-4 and IL-13 signalling and is approved for type 2 inflammatory diseases such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis; however, the efficacy of DUP to IgG4-related disease (IgG4-RD) is under discussion due to the controversial outcomes based on the several case reports.",
                    "score_reranked": -0.05842754244804382
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34572281",
                    "text": "The dual inhibition of IL-4 and IL-13 activities is due to the blockade of type II IL-4 receptor through the binding of dupilumab with the subunit IL-4R\u03b1.",
                    "score_reranked": -0.12539061903953552
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35394682",
                    "text": "Inhibiting the type 2 inflammatory pathway with dupilumab is associated with an increase in interleukin-4 and interleukin-18 production.",
                    "score_reranked": -0.7733218669891357
                }
            ]
        },
        {
            "id": "513ce3c8bee46bd34c000008",
            "body": "Which human genes are more commonly related to craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/36982425",
                "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                "http://www.ncbi.nlm.nih.gov/pubmed/26289989",
                "http://www.ncbi.nlm.nih.gov/pubmed/36980886",
                "http://www.ncbi.nlm.nih.gov/pubmed/37883470",
                "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                "http://www.ncbi.nlm.nih.gov/pubmed/37070824",
                "http://www.ncbi.nlm.nih.gov/pubmed/36980886",
                "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                "http://www.ncbi.nlm.nih.gov/pubmed/26289989"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36982425",
                    "text": "Transcriptomic Signatures of Single-Suture Craniosynostosis Phenotypes.",
                    "score_reranked": 0.4629807770252228
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                    "text": "The suggested genetic causes of craniosynostosis are pathogenic variants in FGFR1, FGFR2, FGFR3, and TWIST1 genes.",
                    "score_reranked": 0.32588592171669006
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26289989",
                    "text": "Clinical and genetic characteristics of craniosynostosis in Hungary.",
                    "score_reranked": -0.026497691869735718
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36980886",
                    "text": "Review of Recurrently Mutated Genes in Craniosynostosis Supports Expansion of Diagnostic Gene Panels.",
                    "score_reranked": -0.04514142870903015
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37883470",
                    "text": "We hypothesized that the two noncoding genomic regions identified by a GWAS for craniosynostosis contain distal regulatory elements for the risk genes BMPER and BMP2.",
                    "score_reranked": -0.2128821313381195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                    "text": "Craniosynostosis is one of the major genetic disorders affecting 1 in 2,100-2,500 live newborn children.",
                    "score_reranked": -0.42455610632896423
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37070824",
                    "text": "Systematic Review of Nonsyndromic Craniosynostosis: Genomic Alterations and Impacted Signaling Pathways.",
                    "score_reranked": -0.5095844268798828
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36980886",
                    "text": "We provide a systematic review of genetic literature on craniosynostosis over the last 5 years, including additional results from resequencing a 42-gene panel in 617 affected individuals.",
                    "score_reranked": -0.6647509336471558
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32510873",
                    "text": "On the other hand, it would be important to include other genes, such as TCF12 (OMIM 600,480), MSX2 (OMIM 123,101), RAB23 (OMIM 606,144), and EFNB1 (OMIM 300,035), to determine their participation in craniosynostosis in the Mexican population.",
                    "score_reranked": -0.7587413787841797
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26289989",
                    "text": "The purpose of this study was to investigate the clinical and molecular characteristics of craniosynostoses in Hungary, including the classification of patients and the genetic analysis of the syndromic forms.",
                    "score_reranked": -1.031896948814392
                }
            ]
        },
        {
            "id": "553f78c7ab98a37113000008",
            "body": "Are transcribed ultraconserved regions involved in cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                "http://www.ncbi.nlm.nih.gov/pubmed/17785203",
                "http://www.ncbi.nlm.nih.gov/pubmed/35015757",
                "http://www.ncbi.nlm.nih.gov/pubmed/35978878",
                "http://www.ncbi.nlm.nih.gov/pubmed/27447964",
                "http://www.ncbi.nlm.nih.gov/pubmed/28916343",
                "http://www.ncbi.nlm.nih.gov/pubmed/36622962",
                "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                "http://www.ncbi.nlm.nih.gov/pubmed/35015757"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35626721",
                    "text": "Transcribed Ultraconserved Regions in Cancer.",
                    "score_reranked": 1.1749303340911865
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17785203",
                    "text": "Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas.",
                    "score_reranked": 1.128103494644165
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015757",
                    "text": "The transcribed ultraconserved regions (T-UCRs) express long ncRNAs involved in human carcinogenesis.",
                    "score_reranked": 1.0486081838607788
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35978878",
                    "text": "Role of transcribed ultraconserved regions in gastric cancer and therapeutic perspectives.",
                    "score_reranked": 0.9759726524353027
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27447964",
                    "text": "Ultraconserved long non-coding RNA uc.63 in breast cancer.",
                    "score_reranked": 0.8485485315322876
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916343",
                    "text": "The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer.",
                    "score_reranked": 0.6561789512634277
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36622962",
                    "text": "Transcribed Ultraconserved Regions: New regulators in cancer signaling and potential biomarkers.",
                    "score_reranked": 0.5721867084503174
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28382457",
                    "text": "Expression and function of Uc.160+, a transcribed ultraconserved region, in gastric cancer.",
                    "score_reranked": 0.510496973991394
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24384562",
                    "text": "Transcribed ultraconserved region in human cancers.",
                    "score_reranked": 0.48005154728889465
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35015757",
                    "text": "Among these T-UCRs, the greatest variation was observed for antisense ultraconserved element 83 (uc.83-), which was upregulated in human lung cancer tissues compared with adjacent non cancerous tissues.",
                    "score_reranked": -0.6259563565254211
                }
            ]
        },
        {
            "id": "56d06e043975bb303a000011",
            "body": "In which breast cancer patients can palbociclib be used?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39948973",
                "http://www.ncbi.nlm.nih.gov/pubmed/39851968",
                "http://www.ncbi.nlm.nih.gov/pubmed/39662069",
                "http://www.ncbi.nlm.nih.gov/pubmed/39662069",
                "http://www.ncbi.nlm.nih.gov/pubmed/40145289",
                "http://www.ncbi.nlm.nih.gov/pubmed/39727671",
                "http://www.ncbi.nlm.nih.gov/pubmed/40109794",
                "http://www.ncbi.nlm.nih.gov/pubmed/39851968",
                "http://www.ncbi.nlm.nih.gov/pubmed/40244189",
                "http://www.ncbi.nlm.nih.gov/pubmed/39820840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39948973",
                    "text": "[A Case of Advanced Breast Cancer Resected after the Combined Therapy of Palbociclib and Letrozole].",
                    "score_reranked": 2.138417959213257
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39851968",
                    "text": "This study aimed to evaluate the real-world PFS and OS for palbociclib and ribociclib when combined with AIs in patients with HR+/HER2- advanced breast cancer.",
                    "score_reranked": 1.7426315546035767
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39662069",
                    "text": "Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer.",
                    "score_reranked": 1.7079477310180664
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39662069",
                    "text": "This study included all patients who received palbociclib for hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2-MBC) at Ogaki Municipal Hospital between January 2018 and November 2023.",
                    "score_reranked": 1.3002407550811768
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40145289",
                    "text": "Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2- Metastatic Breast Cancer.",
                    "score_reranked": 1.2454830408096313
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39727671",
                    "text": "Dose reductions in CDK4/6 inhibitors, such as ribociclib and palbociclib, are often necessary due to treatment-related toxicities in patients with advanced breast cancer.",
                    "score_reranked": 1.1547985076904297
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40109794",
                    "text": "Therapeutic Response After 10 Months of Treatment With Letrozole and Palbociclib in a Postmenopausal Woman With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Metastatic Breast Cancer and Skin Involvement.",
                    "score_reranked": 0.9847489595413208
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39851968",
                    "text": "Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2- Advanced Breast Cancer.",
                    "score_reranked": 0.8268746137619019
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40244189",
                    "text": "We conducted a retrospective cohort study analyzing the outcomes of 95 patients with metastatic ER-positive, HER2-negative breast cancer (BC) treated with CDK4/6 inhibitors (ribociclib, palbociclib, and abemaciclib) in combination with endocrine therapy.",
                    "score_reranked": 0.3694179952144623
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39820840",
                    "text": "This review focuses on both the scientific background as well as all available clinical data of CDK4/6i, with particular emphasis on their use in early breast cancer.",
                    "score_reranked": 0.08040431141853333
                }
            ]
        },
        {
            "id": "56d8b27651531f7e33000003",
            "body": "Do patients with Pendred syndrome present congenital deafness?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                "http://www.ncbi.nlm.nih.gov/pubmed/7492068",
                "http://www.ncbi.nlm.nih.gov/pubmed/10602116",
                "http://www.ncbi.nlm.nih.gov/pubmed/27509681",
                "http://www.ncbi.nlm.nih.gov/pubmed/17365057",
                "http://www.ncbi.nlm.nih.gov/pubmed/10602116",
                "http://www.ncbi.nlm.nih.gov/pubmed/7492068",
                "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                "http://www.ncbi.nlm.nih.gov/pubmed/10902795"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                    "text": "Patients with Pendred syndrome represent challenging cochlear implant candidates, combining goiter, severe-to-profound hearing loss, and inner-ear dysplasias.",
                    "score_reranked": 1.6335721015930176
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                    "text": "Data of patients with Pendred syndrome, who had undergone cochlear implantation in the 10-year period 1999-2008, were evaluated.",
                    "score_reranked": 0.8439247608184814
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7492068",
                    "text": "This paper shows that patients with Pendred's syndrome may have goiter at birth or develop it between 8 and 14 years, that their deafness is bilateral and profound, and that their perchlorate discharge tests are positive.",
                    "score_reranked": 0.694021463394165
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10602116",
                    "text": "Pendred syndrome comprises congenital sensorineural hearing loss, thyroid goiter, and positive perchlorate discharge test.",
                    "score_reranked": 0.6045873165130615
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27509681",
                    "text": "Pendred syndrome is an autosomal recessive familial disorder, defined as a sensorineural deafness coinciding with a goiter related to an iodine organification defect.",
                    "score_reranked": 0.5096827745437622
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17365057",
                    "text": "Pendred syndrome, defined as the constellation of goiter, sensori-neural hearing loss, and positive perchlorate discharge test, is the most frequent cause of congenital deafness.",
                    "score_reranked": 0.4292477071285248
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10602116",
                    "text": "The present results question the sensitivity of the perchlorate test for the diagnosis of Pendred syndrome and support the use of a molecular analysis of the PDS gene in the assessment of individuals with severe to profound congenital hearing loss associated with inner ear morphological anomaly even in the absence of a thyroid goiter.",
                    "score_reranked": 0.30023303627967834
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7492068",
                    "text": "Relatives of Pendred's syndrome patients showed mild low-frequency sensorineural hearing loss without goiter and normal perchlorate discharge test results in half the cases, and a slight drop in the perchlorate discharge test results with normal hearing and without goiter in the other half.",
                    "score_reranked": 0.09685447812080383
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21917203",
                    "text": "Cochlear implantation in Pendred syndrome.",
                    "score_reranked": -0.07792085409164429
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10902795",
                    "text": "Pendred's syndrome is a combination of congenital sensorineural hearing loss and iodine organification defect leading to a positive perchlorate test and goiter.",
                    "score_reranked": -0.5112606287002563
                }
            ]
        },
        {
            "id": "571e1e11bb137a4b0c000004",
            "body": "List side effects of SGLT2 inhibitors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25230708",
                "http://www.ncbi.nlm.nih.gov/pubmed/28440009",
                "http://www.ncbi.nlm.nih.gov/pubmed/38957943",
                "http://www.ncbi.nlm.nih.gov/pubmed/40183146",
                "http://www.ncbi.nlm.nih.gov/pubmed/38223287",
                "http://www.ncbi.nlm.nih.gov/pubmed/34749920",
                "http://www.ncbi.nlm.nih.gov/pubmed/32725160",
                "http://www.ncbi.nlm.nih.gov/pubmed/32725160",
                "http://www.ncbi.nlm.nih.gov/pubmed/28500396",
                "http://www.ncbi.nlm.nih.gov/pubmed/35582186"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25230708",
                    "text": "The list of side effects observed under SGLT2 inhibition includes increased rates of genitourinary infections, balanitis, vulvovaginitis, hypotensive episodes and acute deterioration of kidney function.",
                    "score_reranked": 1.1106719970703125
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28440009",
                    "text": "SGLT2 inhibitors are an exciting addition to the list of available agents for T2DM, and may be suitable for various types of patients who need additional glycaemic control.",
                    "score_reranked": 0.2939758598804474
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38957943",
                    "text": "General physicians in Australia and Aotearoa New Zealand are familiar with the therapeutic knowledge and side effects of SGLT2is.",
                    "score_reranked": 0.2763358950614929
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40183146",
                    "text": "This review sought to summarise the safety overview of commercially available SGLT2 inhibitors.",
                    "score_reranked": 0.07142311334609985
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38223287",
                    "text": "Complications Secondary to the Use Of Sglt2 Inhibitors in Oncological Patients: A Series of 5 Cases.",
                    "score_reranked": 0.03239688277244568
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34749920",
                    "text": "IDF and Medicines Patent Pool welcome inclusion of SGLT2 inhibitors to WHO Essential Medicines List.",
                    "score_reranked": -0.09873220324516296
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725160",
                    "text": "This study aimed to develop a list of best practices for the safe use and monitoring of SGLT-2 inhibitors in people with T2DM.",
                    "score_reranked": -0.21534153819084167
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32725160",
                    "text": "A list of best practice statements was developed using the Delphi method, which can be utilized by clinicians to guide the safe use and monitoring of SGLT-2 inhibitors in people with T2DM.",
                    "score_reranked": -0.2644798457622528
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28500396",
                    "text": "SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.",
                    "score_reranked": -0.34316304326057434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35582186",
                    "text": "Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?",
                    "score_reranked": -0.9675014019012451
                }
            ]
        },
        {
            "id": "552fa32fbc4f83e828000001",
            "body": "Is CD56 useful in Ewing sarcoma prognosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9692823",
                "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                "http://www.ncbi.nlm.nih.gov/pubmed/35537008",
                "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                "http://www.ncbi.nlm.nih.gov/pubmed/33610950",
                "http://www.ncbi.nlm.nih.gov/pubmed/15349982",
                "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                "http://www.ncbi.nlm.nih.gov/pubmed/9692823",
                "http://www.ncbi.nlm.nih.gov/pubmed/16528378",
                "http://www.ncbi.nlm.nih.gov/pubmed/33610950"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9692823",
                    "text": "Identification of CD56 and CD57 by flow cytometry in Ewing's sarcoma or primitive neuroectodermal tumor.",
                    "score_reranked": 0.9792437553405762
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                    "text": "Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry.",
                    "score_reranked": 0.8157652616500854
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35537008",
                    "text": "Ash and colleagues have shown that the separation of such cases into high- and low-risk groups by using CD56 negativity of the tumor cells is an improvement over current methods with a 100% 10-year progression-free survival in CD56- nonpelvic local isolated Ewing sarcoma patients.",
                    "score_reranked": 0.7938127517700195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                    "text": "There was a highly significant correlation between CD56 expression and progression-free survival (PFS; 69% in low/negative expression versus 30% in high expression groups, P = 0.024).",
                    "score_reranked": 0.6702148914337158
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610950",
                    "text": "CD56 expression could be used as a prognostic factor in ESFT, although given the results herein obtained, we recommend a prospective validation in independent series including localized and disseminated tumors in ESFT.",
                    "score_reranked": 0.5087034702301025
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15349982",
                    "text": "We describe three patients with Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) and one patient with neuroblastoma in which flow cytometry immunophenotyping (FCI) on the fine-needle aspirate (FNA) and bone marrow aspirate (BMA) demonstrated an abnormal population of cells that were CD45(-) and CD16/CD56(+).",
                    "score_reranked": 0.48009970784187317
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21467162",
                    "text": "Multiparameter flow cytometry (MPFC) was used to detect ES cells in bone marrow (BM) of ES patients at diagnosis and to evaluate the prognostic significance of CD56 expression in BM samples.",
                    "score_reranked": 0.47955384850502014
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9692823",
                    "text": "CD56 and CD57 are commonly considered as natural killer and neuroectodermal markers, but their expression has been identified in a wide spectrum of neoplasms including some cases of Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET).",
                    "score_reranked": 0.3462050259113312
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16528378",
                    "text": "Paired antibodies for each tumor type determined by visual assessment of cluster analysis data and statistical calculations of specificity, sensitivity, and predictive values showed that EMA/CK7 for synovial sarcoma, nestin/S100 for malignant peripheral nerve sheath tumor, and membranous CD99/Fli-1 for Ewing sarcoma yielded high specificity and positive predictive values.",
                    "score_reranked": -0.12956783175468445
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33610950",
                    "text": "Despite the low proportion of tumors with CD56 immunoreactivity, CD56 expression was shown to correlate with both poor PFS (p < 0.001) and poor OS (p < 0.001) in the present series.",
                    "score_reranked": -0.3524254262447357
                }
            ]
        },
        {
            "id": "5509f433c2af5d5b70000008",
            "body": "What is the method FASP used for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/32484334",
                "http://www.ncbi.nlm.nih.gov/pubmed/39788007",
                "http://www.ncbi.nlm.nih.gov/pubmed/34833908",
                "http://www.ncbi.nlm.nih.gov/pubmed/31474963",
                "http://www.ncbi.nlm.nih.gov/pubmed/31655642",
                "http://www.ncbi.nlm.nih.gov/pubmed/32484334",
                "http://www.ncbi.nlm.nih.gov/pubmed/31655642",
                "http://www.ncbi.nlm.nih.gov/pubmed/34028441",
                "http://www.ncbi.nlm.nih.gov/pubmed/34833908",
                "http://www.ncbi.nlm.nih.gov/pubmed/31655642"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484334",
                    "text": "The new method was compared to the standard overnight digestion FASP protocol, and no statistical differences were found for more than 92.4%, 92%, and 93.3% of the proteins identified by studying the proteome of",
                    "score_reranked": 0.5581555366516113
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39788007",
                    "text": "FASP isolates bacteria from food samples through multi-filter preprocessing, significantly enhancing the specificity, sensitivity, and reproducibility of the subsequent biosensor analysis.",
                    "score_reranked": 0.5541727542877197
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34833908",
                    "text": "FASP appeared to be the most time efficient procedure with a low miscleavage rate when used for a biological sample aliquot, but quantitation was less reproducible.",
                    "score_reranked": 0.41927435994148254
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31474963",
                    "text": "A Robust and Universal Metaproteomics Workflow for Research Studies and Routine Diagnostics Within 24 h Using Phenol Extraction, FASP Digest, and the MetaProteomeAnalyzer.",
                    "score_reranked": 0.28070512413978577
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31655642",
                    "text": "In contrast to the majority of sample preparation methods, FASP allows digestion of proteins with a variety of enzymes and a straightforward monitoring of protein-to-peptide conversion.",
                    "score_reranked": 0.18323233723640442
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32484334",
                    "text": "After a modification of the FASP-tube, the steps of protein reduction, protein alkylation, and protein digestion of complex proteomes are done in just 5.25 min, each one under the effects of an ultrasonic field (7 cycles: 30 s on and 15 s off).",
                    "score_reranked": 0.16693177819252014
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31655642",
                    "text": "Understanding principles of the method gives guidance in applying FASP to different types of samples in optimization of conditions of the FASP-workflow.",
                    "score_reranked": 0.12931224703788757
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34028441",
                    "text": "Bottom-up proteomics workflows like FASP increasingly rely on LC-MS/MS methods performed in data-independent analysis (DIA) mode, a scanning method that allows deep proteome coverage and low incidence of missing values.",
                    "score_reranked": -0.15821871161460876
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34833908",
                    "text": "A prior protein precipitation step improved the quantitation by FASP due to significantly higher peak areas for plasma and a much better reproducibility for milk.",
                    "score_reranked": -0.1897743046283722
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31655642",
                    "text": "Successful application of FASP requires optimized properties of sample lysate and its amount, use of ultrafiltration units with membranes having large molecular mass cut-offs and well selected conditions for protein digestion.",
                    "score_reranked": -0.2727738320827484
                }
            ]
        },
        {
            "id": "553fa2201d53b76422000005",
            "body": "What is the role of extracellular signal-related kinases 1 and 2 (ERK1/2) proteins in craniosynostosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23354439",
                "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                "http://www.ncbi.nlm.nih.gov/pubmed/23566293",
                "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                "http://www.ncbi.nlm.nih.gov/pubmed/23566293",
                "http://www.ncbi.nlm.nih.gov/pubmed/33656806",
                "http://www.ncbi.nlm.nih.gov/pubmed/27034231",
                "http://www.ncbi.nlm.nih.gov/pubmed/27034231",
                "http://www.ncbi.nlm.nih.gov/pubmed/23566293"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23354439",
                    "text": "Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis.",
                    "score_reranked": 1.7767837047576904
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                    "text": "Furthermore, treatment of the mutant mice with U0126, an inhibitor of mitogen-activated protein (MAP) kinase kinase 1 and 2 (MEK1/2) that blocks phosphorylation and activation of ERK1/2, significantly inhibits craniosynostosis.",
                    "score_reranked": 0.9556553363800049
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23566293",
                    "text": "The causes of sagittal nonsyndromic craniosynostosis (sNSC) have not been well understood and the role that MAPK/ERK signaling cascade plays in this condition warrants an investigation.",
                    "score_reranked": 0.7343670129776001
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                    "text": "These results illustrate a pathogenic role for ERK activation in craniosynostosis resulting from FGFR2 with the S252W substitution and introduce a new concept of small-molecule inhibitor-mediated prevention and therapy for diseases caused by gain-of-function mutations in the human genome.",
                    "score_reranked": 0.5967204570770264
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17694057",
                    "text": "RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.",
                    "score_reranked": 0.21829238533973694
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23566293",
                    "text": "The MAPK/ERK signaling pathway has been implicated in several craniosynostosis syndromes and represents a plausible target for therapeutic management of craniosynostosis.",
                    "score_reranked": 0.21000149846076965
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33656806",
                    "text": "Altogether, our study reveals a novel mechanotransduction signalling axis, PC1-ERK-RUNX2, which affects osteoblastic differentiation in cranial suture cells from trigonocephaly and dolichocephaly patients.",
                    "score_reranked": 0.2094726860523224
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034231",
                    "text": "This study identifies FGFR2c-mediated ERK-MAPK signaling as a key mediator of craniofacial growth and coronal suture development.",
                    "score_reranked": 0.11608806252479553
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27034231",
                    "text": "Insight into the molecular mechanism of craniosynostosis has identified the ERK-MAPK signaling cascade as a critical regulator of suture patency.",
                    "score_reranked": -0.12412664294242859
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23566293",
                    "text": "MAPK/ERK Signaling Pathway Analysis in Primary Osteoblasts From Patients With Nonsyndromic Sagittal Craniosynostosis.",
                    "score_reranked": -0.3487948477268219
                }
            ]
        },
        {
            "id": "52fa73c62059c6d71c000058",
            "body": "Are there any urine biomarkers for chronic kidney disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40311474",
                "http://www.ncbi.nlm.nih.gov/pubmed/40293565",
                "http://www.ncbi.nlm.nih.gov/pubmed/40243426",
                "http://www.ncbi.nlm.nih.gov/pubmed/40311474",
                "http://www.ncbi.nlm.nih.gov/pubmed/40293565",
                "http://www.ncbi.nlm.nih.gov/pubmed/40150347",
                "http://www.ncbi.nlm.nih.gov/pubmed/40370722",
                "http://www.ncbi.nlm.nih.gov/pubmed/39848232",
                "http://www.ncbi.nlm.nih.gov/pubmed/40143452",
                "http://www.ncbi.nlm.nih.gov/pubmed/40370722"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40311474",
                    "text": "A portable sweat biosensor for multiple chronic kidney diseases biomarkers detection.",
                    "score_reranked": 1.2859539985656738
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40293565",
                    "text": "Role of traditional and new biomarkers in the assessment of chronic kidney diseases: a comprehensive analysis of the biochemical, molecular and clinical dimensions.",
                    "score_reranked": 1.149846076965332
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40243426",
                    "text": "Targeted Analysis of Serum and Urinary Metabolites for Early Chronic Kidney Disease.",
                    "score_reranked": 1.1497693061828613
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40311474",
                    "text": "Continuous and quantitative measurement of toxin biomarkers in biological fluids constitutes a significant advancement in the proactive management of chronic kidney diseases (CKD).",
                    "score_reranked": 1.0122359991073608
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40293565",
                    "text": "This study's objective is to test and compare the efficacy of conventional and innovative biomarkers in evaluating kidney function and disease.",
                    "score_reranked": 0.47906818985939026
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40150347",
                    "text": "The use of multiple biomarkers in the diagnosis of kidney disease has the potential to enhance both specificity and sensitivity, enabling early detection and intervention that could ultimately reduce morbidity and mortality rates.",
                    "score_reranked": 0.3400944769382477
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40370722",
                    "text": "Application of biomarkers in the diagnosis of kidney disease.",
                    "score_reranked": 0.3048922121524811
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39848232",
                    "text": "Traditional biomarkers, such as estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (uACR), have long been central to chronic kidney disease (CKD) diagnosis and management, leading to a standardized CKD classification system.",
                    "score_reranked": 0.15797832608222961
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40143452",
                    "text": "Developments in albuminuria testing: A key biomarker for detection, prognosis and surveillance of kidney and cardiovascular disease-A practical update for clinicians.",
                    "score_reranked": -0.030067533254623413
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40370722",
                    "text": "With the aim of reasonable applying these markers to the early detection, accurate diagnosis, and scientific management of kidney disease, thereby mitigating the threat posed by kidney disease to human health.",
                    "score_reranked": -0.810285210609436
                }
            ]
        },
        {
            "id": "533f9df0c45e133714000016",
            "body": "What is being measured with an accelerometer in back pain patients",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20921030",
                "http://www.ncbi.nlm.nih.gov/pubmed/21872993",
                "http://www.ncbi.nlm.nih.gov/pubmed/20921030",
                "http://www.ncbi.nlm.nih.gov/pubmed/35551113",
                "http://www.ncbi.nlm.nih.gov/pubmed/36680881",
                "http://www.ncbi.nlm.nih.gov/pubmed/34798245",
                "http://www.ncbi.nlm.nih.gov/pubmed/21872993",
                "http://www.ncbi.nlm.nih.gov/pubmed/9520229",
                "http://www.ncbi.nlm.nih.gov/pubmed/23560880",
                "http://www.ncbi.nlm.nih.gov/pubmed/28637603"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921030",
                    "text": "To compare self-report measures of daily activities with objective activity data to determine whether patients with chronic lower back pain report their activity levels as accurately as controls do.",
                    "score_reranked": 1.9718210697174072
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21872993",
                    "text": "New patients in a chronic pain specialty clinic completed questionnaires to assess the predictors of physical activity and engaged in 5 days of home data collection wearing an accelerometer to assess physical activity in daily life, which is how disability was operationalized in this study.",
                    "score_reranked": 1.8066856861114502
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20921030",
                    "text": "The relationship between objectively and subjectively measured activity levels in people with chronic low back pain.",
                    "score_reranked": 1.0445704460144043
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35551113",
                    "text": "This study investigated whether objective and subjective physical activity measures predict pain intensity and disability levels 6\u00a0months later in patients with chronic LBP.",
                    "score_reranked": 0.8567111492156982
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36680881",
                    "text": "Role of the interaction between lumbar kinematics and accelerometer-measured physical activity in bodily pain, physical functioning and work ability among health care workers with low back pain.",
                    "score_reranked": 0.7011713981628418
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34798245",
                    "text": "In this study, we aim to objectively characterize the free-living physical activity of people with low back pain in comparison to healthy controls using accelerometers, and we aim to derive a set of LBP-specific physical activity minutes thresholds that may be used as targets for future physical activity interventions.",
                    "score_reranked": 0.546796441078186
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21872993",
                    "text": "Factors contributing to physical activity in a chronic low back pain clinical sample: a comprehensive analysis using continuous ambulatory monitoring.",
                    "score_reranked": 0.5461363792419434
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9520229",
                    "text": "Ambulatory accelerometry to quantify motor behaviour in patients after failed back surgery: a validation study.",
                    "score_reranked": 0.021801143884658813
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23560880",
                    "text": "Does a patient's physical activity predict recovery from an episode of acute low back pain? A prospective cohort study.",
                    "score_reranked": -0.017984837293624878
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637603",
                    "text": "To determine the test-retest reliability of the International Physical Activity Questionnaire (IPAQ) long-version and the Baecke Physical Activity Questionnaire (BPAQ) and their criterion-related validity against data derived from accelerometers in patients with chronic LBP.",
                    "score_reranked": -0.245054692029953
                }
            ]
        },
        {
            "id": "56a3a386496b62f23f000007",
            "body": "List the releases of JASPAR database",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19906716",
                "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                "http://www.ncbi.nlm.nih.gov/pubmed/16381983",
                "http://www.ncbi.nlm.nih.gov/pubmed/16381983",
                "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                "http://www.ncbi.nlm.nih.gov/pubmed/31701148",
                "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                "http://www.ncbi.nlm.nih.gov/pubmed/34850907",
                "http://www.ncbi.nlm.nih.gov/pubmed/40230362",
                "http://www.ncbi.nlm.nih.gov/pubmed/39842990"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19906716",
                    "text": "As binding models are refined by newer data, the JASPAR database now uses versioning of matrices: in this release, 12% of the older models were updated to improved versions.",
                    "score_reranked": 1.3784584999084473
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                    "text": "The heart of the JASPAR database-the JASPAR CORE sub-database-has increased by 12% in size, and three new specialized sub-databases have been added.",
                    "score_reranked": 1.1073589324951172
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16381983",
                    "text": "In this new release, JASPAR grows into a meta-database of collections of TFBS models derived by diverse approaches.",
                    "score_reranked": 0.4306153357028961
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16381983",
                    "text": "The new release of JASPAR is available at http://jaspar.genereg.net.",
                    "score_reranked": 0.28290829062461853
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                    "text": "JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update.",
                    "score_reranked": -0.011561483144760132
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31701148",
                    "text": "All the data is available through the JASPAR website, its associated RESTful API, and through the JASPAR2020 R/Bioconductor package.",
                    "score_reranked": -0.26036301255226135
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18006571",
                    "text": "JASPAR is available at http://jaspar.genereg.net.",
                    "score_reranked": -0.2880796194076538
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34850907",
                    "text": "All the data is accessible through the JASPAR website, its associated RESTful API, the R/Bioconductor data package, and a new Python package, pyJASPAR, that facilitates serverless access to the data.",
                    "score_reranked": -0.3489123284816742
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40230362",
                    "text": "The journals were characterized based on their index status in PubMed, Master Journal List, Journal Citation Reports (JCR), MEDLINE, or Directory of Open Access Journals.",
                    "score_reranked": -0.7729285955429077
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39842990",
                    "text": "TFinder searches for Individual Motifs in different formats, including IUPAC codes and JASPAR entries.",
                    "score_reranked": -0.8225291967391968
                }
            ]
        },
        {
            "id": "56c1f038ef6e394741000051",
            "body": "List symptoms of the IFAP syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15370546",
                "http://www.ncbi.nlm.nih.gov/pubmed/37191591",
                "http://www.ncbi.nlm.nih.gov/pubmed/22615524",
                "http://www.ncbi.nlm.nih.gov/pubmed/18204861",
                "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                "http://www.ncbi.nlm.nih.gov/pubmed/10398262",
                "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                "http://www.ncbi.nlm.nih.gov/pubmed/14708110",
                "http://www.ncbi.nlm.nih.gov/pubmed/15848992",
                "http://www.ncbi.nlm.nih.gov/pubmed/33253727"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15370546",
                    "text": "To report the ocular findings in two siblings with IFAP and their mother and to review the natural course of the keratopathy of this disease.",
                    "score_reranked": 0.7187038660049438
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37191591",
                    "text": "Meibomian Gland Dysfunction as a Manifestation of IFAP Syndrome.",
                    "score_reranked": 0.44071295857429504
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22615524",
                    "text": "IFAP Syndrome with Rickets and Normal Vitamin D Status.",
                    "score_reranked": 0.3506093919277191
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18204861",
                    "text": "In addition, another three patients, previously described as having IFAP syndrome (OMIM %308205), may also have ACD syndrome.",
                    "score_reranked": 0.30164018273353577
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                    "text": "Expanding the phenotype of IFAP/BRESECK syndrome: a new case with severe hypogammaglobulinemia.",
                    "score_reranked": 0.1531771719455719
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10398262",
                    "text": "IFAP syndrome is considered to be an X-linked recessive trait.",
                    "score_reranked": 0.09763118624687195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24090718",
                    "text": "Additional features not previously reported in IFAP syndrome, include severe hypogammaglobulinemia and congenital rectourethral fistula.",
                    "score_reranked": 0.08324050903320312
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14708110",
                    "text": "What is IFAP syndrome?",
                    "score_reranked": -0.06382647156715393
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15848992",
                    "text": "We herein describe a 3-year-old girl with clinical and histological features typical of IFAP.",
                    "score_reranked": -0.10013467073440552
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33253727",
                    "text": "Hereditary Mucoepithelial Dysplasia and Autosomal-Dominant IFAP Syndrome Is a Clinical Spectrum Due to SREBF1 Variants.",
                    "score_reranked": -0.5964751243591309
                }
            ]
        },
        {
            "id": "531a34d5b166e2b806000036",
            "body": "Which gene is required for the efficient function of clopidogrel?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40295977",
                "http://www.ncbi.nlm.nih.gov/pubmed/37326604",
                "http://www.ncbi.nlm.nih.gov/pubmed/32493215",
                "http://www.ncbi.nlm.nih.gov/pubmed/39245547",
                "http://www.ncbi.nlm.nih.gov/pubmed/34471538",
                "http://www.ncbi.nlm.nih.gov/pubmed/21706290",
                "http://www.ncbi.nlm.nih.gov/pubmed/40295977",
                "http://www.ncbi.nlm.nih.gov/pubmed/34471538",
                "http://www.ncbi.nlm.nih.gov/pubmed/21706290",
                "http://www.ncbi.nlm.nih.gov/pubmed/40295977"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40295977",
                    "text": "The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.",
                    "score_reranked": 1.3465315103530884
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37326604",
                    "text": "Rapid detection of single nucleotide polymorphisms (SNPs) in the CYP2C19 gene is of great significance for clopidogrel-accurate medicine.",
                    "score_reranked": 1.2961796522140503
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32493215",
                    "text": "Approximately 20% of the population are unable to activate clopidogrel as they possess the CYP2C19*2 loss-of function (LoF) allele.",
                    "score_reranked": 1.1745154857635498
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39245547",
                    "text": "Approximately 30% of individuals inherit a loss-of-function (LoF) polymorphism in the CYP2C19 gene, leading to reduced formation of the active clopidogrel metabolite.",
                    "score_reranked": 0.5116615295410156
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471538",
                    "text": "Among the clopidogrel-treated patients, we observed 64.1% polymorphism (hetero + mutant) of CYP2C19*2 (loss-of-function allele) and 22.7% (hetero + mutant) of CYP2C19*17 (gain-of-function allele).",
                    "score_reranked": 0.4301871359348297
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21706290",
                    "text": "Polymorphisms of genes encoding the cytochrome enzymes and P-glycoprotein involved in clopidogrel absorption are regarded as major determinants of the interindividual variability in the clopidogrel-induced platelet inhibition.",
                    "score_reranked": 0.31713977456092834
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40295977",
                    "text": "Genetic variations in the CYP2C19 gene, which encodes the major enzyme responsible for activating clopidogrel, may influence response to Clopidogrel antiplatelet therapy.",
                    "score_reranked": 0.25717929005622864
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34471538",
                    "text": "We performed genotyping of patients treated with clopidogrel and aspirin by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and tetra-primer amplification refractory mutation system PCR (T-ARMS-PCR) methods.",
                    "score_reranked": 0.06343761086463928
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21706290",
                    "text": "Genetic determinants of platelet response to clopidogrel.",
                    "score_reranked": -0.2469482719898224
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40295977",
                    "text": "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150\u00a0mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy.",
                    "score_reranked": -0.846588134765625
                }
            ]
        },
        {
            "id": "56c1f029ef6e39474100004a",
            "body": "Is valproic acid effective for glioblastoma treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23680820",
                "http://www.ncbi.nlm.nih.gov/pubmed/25066904",
                "http://www.ncbi.nlm.nih.gov/pubmed/25066904",
                "http://www.ncbi.nlm.nih.gov/pubmed/26985579",
                "http://www.ncbi.nlm.nih.gov/pubmed/39428930",
                "http://www.ncbi.nlm.nih.gov/pubmed/31544169",
                "http://www.ncbi.nlm.nih.gov/pubmed/25648357",
                "http://www.ncbi.nlm.nih.gov/pubmed/27298401",
                "http://www.ncbi.nlm.nih.gov/pubmed/22668241",
                "http://www.ncbi.nlm.nih.gov/pubmed/22668241"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23680820",
                    "text": "Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.",
                    "score_reranked": 1.3294003009796143
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904",
                    "text": "Several clinical studies have reported that valproic acid could prolong survival of GBM patients.",
                    "score_reranked": 1.0376108884811401
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25066904",
                    "text": "Survival analysis for valproic acid use in adult glioblastoma multiforme: a meta-analysis of individual patient data and a systematic review.",
                    "score_reranked": 0.7911938428878784
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26985579",
                    "text": "Does valproic acid affect tumor growth and improve survival in glioblastomas?",
                    "score_reranked": 0.6798689365386963
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39428930",
                    "text": "Valproic Acid and Celecoxib Enhance the Effect of Temozolomide on Glioblastoma Cells.",
                    "score_reranked": 0.2982819378376007
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31544169",
                    "text": "Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma.",
                    "score_reranked": 0.2696249186992645
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25648357",
                    "text": "The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells.",
                    "score_reranked": 0.09489807486534119
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27298401",
                    "text": "Valproate in Adjuvant Glioblastoma Treatment.",
                    "score_reranked": 0.0800754725933075
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22668241",
                    "text": "Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.",
                    "score_reranked": -0.5967494249343872
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22668241",
                    "text": "We provide a comprehensive review of the mechanisms of action of valproate in gliomas, of its potential side effects and of the published clinical results obtained with this drug in glioblastomas.",
                    "score_reranked": -0.9275689125061035
                }
            ]
        },
        {
            "id": "56cdf40d5795f9a73e00003d",
            "body": "Which transcription factor is considered as a master regulator of lysosomal genes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33795648",
                "http://www.ncbi.nlm.nih.gov/pubmed/23609508",
                "http://www.ncbi.nlm.nih.gov/pubmed/25750174",
                "http://www.ncbi.nlm.nih.gov/pubmed/33373332",
                "http://www.ncbi.nlm.nih.gov/pubmed/32312748",
                "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                "http://www.ncbi.nlm.nih.gov/pubmed/32312748",
                "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                "http://www.ncbi.nlm.nih.gov/pubmed/36325146"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33795648",
                    "text": "Transcription factor EB (TFEB), a well-known master regulator of autophagy and lysosomal biogenesis, is a member of the microphthalmia family of transcription factors (MiT family).",
                    "score_reranked": 2.218820095062256
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23609508",
                    "text": "The identification of a master regulator, transcription factor EB (TFEB), that regulates lysosomal biogenesis and autophagy has revealed how the lysosome adapts to environmental cues, such as starvation, and targeting TFEB may provide a novel therapeutic strategy for modulating lysosomal function in human disease.",
                    "score_reranked": 1.831679105758667
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25750174",
                    "text": "The diverse functionality of this single organelle requires a very complex and coordinated regulation of its activity with transcription factor EB (TFEB), a master regulator of lysosomal biogenesis, at its core.",
                    "score_reranked": 1.8120367527008057
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33373332",
                    "text": "YAP physically interacted with transcription factor EB (TFEB), a master transcription factor that controls autophagic and lysosomal gene expression, thereby facilitating accumulation of autophagosomes without degradation.",
                    "score_reranked": 1.7177045345306396
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312748",
                    "text": "Transcription factor EB (TFEB) functions as a master controller of lysosomal biogenesis and function during lysosomal stress, controlling most but, importantly, not all lysosomal genes.",
                    "score_reranked": 1.2852060794830322
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                    "text": "Transcription factor EB (TFEB) is the master transcription factor regulating lysosomal biogenesis and autophagy.",
                    "score_reranked": 1.2785323858261108
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32312748",
                    "text": "The gene for the lysosomal protein LAMP3 is a direct target of the transcription factor ATF4.",
                    "score_reranked": 1.0448596477508545
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                    "text": "This novel mechanism of nuclear miRNA regulating gene transcription is conducive to further elucidating the roles of miRNAs in the lysosomal physiological functions and helps to understand the pathogenesis of abnormal autophagy-related diseases.",
                    "score_reranked": 0.20647385716438293
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32764647",
                    "text": "Under external stimuli such as starvation, dephosphorylated TFEB transports into the nucleus to specifically recognize and bind to the coordinated lysosomal expression and regulation (CLEAR) elements at the promotors of autophagy and lysosomal biogenesis-related genes.",
                    "score_reranked": -0.4071725308895111
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36325146",
                    "text": "The subcellular localizations of master transcriptional regulators of lysosomal genes, TFEB, TFE3 and ZKSCAN3 were examined to reveal the potential mechanisms.",
                    "score_reranked": -0.42948785424232483
                }
            ]
        },
        {
            "id": "571529efcb4ef8864c000001",
            "body": "Which antibiotics target peptidoglycan biosynthesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/38619138",
                "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                "http://www.ncbi.nlm.nih.gov/pubmed/38456799",
                "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                "http://www.ncbi.nlm.nih.gov/pubmed/39975250",
                "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                "http://www.ncbi.nlm.nih.gov/pubmed/39878530",
                "http://www.ncbi.nlm.nih.gov/pubmed/40309104",
                "http://www.ncbi.nlm.nih.gov/pubmed/39274911",
                "http://www.ncbi.nlm.nih.gov/pubmed/39700530"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38619138",
                    "text": "Peptidoglycan synthesis is an underutilized drug target in",
                    "score_reranked": 0.6235769987106323
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                    "text": "Peptidoglycan biochemistry is finely tuned to maintain the polymer's functions and is intimately connected to antibiotic-resistance mechanisms.",
                    "score_reranked": 0.4795655310153961
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38456799",
                    "text": "Peptidoglycan (PG), an essential exoskeletal polymer in bacteria, is a well-known antibiotic target.",
                    "score_reranked": 0.21448788046836853
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                    "text": "Cell-wall-modifying enzymes present a unique opportunity for the discovery of antibiotics and antibiotic adjuvants.",
                    "score_reranked": 0.08921054005622864
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39975250",
                    "text": "MraY, a bacterial enzyme crucial for the synthesis of peptidoglycans, represents a promising yet underexplored target for the development of effective antibacterial agents.",
                    "score_reranked": 0.037703901529312134
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                    "text": "The unique chemical template of the peptidoglycan has been a target of numerous chemical biology approaches for investigating its functions and modulation.",
                    "score_reranked": -0.09336462616920471
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39878530",
                    "text": "Peptidoglycan (PG) is an important bacterial macromolecule that confers cell shape and structural integrity, and is a key antibiotic target.",
                    "score_reranked": -0.13733771443367004
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40309104",
                    "text": "Cell wall peptidoglycan is a defining component of bacterial cells, and its biosynthesis is a major target for medically important antibiotics.",
                    "score_reranked": -0.18063247203826904
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39274911",
                    "text": "The cell wall is an indispensable element of bacterial cells and a long-known target of many antibiotics.",
                    "score_reranked": -0.18289637565612793
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39700530",
                    "text": "We present recent efforts to understand the peptidoglycan as a functional component of antibiotic resistance, and as a target for antimicrobial therapy.",
                    "score_reranked": -0.22940006852149963
                }
            ]
        },
        {
            "id": "52b2ec744003448f55000001",
            "body": "Can Levoxyl (levothyroxine sodium) cause insomnia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40318905",
                "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                "http://www.ncbi.nlm.nih.gov/pubmed/7779834",
                "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                "http://www.ncbi.nlm.nih.gov/pubmed/26754848",
                "http://www.ncbi.nlm.nih.gov/pubmed/40318905",
                "http://www.ncbi.nlm.nih.gov/pubmed/36226421",
                "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                "http://www.ncbi.nlm.nih.gov/pubmed/37847271",
                "http://www.ncbi.nlm.nih.gov/pubmed/34983880"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40318905",
                    "text": "This review synthesizes literature on how commonly prescribed medications-antihypertensives, statins, antidepressants, levothyroxine, proton pump inhibitors, phosphodiesterase type 5 inhibitors, and metformin-affect sleep.",
                    "score_reranked": 1.7953674793243408
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                    "text": "Validation of the Thyrotoxicosis-associated Insomnia Model Induced by Thyroxine through Sympathetic Stimulation: Face, Construct and Predictive Perspectives.",
                    "score_reranked": 1.1014518737792969
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7779834",
                    "text": "Although daytime somnolence and low levels of total T4 can mimic hypothyroidism, in this case sertraline only displaced the bound-fraction of total T4 and was not associated with true hypothyroidism.",
                    "score_reranked": 1.077286720275879
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                    "text": "The results of comprehensive analysis show that the established thyrotoxicosis-associated insomnia model meets the validity requirement to establish an appropriate animal model of insomnia.",
                    "score_reranked": 0.676530122756958
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26754848",
                    "text": "At 4\u00a0years of age, the patient continued to suffer from mental retardation, hyperactivity, insomnia, and reduced resting energy expenditure (REE), despite daily thyroxine (L-T4) therapy.",
                    "score_reranked": 0.3558507263660431
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40318905",
                    "text": "Levothyroxine does not significantly disrupt sleep, and evening administration may enhance hypothyroidism management.",
                    "score_reranked": 0.17764124274253845
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36226421",
                    "text": "The patient had a history of bipolar II disorder, recurrent depressive disorder and hypothyroidism, and presented to the psychiatric emergency department with a one-week history of delusions of persecutory character and increasing insomnia.",
                    "score_reranked": -0.09387633204460144
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                    "text": "Combined with the characteristics of chronic onset of clinical insomnia, an insomnia model induced by long-term intraperitoneal injection of thyroid hormone has been created in our laboratory.",
                    "score_reranked": -0.657690167427063
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37847271",
                    "text": "Common symptoms of thyrotoxicosis include anxiety, insomnia, palpitations, unintentional weight loss, diarrhea, and heat intolerance.",
                    "score_reranked": -1.8488339185714722
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/34983880",
                    "text": "Clinical data show that insomnia patients with high levels of thyroxine and often accompanied by cardiovascular problems, a common mechanism underlying all of these physiological disruptions is the sympathetic nervous system.",
                    "score_reranked": -2.5370466709136963
                }
            ]
        },
        {
            "id": "530e42e65937551c09000007",
            "body": "Is fatigue prevalent in patients receiving treatment for glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                "http://www.ncbi.nlm.nih.gov/pubmed/25006033"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                    "text": "This study demonstrated a progressive increase in physical fatigue in patients with glioblastoma relapse treated with irinotecan-bevacizumab.",
                    "score_reranked": 1.837834358215332
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "Only fatigue appeared to be more common in glioblastoma patients than in healthy controls (48% vs 11%; P < .001) but not the frequency of sleepiness (22% vs 19%; P = .43).",
                    "score_reranked": 1.351209282875061
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                    "text": "The combination of irinotecan-bevacizumab is effective in patients with glioblastoma relapse but fatigue is a commonly reported side effect.",
                    "score_reranked": 1.233569860458374
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                    "text": "[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].",
                    "score_reranked": 1.2305798530578613
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "Female sex was associated with increased fatigue frequency among glioblastoma patients but not among control participants.",
                    "score_reranked": 1.1630992889404297
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "Our findings indicate that glioblastoma patients are frequently affected by fatigue at baseline, suggesting that factors other than those related to radio- or chemotherapy have significant impact, particularly depression and tumor localization.",
                    "score_reranked": 0.8281481266021729
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "Prevalence and predictors of fatigue in glioblastoma: a prospective study.",
                    "score_reranked": 0.56610107421875
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "The main goal of this study was to assess frequency, clinical correlates, and independent predictors of fatigue in a homogeneous cohort of well-defined glioblastoma patients at baseline prior to combined radio-chemotherapy.",
                    "score_reranked": 0.4630819857120514
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21514945",
                    "text": "The Norris Visual Analog Scale (VAS Norris) and the Multidimensional Fatigue Inventory-20 (MFI) tools were undertaken by 39 patients with glioblastoma relapse treated with irinotecan-bevacizumab, initially before the first cycle and thereafter with each cycle up until tumor progression.",
                    "score_reranked": -0.13066980242729187
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25006033",
                    "text": "We prospectively included 65 glioblastoma patients at postsurgical baseline and assessed fatigue, sleepiness, mean bedtimes, mood disturbances, and clinical characteristics such as clinical performance status, presenting symptomatology, details on neurosurgical procedure, and tumor location and diameter as well as pharmacological treatment including antiepileptic drugs, antidepressants, and use of corticosteroids.",
                    "score_reranked": -0.6358314752578735
                }
            ]
        },
        {
            "id": "53358cd2d6d3ac6a3400004e",
            "body": "List two common features of Tay syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20687499",
                "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                "http://www.ncbi.nlm.nih.gov/pubmed/30919937",
                "http://www.ncbi.nlm.nih.gov/pubmed/39708391",
                "http://www.ncbi.nlm.nih.gov/pubmed/8205320",
                "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                "http://www.ncbi.nlm.nih.gov/pubmed/37927205",
                "http://www.ncbi.nlm.nih.gov/pubmed/37927205",
                "http://www.ncbi.nlm.nih.gov/pubmed/19815695"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20687499",
                    "text": "The original two cases were described by Tay in oriental siblings, whose parents were first cousins; thus the disease is also known as Tay syndrome.",
                    "score_reranked": 0.5798640251159668
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                    "text": "A comprehensive list of human microdeletion and microduplication syndromes.",
                    "score_reranked": 0.45620498061180115
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30919937",
                    "text": "Overlap syndromes with combined hallmark features of different NER disorders can occur and sporadic presentations showing extra features of the hematological disorder Fanconi Anemia or neurological manifestations mimicking Hungtinton disease-like syndromes have been described.",
                    "score_reranked": 0.42535415291786194
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39708391",
                    "text": "The data presented in this study, which includes a detailed list of 374 IMDs with dysmorphic characteristics categorized by affected organs (such as head and face, nose, mouth and tongue, eye, ear, hands and feet, and others), as well as an overview of important clinical features and recommended diagnostic strategies, could be valuable for professionals in the field of healthcare.",
                    "score_reranked": 0.3182162344455719
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8205320",
                    "text": "These patients' features are discussed in the light of a practical classification scheme which is based upon a check-list of clinical abnormalities associated with trichothiodystrophy syndromes (Van Neste, 1991).",
                    "score_reranked": 0.18700829148292542
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                    "text": "This comprehensive list of MMS will aid further study of CNV disorders as well as serve as a resource for clinical laboratories performing diagnostic CNV testing.",
                    "score_reranked": 0.117857426404953
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36435749",
                    "text": "The phenotypic spectrum of human microdeletion and microduplication syndromes (MMS) is heterogeneous but often involves intellectual disability, autism spectrum disorders, dysmorphic features and/or multiple congenital anomalies.",
                    "score_reranked": -0.0685412585735321
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927205",
                    "text": "We uploaded two-dimensional face pictures of 145 children affected by genetic conditions with typical phenotypic traits.",
                    "score_reranked": -0.7098680734634399
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37927205",
                    "text": "Face2Gene (FDNA Inc) is an innovative computer-aided phenotyping tool that analyses patient's portraits and suggests 30 candidate syndromes with similar morphology in a prioritized list.",
                    "score_reranked": -1.0360394716262817
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815695",
                    "text": "DNA from 31 cell lines, representing many of the common alleles for Tay Sachs disease, Canavan disease, familial dysautonomia, mucolipidosis IV, Niemann-Pick disease type A, Fanconi anemia type C, Bloom syndrome, Gaucher disease, and glycogen storage disease, was prepared by the Repository and tested in six clinical laboratories using three different PCR-based assay platforms.",
                    "score_reranked": -1.043013095855713
                }
            ]
        },
        {
            "id": "52b2d405f828ad283c000009",
            "body": "Which cell types are known to be driving Rheumatoid Arthritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17442097",
                "http://www.ncbi.nlm.nih.gov/pubmed/31468238",
                "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                "http://www.ncbi.nlm.nih.gov/pubmed/31468238",
                "http://www.ncbi.nlm.nih.gov/pubmed/37108093",
                "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                "http://www.ncbi.nlm.nih.gov/pubmed/17442097",
                "http://www.ncbi.nlm.nih.gov/pubmed/37852410",
                "http://www.ncbi.nlm.nih.gov/pubmed/25775189"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17442097",
                    "text": "Rheumatoid arthritis synovial fibroblasts and macrophages, both cell types with pivotal roles in inflammation and destruction, but also T cells and B cells are crucial for complex network in the inflamed synovium.",
                    "score_reranked": 1.340760350227356
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31468238",
                    "text": "This review provides a summary of recent molecular findings that have refined our understanding of the cell types that constitute human synovial tissue, particularly in patients with rheumatoid arthritis (RA).",
                    "score_reranked": 0.6535401344299316
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                    "text": "Synovial biology and T cells in rheumatoid arthritis.",
                    "score_reranked": 0.6046143770217896
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31468238",
                    "text": "Broadly speaking, the ~\u200920 cell types thus far identified in RA synovium seem to be fairly well conserved across patients, despite extensive heterogeneity in patient clinical features, stage of disease, and treatment responses.",
                    "score_reranked": 0.164882093667984
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37108093",
                    "text": "The Search for the Pathogenic T Cells in the Joint of Rheumatoid Arthritis: Which T-Cell Subset Drives Autoimmune Inflammation?",
                    "score_reranked": 0.07693314552307129
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                    "text": "Rather, a new view of rheumatoid arthritis is emerging, which seeks to understand this disease as the product of pathologic cell-cell interactions occurring within a unique and defined environment, the synovium.",
                    "score_reranked": -0.3827786147594452
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16112560",
                    "text": "Rheumatoid arthritis synovium may be one of the most striking examples of pathologic, organ-specific interactions between immune system cells and resident tissue cell populations.",
                    "score_reranked": -0.38774406909942627
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17442097",
                    "text": "Each cell type contributes significantly to the initiation and perpetuation of this deleterious concert, especially in rheumatoid arthritis.",
                    "score_reranked": -0.7359740734100342
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37852410",
                    "text": "Therefore, we aimed to identify underlying common and distinct molecular signatures and pathways among ten types of tissue and cells obtained from patients with RA.",
                    "score_reranked": -0.9777132272720337
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25775189",
                    "text": "Although our understandings of the pathogenic processes that drive disease in RA remain incomplete, remarkable advances over the past year can be highlighted.",
                    "score_reranked": -1.498796820640564
                }
            ]
        },
        {
            "id": "550324d7e9bde6963400002f",
            "body": "What is the association between personality trait of neuroticism and risk for Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23040035",
                "http://www.ncbi.nlm.nih.gov/pubmed/23706517",
                "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                "http://www.ncbi.nlm.nih.gov/pubmed/23706517",
                "http://www.ncbi.nlm.nih.gov/pubmed/29846724",
                "http://www.ncbi.nlm.nih.gov/pubmed/31486975",
                "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                "http://www.ncbi.nlm.nih.gov/pubmed/38450380",
                "http://www.ncbi.nlm.nih.gov/pubmed/23040035"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040035",
                    "text": "Neuroticism (r = 0.26), low agreeableness (r = -0.34), and some facets were also significantly associated with advanced stages of neurofibrillary tangles, but the associations between personality traits and risk of clinical dementia were mostly unchanged by controlling for the extent of neurofibrillary tangles and A\u03b2 neuritic plaques.",
                    "score_reranked": 2.8026652336120605
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706517",
                    "text": "Individuals with scores in the top quartile of neuroticism (hazard ratio = 3.1; 95% confidence interval = 1.6-6.0) or the lowest quartile of conscientiousness (hazard ratio = 3.3; 95% confidence interval = 1.4-7.4) had a threefold increased risk of incident AD.",
                    "score_reranked": 1.858973503112793
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                    "text": "Personality and risk for Alzheimer's disease in adults 72 years of age and older: a 6-year follow-up.",
                    "score_reranked": 1.3264827728271484
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23706517",
                    "text": "Personality and risk of Alzheimer's disease: new data and meta-analysis.",
                    "score_reranked": 1.301019310951233
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29846724",
                    "text": "Personality, especially the dimensions of neuroticism and conscientiousness, has prospectively predicted the risk of incident Alzheimer's disease (AD).",
                    "score_reranked": 1.124668002128601
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31486975",
                    "text": "Personality traits such as Neuroticism and Conscientiousness are associated with Alzheimer disease (AD) pathophysiology in cognitively normal (CN) and impaired individuals, and may represent potential risk or resilience factors, respectively.",
                    "score_reranked": 1.0889780521392822
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                    "text": "The finding that AD risk is associated with elevated Neuroticism and lower Conscientiousness can be added to the accumulating literature documenting the pathogenic effects of these two traits.",
                    "score_reranked": 1.0424463748931885
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20973606",
                    "text": "We hypothesized that elevated Neuroticism, lower Openness, and lower Conscientiousness would be independently associated with risk of AD.",
                    "score_reranked": 0.20759490132331848
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38450380",
                    "text": "Personality traits and neuropsychiatric symptoms such as neuroticism and depression share genetic overlap and have both been identified as risks factors for development of aging-related neurocognitive decline and Alzheimer's disease (AD).",
                    "score_reranked": 0.03027847409248352
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23040035",
                    "text": "Individuals with higher baseline scores on vulnerability to stress, anxiety, and depression (neuroticism: odds ratio, 2.0; 95% confidence interval, 1.2-3.5), or lower scores on order and competence (conscientiousness: odds ratio, 0.4; 95% confidence interval, 0.2-0.9) were less likely to remain asymptomatic in the presence of AD neuropathology.",
                    "score_reranked": -0.5277984142303467
                }
            ]
        },
        {
            "id": "52f125332059c6d71c000007",
            "body": "What is the mode of action of everolimus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31840244",
                "http://www.ncbi.nlm.nih.gov/pubmed/10767777",
                "http://www.ncbi.nlm.nih.gov/pubmed/22139982",
                "http://www.ncbi.nlm.nih.gov/pubmed/10767777",
                "http://www.ncbi.nlm.nih.gov/pubmed/19620795",
                "http://www.ncbi.nlm.nih.gov/pubmed/37140396",
                "http://www.ncbi.nlm.nih.gov/pubmed/31840244",
                "http://www.ncbi.nlm.nih.gov/pubmed/19620795",
                "http://www.ncbi.nlm.nih.gov/pubmed/39903448",
                "http://www.ncbi.nlm.nih.gov/pubmed/19620795"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840244",
                    "text": "The place of target of rapamycin inhibitors (TOR-I) (sirolimus, everolimus), which have different modes of action from other commonly used immunosuppressive agents, in kidney transplantation remains uncertain.",
                    "score_reranked": 1.6208223104476929
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10767777",
                    "text": "The in vitro immunosuppressive activity as measured by the mixed lymphocyte reaction is more or less comparable to that of SDZ-RAD, although its pharmacological mode of action may be different from that classically described for rapamycin.",
                    "score_reranked": 1.5424089431762695
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22139982",
                    "text": "Small-molecule immunosuppressive agents include calcineurin-inhibitors (cyclosporine, tacrolimus), Target-of-Rapamycin Inhibitors (Sirolimus, Everolimus), inhibitors of nucleotide synthesis and azathioprine.",
                    "score_reranked": 0.42203596234321594
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10767777",
                    "text": "Some of these molecules are still under clinical development as, for example, SDZ-RAD (40-O-(2-hydroxyethyl)rapamycin), an immunosuppressive drug closely related to rapamycin.",
                    "score_reranked": 0.3932853043079376
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19620795",
                    "text": "Vertical therapies of mTOR inhibitor in combination with AKT inhibitors, or newly development of stronger mTOR kinase which can suppress both mTORC1 and mTORC2 are planned at present.",
                    "score_reranked": 0.29934147000312805
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37140396",
                    "text": "To investigate the combined function of the novel oral mTOR inhibitor, everolimus, with antifungal agents and their potential mechanisms against",
                    "score_reranked": 0.23928484320640564
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31840244",
                    "text": "Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.",
                    "score_reranked": -0.001796811819076538
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19620795",
                    "text": "Rapamycin and its related analogs such as Temsirolimus and Everolimus are less toxic for humans compared with other anti-VEGFR inhibitors and has been used as an immunosuppressive agent.",
                    "score_reranked": -0.6605119705200195
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39903448",
                    "text": "Sirolimus and everolimus, allosteric mTOR inhibitors, are widely used in transplant medicine and oncology.",
                    "score_reranked": -1.1669985055923462
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19620795",
                    "text": "mTOR inhibitors such as Temsirolimus (CCI779) and Everolimus (RAD001) are effective for suppressing cell growth with inhibiting mTOR kinase activity.",
                    "score_reranked": -1.2831699848175049
                }
            ]
        },
        {
            "id": "5158a5b8d24251bc05000097",
            "body": "Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39282456",
                "http://www.ncbi.nlm.nih.gov/pubmed/38478511",
                "http://www.ncbi.nlm.nih.gov/pubmed/35363263",
                "http://www.ncbi.nlm.nih.gov/pubmed/39079539",
                "http://www.ncbi.nlm.nih.gov/pubmed/39079539",
                "http://www.ncbi.nlm.nih.gov/pubmed/39282456",
                "http://www.ncbi.nlm.nih.gov/pubmed/36002455",
                "http://www.ncbi.nlm.nih.gov/pubmed/36002455",
                "http://www.ncbi.nlm.nih.gov/pubmed/25140736",
                "http://www.ncbi.nlm.nih.gov/pubmed/35363263"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39282456",
                    "text": "Efforts to connect these variants with splicing quantitative trait loci (sQTLs) have provided functional insights, yet sQTLs reported by existing methods cannot explain many GWAS signals.",
                    "score_reranked": 2.657335042953491
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38478511",
                    "text": "Common variants affecting mRNA splicing are typically identified though splicing quantitative trait locus (sQTL) mapping and have been shown to be enriched for GWAS signals by a similar degree to eQTLs.",
                    "score_reranked": 2.391145944595337
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35363263",
                    "text": "In pancreatic cancer, splicing quantitative trait loci analysis identifies a rs1785932 variant that contributes to decreased risk of disease by influencing ELP2 mRNA splicing and blocking the STAT3 oncogenic pathway.",
                    "score_reranked": 2.0254952907562256
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39079539",
                    "text": "Here, we present an approach that integrates information from GWASs, splicing quantitative trait loci (sQTLs), and PacBio long-read RNA-seq in a disease-relevant model to infer the effects of sQTLs on the ultimate protein isoform products they encode.",
                    "score_reranked": 1.7452144622802734
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39079539",
                    "text": "A major fraction of loci identified by genome-wide association studies (GWASs) mediate alternative splicing, but mechanistic interpretation is hindered by the technical limitations of short-read RNA sequencing (RNA-seq), which cannot directly link splicing events to full-length protein isoforms.",
                    "score_reranked": 1.4958417415618896
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39282456",
                    "text": "A Deep Dive into Statistical Modeling of RNA Splicing QTLs Reveals New Variants that Explain Neurodegenerative Disease.",
                    "score_reranked": 0.9733709096908569
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002455",
                    "text": "Splicing QTL analysis focusing on coding sequences reveals mechanisms for disease susceptibility loci.",
                    "score_reranked": 0.9118518829345703
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/36002455",
                    "text": "Splicing quantitative trait loci (sQTLs) are one of the major causal mechanisms in genome-wide association study (GWAS) loci, but their role in disease pathogenesis is poorly understood.",
                    "score_reranked": 0.1408388912677765
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25140736",
                    "text": "We identify hundreds of single nucleotide polymorphisms (SNPs) as splicing QTLs (sQTLs), including some falling in genome-wide association study SNPs.",
                    "score_reranked": -0.04687175154685974
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/35363263",
                    "text": "Understanding the genetic variation underlying transcript splicing is essential for fully dissecting the molecular mechanisms of common diseases.",
                    "score_reranked": -0.896752119064331
                }
            ]
        },
        {
            "id": "553653a5bc4f83e828000007",
            "body": "Which technique is used for detection of EWS/FLI1 fusion transcripts?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                "http://www.ncbi.nlm.nih.gov/pubmed/40234527",
                "http://www.ncbi.nlm.nih.gov/pubmed/39672769",
                "http://www.ncbi.nlm.nih.gov/pubmed/40170158",
                "http://www.ncbi.nlm.nih.gov/pubmed/40230184",
                "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                "http://www.ncbi.nlm.nih.gov/pubmed/40234527",
                "http://www.ncbi.nlm.nih.gov/pubmed/40230184",
                "http://www.ncbi.nlm.nih.gov/pubmed/39384185"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                    "text": "Molecular techniques for the detection of FET/ETS fusions are widely used to confirm the diagnosis.",
                    "score_reranked": 0.028394371271133423
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                    "text": "Several molecular techniques for the detection of FET/ETS fusions are widely used to confirm the diagnosis.",
                    "score_reranked": 0.011016756296157837
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40234527",
                    "text": "Ewing Sarcoma (EwS) is a rare pediatric malignancy characterized by a unique t(11:22) (q24;q12) translocation resulting in the pathognomonic EWSR1::FLI1 fusion.",
                    "score_reranked": -0.16531452536582947
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39672769",
                    "text": "RNA fusion panel is an evolving technology that can identify multiple fusion transcripts in a single molecular assay, even without prior knowledge of breakpoints or fusion partners.",
                    "score_reranked": -0.19532141089439392
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40170158",
                    "text": "The detection of specific fusion genes from cfRNAs shows potential for monitoring the progression of fusion-related sarcomas in the context of chemotherapy.",
                    "score_reranked": -0.2029179036617279
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40230184",
                    "text": "However, EWSR1 rearrangements have been identified in other malignancies; thus, the detection of chimeric EWSR1 transcripts has become a preferable approach.",
                    "score_reranked": -0.47345635294914246
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39752208",
                    "text": "Its main driver is the reciprocal translocation between the EWSR1 and FLI1 genes ( EWSR1 : FLI1 ).",
                    "score_reranked": -0.7982378005981445
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40234527",
                    "text": "Recent reports indicate that the EWSR1::FLI1 oncofusion drives aberrant expression of numerous transcripts, including Lipoxygenase Homology Domains 1 (LOXHD1).",
                    "score_reranked": -0.899572491645813
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40230184",
                    "text": "For decades, fluorescence in situ hybridization with a break-apart EWSR1 probe has been the diagnostic gold standard.",
                    "score_reranked": -1.0957436561584473
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39384185",
                    "text": "Our design enabled the detection of almost all fusion variants of NGFI-A binding protein 2 (NAB2) with signal transducer and activator of transcription 6 (STAT6) in solitary fibrous tumors, as well as cAMP responsive element binding protein 3 like 1/2 (CREB3L1/2) rearrangements in all low-grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma cases.",
                    "score_reranked": -1.5677212476730347
                }
            ]
        },
        {
            "id": "5344310baeec6fbd0700000c",
            "body": "Does the CTCF protein co-localize with cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                "http://www.ncbi.nlm.nih.gov/pubmed/40121293",
                "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                "http://www.ncbi.nlm.nih.gov/pubmed/40374602",
                "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                "http://www.ncbi.nlm.nih.gov/pubmed/40374602",
                "http://www.ncbi.nlm.nih.gov/pubmed/39786339",
                "http://www.ncbi.nlm.nih.gov/pubmed/37961446",
                "http://www.ncbi.nlm.nih.gov/pubmed/37536339"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                    "text": "The cryo-EM structure of the cohesin-CTCF complex reveals that this CTCF motif ahead of zinc fingers can only reach its binding site on the STAG1 cohesin subunit when the N terminus of CTCF faces cohesin.",
                    "score_reranked": 0.8662773370742798
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40121293",
                    "text": "First, we found via ChIP-seq analysis that cohesins (SMC3, RAD21, and REC8) and condensin (SMC4) share DNA binding sites in close proximity and directly interact with the insulator protein CTCF.",
                    "score_reranked": 0.32500842213630676
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                    "text": "CTCF and R-loops are boundaries of cohesin-mediated DNA looping.",
                    "score_reranked": -0.18957456946372986
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                    "text": "Using single-molecule imaging, we demonstrate that a critical N-terminal motif of CTCF blocks cohesin translocation and DNA looping.",
                    "score_reranked": -0.26196086406707764
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40374602",
                    "text": "To better characterize static and dynamically extruding chromatin loop structures, we use MNase-based 3D genome assays to simultaneously determine CTCF and cohesin localization as well as the 3D contacts they mediate.",
                    "score_reranked": -0.5329757928848267
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                    "text": "Cohesin and CCCTC-binding factor (CTCF) are key regulatory proteins of three-dimensional (3D) genome organization.",
                    "score_reranked": -0.5376821756362915
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40374602",
                    "text": "High-resolution CTCF footprinting reveals impact of chromatin state on cohesin extrusion.",
                    "score_reranked": -0.6966077089309692
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39786339",
                    "text": "Using quantitative and super-resolution microscopy, we show that the transition from a Condensin to a Cohesin-based genome organization occurs dynamically over 2 h. While a significant fraction of Condensins remains chromatin-bound until early G1, Cohesin-STAG1 and its boundary factor CTCF are rapidly imported into daughter nuclei in telophase, immediately bind chromosomes as individual complexes, and are sufficient to build the first interphase TAD structures.",
                    "score_reranked": -0.8023638725280762
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37961446",
                    "text": "While CTCF is known to anchor many cohesin-mediated loops, the looped chromatin fiber appears to predominantly exist in a poorly characterized actively extruding state.",
                    "score_reranked": -0.8126623630523682
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/37536339",
                    "text": "Finally, we show that RNA-DNA hybrids (R-loops) block cohesin-mediated DNA compaction in\u00a0vitro and are enriched with cohesin subunits in\u00a0vivo, likely forming TAD boundaries.",
                    "score_reranked": -0.8460841178894043
                }
            ]
        },
        {
            "id": "56c868a95795f9a73e000017",
            "body": "What is the application of the Bimolecular Fluorescence Complementation (BiFC) assay in Drosophila embryos?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30565126",
                "http://www.ncbi.nlm.nih.gov/pubmed/30565126",
                "http://www.ncbi.nlm.nih.gov/pubmed/21276241",
                "http://www.ncbi.nlm.nih.gov/pubmed/25151172",
                "http://www.ncbi.nlm.nih.gov/pubmed/21276241",
                "http://www.ncbi.nlm.nih.gov/pubmed/16454041",
                "http://www.ncbi.nlm.nih.gov/pubmed/25151172",
                "http://www.ncbi.nlm.nih.gov/pubmed/38932691",
                "http://www.ncbi.nlm.nih.gov/pubmed/38525241",
                "http://www.ncbi.nlm.nih.gov/pubmed/16454041"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30565126",
                    "text": "In this chapter, we report the method of bimolecular fluorescence complementation (BiFC) in tissue culture and developing tissues of Drosophila, which allows the visualization of subcellular localization of protein-protein interactions in living cells.",
                    "score_reranked": 2.1291615962982178
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30565126",
                    "text": "Bimolecular Fluorescence Complementation (BiFC) in Tissue Culture and in Developing Tissues of Drosophila to Study Protein-Protein Interactions.",
                    "score_reranked": 1.822261095046997
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241",
                    "text": "Visualization of protein interactions in living Drosophila embryos by the bimolecular fluorescence complementation assay.",
                    "score_reranked": 1.7671862840652466
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25151172",
                    "text": "Bimolecular fluorescence complementation (BiFC) in live Drosophila embryos.",
                    "score_reranked": 1.7645378112792969
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21276241",
                    "text": "Using a Hox protein partnership as a test case, we investigated the suitability of BiFC for the study of protein interactions in the living Drosophila embryo.",
                    "score_reranked": 1.467465877532959
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041",
                    "text": "Using fluorescent proteins, we previously developed a bimolecular fluorescence complementation (BiFC) assay and a multicolor BiFC assay to visualize protein-protein interactions in living cells.",
                    "score_reranked": 1.2006195783615112
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25151172",
                    "text": "Bimolecular fluorescence complementation (BiFC) is a powerful method for studying protein-protein interactions in different cell types and organisms.",
                    "score_reranked": 0.8718020915985107
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38932691",
                    "text": "Functional analysis of protein interactions using coupled bi-fluorescence complementation/GFP nanobody techniques.",
                    "score_reranked": 0.4227311909198761
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/38525241",
                    "text": "Dual-transgenic BiFC vector systems for protein-protein interaction analysis in plants.",
                    "score_reranked": 0.12593448162078857
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16454041",
                    "text": "Identification of new fluorescent protein fragments for bimolecular fluorescence complementation analysis under physiological conditions.",
                    "score_reranked": -0.30390462279319763
                }
            ]
        },
        {
            "id": "54dcb29dc0bb8dce23000004",
            "body": "Which pathological condition of the heart is known as hypertrophic cardiomyopathy (HCM)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/39858621",
                "http://www.ncbi.nlm.nih.gov/pubmed/39858621",
                "http://www.ncbi.nlm.nih.gov/pubmed/40242137",
                "http://www.ncbi.nlm.nih.gov/pubmed/40223237",
                "http://www.ncbi.nlm.nih.gov/pubmed/32217077",
                "http://www.ncbi.nlm.nih.gov/pubmed/39476121",
                "http://www.ncbi.nlm.nih.gov/pubmed/39990836",
                "http://www.ncbi.nlm.nih.gov/pubmed/39990836",
                "http://www.ncbi.nlm.nih.gov/pubmed/39866219",
                "http://www.ncbi.nlm.nih.gov/pubmed/39866219"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39858621",
                    "text": "Since its first pathological description over 65 years ago, hypertrophic cardiomyopathy (HCM), with a worldwide prevalence of 1:500, has emerged as the most common genetically determined cardiac disease.",
                    "score_reranked": 0.8730536699295044
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39858621",
                    "text": "Hypertrophic Cardiomyopathy: New Clinical and Therapeutic Perspectives of an \"Old\" Genetic Myocardial Disease.",
                    "score_reranked": 0.5637079477310181
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40242137",
                    "text": "Hypertrophic cardiomyopathy (HCM) is a complex genetic disorder that has garnered significant attention because of its diverse manifestations, including arrhythmias and heightened risk of sudden cardiac death.",
                    "score_reranked": 0.5045835971832275
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40223237",
                    "text": "As a special type of hypertrophic cardiomyopathy (HCM), apical HCM (ApHCM) has different clinical characteristics while its nature history and prognosis are not well recognized.",
                    "score_reranked": 0.37825682759284973
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32217077",
                    "text": "Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and is characterized by asymmetric left ventricular hypertrophy and diastolic dysfunction, and a frequent cause of sudden cardiac death at young age.",
                    "score_reranked": 0.37246623635292053
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39476121",
                    "text": "The importance of accurate differentiation between these two entities cannot be highlighted enough-it is estimated that half of the cases of sudden cardiac death in young athletes aged 19-29 are caused by cardiomyopathies, primarily hypertrophic cardiomyopathy (HCM).",
                    "score_reranked": 0.34839776158332825
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39990836",
                    "text": "Hypertrophic cardiomyopathy (HCM) is the most common type of primary cardiomyopathy that causes sudden cardiac death in adolescents and athletes.",
                    "score_reranked": 0.3436097204685211
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39990836",
                    "text": "Myocardial fibrosis is the most important histopathological characterization in HCM and is regarded as the primary cause of malignant ventricular arrhythmia, cardiac remodeling, and heart failure.",
                    "score_reranked": -0.2841355502605438
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39866219",
                    "text": "To elaborate the main pathogenic genes and phenotypic prognosis in HCM to promote a better understanding of this genetic disease.",
                    "score_reranked": -0.8014928102493286
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/39866219",
                    "text": "Many studies have explored the clinical symptoms and prognosis of HCM, emphasizing the importance of genotype in evaluating patient prognosis and guiding the clinical management of HCM.",
                    "score_reranked": -1.14566171169281
                }
            ]
        },
        {
            "id": "516e5f41298dcd4e5100007f",
            "body": "What is the genetic basis of Rubinstein-Taybi syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/40138169",
                "http://www.ncbi.nlm.nih.gov/pubmed/40372223",
                "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                "http://www.ncbi.nlm.nih.gov/pubmed/40387003",
                "http://www.ncbi.nlm.nih.gov/pubmed/40385674",
                "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                "http://www.ncbi.nlm.nih.gov/pubmed/40138169",
                "http://www.ncbi.nlm.nih.gov/pubmed/40301961"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40138169",
                    "text": "Understanding the diverse clinical presentations and genetic basis of diseases associated with iris abnormalities is essential for accurate diagnosis and effective management.",
                    "score_reranked": 0.29462721943855286
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40372223",
                    "text": "To explore the genetic etiology of a child with Renpenning syndrome (RS), and review the literature on the clinical characteristics and gene mutations of RS.",
                    "score_reranked": 0.28559449315071106
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                    "text": "Defects in genes encoding histones lead to the expression of abnormal histone proteins.",
                    "score_reranked": 0.09366920590400696
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40387003",
                    "text": "The condition is linked to mutations in 11 genes involved in the formation of LROs.",
                    "score_reranked": -0.09037765860557556
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40385674",
                    "text": "Genetic studies ruled out chromosomal disorders and",
                    "score_reranked": -0.4208061099052429
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                    "text": "In this review article, the molecular basis of histone structure and function is first explained, followed by a summary of the histone-related syndromes.",
                    "score_reranked": -0.4999835193157196
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                    "text": "Molecular and clinical aspects of histone-related disorders.",
                    "score_reranked": -0.5722423791885376
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                    "text": "Histone-related disorders encompass the syndromes induced by pathogenic variants in genes encoding histones, genes encoding histone modification enzymes, and genes encoding subunits of chromatin remodeler and epigenetic reader complexes.",
                    "score_reranked": -0.6598536968231201
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40138169",
                    "text": "We included all studies describing the clinical characteristics, pathogenic variants, and associated syndromes of congenital aniridia.",
                    "score_reranked": -0.7632861137390137
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/40301961",
                    "text": "To date, 72 histone-related disorders have been described including 7 syndromes due to defects in histone genes, 35 syndromes due to histone modifications defects, 26 syndromes due to defects in chromatin remodeling, and 4 due to defects in epigenetic readers.",
                    "score_reranked": -1.2762418985366821
                }
            ]
        },
        {
            "id": "511a51331159fa8212000009",
            "body": "What is the function of the viral KP4 protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21116630",
                "http://www.ncbi.nlm.nih.gov/pubmed/11901234",
                "http://www.ncbi.nlm.nih.gov/pubmed/11532143",
                "http://www.ncbi.nlm.nih.gov/pubmed/8145639",
                "http://www.ncbi.nlm.nih.gov/pubmed/7966296",
                "http://www.ncbi.nlm.nih.gov/pubmed/21116630",
                "http://www.ncbi.nlm.nih.gov/pubmed/7582897",
                "http://www.ncbi.nlm.nih.gov/pubmed/7582897",
                "http://www.ncbi.nlm.nih.gov/pubmed/23219466",
                "http://www.ncbi.nlm.nih.gov/pubmed/29556246"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116630",
                    "text": "Killer protein 4 (KP4) is a well studied viral toxin secreted by the maize smut fungus Ustilago maydis that kills sensitive Ustilago strains as well as inhibits Fusarium and plant root growth by inhibiting calcium uptake.",
                    "score_reranked": 1.2256263494491577
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11901234",
                    "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.",
                    "score_reranked": 0.8309811353683472
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11532143",
                    "text": "KP4 is a virally encoded fungal toxin secreted by the P4 killer strain of Ustilago maydis.",
                    "score_reranked": 0.8309811353683472
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8145639",
                    "text": "Structure and heterologous expression of the Ustilago maydis viral toxin KP4.",
                    "score_reranked": 0.7702810764312744
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7966296",
                    "text": "KP4 is a virally encoded and highly specific toxin that kills fungi closely related to the fungus Ustilago maydis.",
                    "score_reranked": 0.6482919454574585
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21116630",
                    "text": "The KP4 killer protein gene family.",
                    "score_reranked": 0.5234450101852417
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897",
                    "text": "The P4 strain of the corn smut fungus, Ustilago maydis, secretes a fungal toxin, KP4, encoded by a fungal virus (UMV4) that persistently infects its cells.",
                    "score_reranked": -0.17540082335472107
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7582897",
                    "text": "In symbiosis with the host fungus, UMV4 encodes KP4 to kill other competitive strains of U. maydis, thereby promoting both host and virus survival.",
                    "score_reranked": -0.33200308680534363
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23219466",
                    "text": "There are three killer types (P1, P4 and P6) that secrete KP1, KP4 and KP6 toxins, respectively, which are produced only by strains persistently infected with double-stranded RNA viruses (UmV) in the cell cytoplasm.",
                    "score_reranked": -0.4841361343860626
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29556246",
                    "text": "Recombinant Promoter (MUASCsV8CP) Driven Totiviral Killer Protein 4 (KP4) Imparts Resistance Against Fungal Pathogens in Transgenic Tobacco.",
                    "score_reranked": -1.0703074932098389
                }
            ]
        }
    ]
}